Current Bibliographies in Medicine 96-1

Cervical Cancer

CBM  96-1



Cervical Cancer


January 1993 through March 1996

926 Citations




Prepared by


Lori J. Klein, M.A.L.S., National Library of Medicine

Edward L. Trimble, M.D., M.P.H., National Cancer Institute















U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health


National Library of Medicine
Reference Section
8600 Rockville Pike
Bethesda, Maryland  20894


1996



National Library of Medicine Cataloging in Publication




Klein, Lori
Cervical cancer : January 1993 through March 1996 :
926 citations / prepared by Lori J. Klein, Edward L.
Trimble. -- Bethesda, Md. (8600 Rockville Pike, Bethesda
20894) :  U.S. Dept. of Health and Human Services,
Public Health Service, National Institutes of Health,
National Library of Medicine, Reference Section ;
Pittsburgh, PA : Sold by the Supt. of Docs., U.S. G.P.O.,
1996. -- (Current bibliographies in medicine ; 96-1)

Prepared in support of the National Institutes of
Health Consensus Development Conference on Cervical Cancer,
held in Bethesda, Md., April 1-3, 1996.

1. Cervix Neoplasms - bibliography  I. Trimble, Edward
L. 
II. National Library of Medicine (U.S.).  Reference
Section 
III. National Institutes of Health Consensus Development
Conference on Cervical Cancer (1996 : Bethesda, Md.) 
IV.
Title  V.  Series

02NLM: ZW 1 N272 no.96-1





SERIES  NOTE


Current Bibliographies in Medicine (CBM) is a continuation
in part of the National Library of Medicine's
Literature Search Series, which ceased in 1987 with No.
87-15.  In 1989 it also subsumed the Specialized
Bibliography Series.  Each bibliography in the new series
covers a distinct subject area of biomedicine and is
intended to fulfill a current awareness function. 
Citations are usually derived from searching a variety of
online databases.  NLM databases utilized include MEDLINE ,
AVLINE , BIOETHICSLINE , CANCERLIT , CATLINE , HEALTH,
POPLINE  and TOXLINE .  The only criterion for the inclusion
of a particular published work is its relevance to the topic
being presented; the format, ownership, or location of the
material is not considered. 

Comments and suggestions on this series may be addressed
to:

Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD  20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: patrias@nlm.nih.gov


Ordering Information:

Current Bibliographies in Medicine is sold by the
Superintendent of Documents, U.S. Government Printing
Office, P.O. 371954, Pittsburgh, PA  15250-7954.  To order
the entire CBM series for calendar year 1996
(approximately 10 bibliographies), send $47.00 ($58.75
foreign) to the Superintendent of Documents citing GPO
List ID: CBM96.  For your convenience an order blank is
given inside the back cover.  Orders for individual
bibliographies in the series ($5.50, $6.88 foreign) should
be sent to the Superintendent of Documents citing the
title, CBM number, and the GPO List ID given above.


Internet Access:

The Current Bibliographies in Medicine series is also
available at no cost to anyone with Internet access
throughFTP (File Transfer Protocol).  FTP to
nlmpubs.nlm.nih.gov
and login as anonymous.  The index file in the
"bibs" directory provides information on the
bibliographies available.






Use of funds for printing this periodical has been
approved by the Director of the Office of Management 
and Budget through September 30, 1996. 


CERVICAL CANCER



The introduction of the Papanicolaou (Pap) test fifty
years ago has led to a steep decline in deaths from
cervical cancer.  Nonetheless, this form of cancer
accounts for 65% of all malignancies in American women
and 5,000 cancer deaths in the United States each year. 
Worldwide, cervical cancer remains the leading
cause of cancer deaths among women.

This bibliography was prepared for the National Institutes
of Health Consensus Development Conference on
Cervical Cancer held in Bethesda, MD on April 1-3, 1996. 
The conference focused on treatment and
quality-of-life issues for women with cervical cancer. 
For women with early-stage disease, these include
pretreatment imaging, the role of lymph node resection,
primary surgery and radiotherapy, and adjuvant
treatment.  For women with advanced-stage disease,
critical issues include optimal radiotherapy techniques,
neoadjuvant and concomitant chemotherapy, pelvic
exenteration, and palliative treatment.

Many unanswered questions remain as to how best to treat
women with preinvasive disease of the cervix. 
Although the issues were reviewed at the Consensus
Conference, the main focus of the Conference was
cervical cancer.  The bibliography, therefore,
concentrates on treatment issues in invasive disease. 
Included are journal articles, conference proceedings and
papers, and dissertations from 1993 through early 1996
related to the subject matter.  The bibliography has been
organized along the same lines as the conference,
with the first small section dealing with improving and
strengthening efforts to prevent cervical cancer.  The
next sections cover the management of early-stage disease,
then advanced-stage and recurrent cervical
cancer.  The last section includes references to new
directions in research. Most references are included
only under a single category.

The compilers wish to thank Adam Glazer, National
Library of Medicine, for his production assistance.


SEARCH  STRATEGY

A variety of online databases are usually searched in
preparing bibliographies in the CBM series.  To assist you
in updating or otherwise manipulating the material in this
search, the strategy used for the NLM's MEDLINE
database is given below.  Please note that the search
strategies presented here differ from individual demand
searches in that they are generally broadly formulated and
irrelevant citations edited out prior to printing.


SS 1 = CERVIX NEOPLASMS AND THERAPY& (PX)

SS 2 = *CERVIX NEOPLASMS

SS 3 = (TW) CERVIX OR CERVICAL

SS 4 = NEOPLASMS (PX)

SS 5 = (TW) ALL INVAD: OR ALL INVAS: OR STAGE OR 
STAGING OR STAGES OR FIGO

SS 6 = 3 AND 4 AND 5

SS 7 = CERVICAL INTRAEPITHELIAL NEOPLASIA OR 
CERVIX DYSPLASIA OR PRECANCEROUS CONDITIONS OR  
EXP THYROID NEOPLASMS

SS 8 = 6 AND NOT 7

SS 9 = 1 OR 2 OR 8

SS 10 = 9 AND HUMAN


GRATEFUL MED  and INTERNET GRATEFUL MED 

To make online searching easier and more efficient, the
Library offers GRATEFUL MED, microcomputer-based
software that provides a user-friendly interface to most
NLM databases.  This software was specifically
developed for health professionals and features multiple
choice menus and "fill in the blank" screens for easy
search preparation.  GRATEFUL MED runs on an IBM PC (or
IBM-compatible) with DOS 2.0 or a Macintosh,
and requires a Hayes (or Hayes-compatible) modem.  It may
be purchased from the National Technical
Information Service in Springfield, Virginia, for $29.95
(plus $3.00 per order for shipping).  For your
convenience, an order blank has been enclosed at the back
of this bibliography.

INTERNET GRATEFUL MED is available from the World Wide
Web.  The user with Internet access and an
NLM user account need only point a compatible Web browser
(Netscape Navigator is strongly recommended)
to http://www.igm.nlm.nih.gov.  No other software at the
user end is required.  At present, MEDLINE is the
only NLM database available through INTERNET GRATEFUL MED,
but the Library expects to add access
to other files rapidly. 

SAMPLE  CITATIONS

Citations in this bibliographic series are formatted
according to the rules established for Index Medicus *. 
Sample journal and monograph citations appear below.  For
journal articles written in a foreign language, the
English translation of the title is placed in brackets;
for monographs, the title is given in the original language. 
In both cases the language of publication is shown by a
three letter abbreviation appearing at the end of the
citation.

Journal Article:

Authors                  Article Title

Hopkins MP, Morley GW. Microinvasive squamous cell
carcinoma of the cervix.
J Reprod Med 1994 Sep;39(9):671-3.

Abbreviated Journal         Date  Volume  Issue 
Pages
Title

Dissertation:

Author                Title                   
Place of Institution

Sun Y. Serologic markers of human papillomavirus
associated cervical cancer [dissertation]. [Baltimore
(MD)]: Johns Hopkins Univ.; 1994. 193 p. 
Available from: University Microfilms          
International, Ann Arbor, MI; AAD94-29578. 

Institution                 Date       
Total No. Availability
of Degree of Pages

Conference Paper:

Author             Paper Title                  
Editors

Taguchi T. Clinical studies of CPT-11 in Japan.  In:
Banzet P, Holland JF, Khayat D, Weil M, editors.
Cancer treatment: an update. Presentations given
at the 4th International Congress on          Anticancer
Chemotherapy; 1993 Feb 2-5; Paris, France. Paris:
Springer-Verlag; 1994.            p. 809-12.
Book Title                     Date & Place of      
Place of  Publisher     Date                Pages        
Conference          Publication

_________________________________

*For details of the formats used for references, see the
following publication:

Patrias, Karen. National Library of Medicine
Recommended formats for bibliographic citation. 
Bethesda (MD):  The Library; 1991 Apr. 
Available from: NTIS, Springfield, VA; PB91-182030. 


TABLE  OF  CONTENTS





EFFORTS TO PREVENT CERVICAL CANCER        

Epidemiology
Screening Patterns
Screening
Prevention

MANAGEMENT OF LOW-STAGE CERVICAL CANCER (FIGO I-IIA)

Pathology and Prognostic factors
Imaging
Surgical Assessment and Resection of Lymph Nodes
Diagnosis and Management of Stage IA1
Primary Surgery, Including Treatment in Pregnancy 
Primary Radiotherapy
Quality of Life Considerations
New Surgical Approaches
Adjuvant Therapy After Hysterectomy
Adjuvant Surgery After Radiotherapy

MANAGEMENT OF ADVANCED-STAGE AND RECURRENT CERVICAL
CANCER

Radiotherapy
High- or Low-Dose Rate Brachytherapy
Presurgical Neoadjuvant Chemotherapy or
Concomittant Chemotherapy with Radiotherapy 
Potential Improvements in Radiobiology
Radiotherapy ñ Chemotherapy for Locally Recurrent
Disease
Surgery for Locally Recurrent Disease
Chemotherapy for Stage IVB and Recurrent
Metastatic Disease
Palliative Radiotherapy for Stage IVB Disease 

NEW DIRECTIONS FOR RESEARCH IN CERVICAL CANCER

Radiation Biology
HPV Biology
HPV Immunology and Vaccine Prospects              






EFFORTS TO PREVENT CERVICAL CANCER

Epidemiology


Aareleid T, Pukkala E, Thomson H, Hakama M. Cervical
cancer incidence and mortality trends in Finland and
Estonia: a screened vs. an unscreened population. Eur J
Cancer 1993;29A(5):745-9.

Agarwal SS, Sehgal A, Sardana S, Kumar A, Luthra UK.
Role of male behavior in cervical carcinogenesis among
women with one lifetime sexual partner. Cancer 1993 
Sep 1;72(5):1666-9.

Ali S, Astley SB, Sheldon TA, Peel KR, Wells M. Detection
and measurement of DNA adducts in the cervix of
smokers and non-smokers. Int J Gynecol Cancer 1994;
4(3):188-93.

Azevedo G, Mendonca S. [Cancer in the female population in
Brazil]. Rev Saude Publica 1993 Feb;27(1):68-75.  (Por).

Batieha AM, Armenian HK, Norkus EP, Morris JS, Spate
VE, Comstock GW. Serum micronutrients and the
subsequent risk of cervical cancer in a population-based
nested case-control study. Cancer Epidemiol Biomarkers
Prev 1993 Jul-Aug;2(4):335-9.

Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush
BB, Scott DR, Cadell DM, Kurman RJ, Manos MM.
Determinants of genital human papillomavirus infection in
low-risk women in Portland, Oregon. Sex Transm Dis
1993 Sep-Oct;20(5):274-8.

Becker TM, Wheeler CM, McGough NS, Parmenter CA,
Stidley CA, Jamison SF, Jordan SW. Cigarette smoking
and other risk factors for cervical dysplasia in
southwestern Hispanic and non-Hispanic white women.
Cancer Epidemiol Biomarkers Prev 1994;3(2):113-9.

Beral V, Hermon C, Munoz N, Devesa SS. Cervical cancer.
Cancer Surv 1994;19-20:265-85.

Berry G, MacLennan R, Shearman R, Jelihovsky T, Cooper
Booth J, Molina R, Martinez L, Salas O, Dabancens A,
Zhiheng C, Yun T, Wei HY, Cuadros A, Aristizabal N,
Modan B, Ron E, Alfandary E, Mati JG, Kenya P, et al.
Invasive squamous-cell cervical carcinoma and combined
oral contraceptives: results from a multinational study. 
Int J Cancer 1993;55(2):228-36.

Birley HD. Human papillomaviruses, cervical cancer and the
developing world. Ann Trop Med Parasitol 1995 Oct;
89(5):453-63.

Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM,
Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV.
Prevalence of human papillomavirus in cervical cancer: a
worldwide perspective. International biological study on
cervical cancer (IBSCC) Study Group. J Natl Cancer Inst
1995 Jun 7;87(11):796-802.  Comment in: J Natl Cancer
Inst 1995 Jun 7;87(11):779-80.

Bosch FX, Munoz N, de Sanjose S, Guerrerro E, Gaffari
AM, Kaldor J, Castellsague X, Shah KV, Chaffari AM
[corrected to Gaffari AM]. Importance of human
papillomavirus endemicity in the incidence of cervical
cancer: an extension of the hypothesis on sexual
behavior. Cancer Epidemiol Biomarkers Prev 1994    
Jul-Aug;3(5):375-9.  Published erratum appears in Cancer
Epidemiol Biomarkers Prev 1994 Dec;3(8):718.

Bosch FX, Munoz N, de Sanjose S, Navarro C, Moreo P,
Ascunce N, Gonzalez LC, Tafur L, Gili M, Larranaga I,
et al. Human papillomavirus and cervical intraepithelial
neoplasia grade III/carcinoma in situ: a case-control study
in Spain and Colombia. Cancer Epidemiol Biomarkers
Prev 1993 Sep-Oct;2(5):415-22.

Brinton LA, Herrero R, Reeves WC, de Britton RC,   
Gaitan E, Tenorio F. Risk factors for cervical cancer by
histology. Gynecol Oncol 1993 Dec;51(3):301-6. 
Comment in: Gynecol Oncol 1993 Dec;51(3):299-300.

Cavalcanti SM, Frugulhetti IC, Passos MR, Fonseca ME,
Oliveira LH. Prevalence of human papillomavirus DNA
in female cervical lesions from Rio de Janeiro, Brazil.
Mem Inst Oswaldo Cruz 1994 Oct-Dec;89(4):575-80.

Cortit LI. Etiopathology of gynecological neoplasia and
contraception. Paper presented at: European Society of
Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Cote T, Schiffman M, Biggar R, Goedert J, Blattner W, et al.
Invasive cervical cancer among women with AIDS:
results of registry linkage [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1993;34:A1546.

Cote T, Schiffman M, Biggar R, Goedert J, Virgo P, 
Blattner W. Invasive cervical cancer among women with
AIDS: results of registry linkage. NACMR Study Group.
Int Conf AIDS 1993 Jun 6-11;9(1):408  (abstract no.  
PO-B14-1637).

Crook T, Farthing A. Human papillomavirus and cervical
cancer. Br J Hosp Med 1993 Jan 20-Feb 2;49(2):131-2.

Das BC, Gopalkrishna V, Das DK, Sharma JK, Singh V,
Luthra UK. Human papillomavirus DNA sequences in
adenocarcinoma of the uterine cervix in Indian women.
Cancer 1993 Jul 1;72(1):147-53.

DeBritton RC, Hildesheim A, De Lao SL, Brinton LA,
Sathya P, Reeves WC. Human papillomaviruses and other
influences on survival from cervical cancer in Panama.
Obstet Gynecol 1993 Jan;81(1):19-24.

Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ,
Walboomers JM. Human papillomavirus and invasive
cervical cancer in Brazil. Br J Cancer 1994 Jan;69(1):
114-9.

Fernandez C, Sharrard RM, Talbot M, Reed BD, Monks N.
Evaluation of the significance of polyamines and their
oxidases in the aetiology of human cervical carcinoma. 
Br J Cancer 1995 Nov;72(5):1194-9.

Gardner JW, Sanborn JS, Slattery ML. Behavioral factors
explaining the low risk for cervical carcinoma in Utah
Mormon women. Epidemiology 1995 Mar;6(2):187-9.

Guo WD, Hsing AW, Li JY, Chen JS, Chow WH, Blot WJ.
Correlation of cervical cancer mortality with reproductive
and dietary factors, and serum markers in China. Int J
Epidemiol 1994 Dec;23(6):1127-32.

Hernandez F, Herruzo A, Aguera J, Gomez T, Calderon
MA, Rodriguez-Oliver MA, Marcos C. [Risk factors for
cervical cancer in women younger than 20 years].    
Prog Obstet Ginecol 1995;38(7):458-64.  (Spa).

Herrero R, Brinton LA, Hartge P, Reeves WC, Brenes MM,
Urcuyo R, Pacheco M, Fuster F, Sierra R. Determinants
of the geographic variation of invasive cervical cancer in
Costa Rica. Bull Pan Am Health Organ 1993;27(1):15-25.

Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, 
Barnes W, Jones S, Tchabo JG, Brinton LA, Copeland C,
Epp J, et al. Determinants of genital human
papillomavirus infection in low-income women in
Washington, D.C. Sex Transm Dis 1993 Sep-Oct;20(5):
279-85.

Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP,
Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P,  
et al. The genetic drift of human papillomavirus type 16 is
a means of reconstructing prehistoric viral spread and the
movement of ancient human populations. J Virol 1993
Nov;67(11):6413-23.

Invasive squamous-cell cervical carcinoma and combined oral
contraceptives: results from a multinational study. WHO
Collaborative Study of Neoplasia and Steroid
Contraceptives. Int J Cancer 1993 Sep 9;55(2):228-36.

Jones WB, Shingleton HM, Russell A, Chmiel JS, Fremgen
AM, Clive RE, Zuber-Ocwieja KE, Winchester DP.
Patterns of care for invasive cervical cancer: results of a
National Survey of 1984 and 1990. Cancer 1995;    
76(10 Suppl):1934-47.

Kjaer SK, Engholm G, Dahl C, Bock JE, Lynge E, Jensen
OM. Case-control study of risk factors for cervical
squamous-cell neoplasia in Denmark. III. Role of oral
contraceptive use. Cancer Causes Control 1993 Nov;4(6):
513-9.

Klevens RM, Fleming PL, Mays M, Frey R. Characteristics
of HIV-infected women with invasive cervical cancer
(ICC), United States.  In: Program and abstracts of the
HIV Infection in Women Conference: Setting a new
agenda; 1995 Feb 22-24; Washington, DC. Richmond
(VA): Philadelphia Sciences Group; 1995. p. 103.

Kosary CL. FIGO stage, histology, histologic grade, age and
race as prognostic factors in determining survival for
cancers of the female gynecological system: an analysis
of 1973-87 SEER cases of cancers of the endometrium,
cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994 
Jan-Feb;10(1):31-46.

Kristiansen E, Jenkins A, Kristensen G, Ask E, Kaern J,
Abeler V, Lindqvist BH, Trope C, Kristiansen BE.
Human papillomavirus infection in Norwegian women
with cervical cancer. APMIS 1994 Feb;102(2):122-8.

La Vecchia C. Depot-medroxyprogesterone acetate, other
injectable contraceptives, and cervical neoplasia.
Contraception 1994 Mar;49(3):223-30.

La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term
impact of reproductive factors on cancer risk.      
Int J Cancer 1993;53(2):215-9.

Lazcano-Ponce EC, Rojas-Martinez R, Lopez-Acuna MP,
Lopez-Carrillo L, Hernandez-Avila M. [Reproductive
risk factors and uterine cervix cancer in Mexico City].
Salud Publica Mex 1993 Jan-Feb;35(1):65-73.  (Spa).

Modifications in the staging for stage I vulvar and stage I
cervical cancer. Report of the FIGO Committee on
Gynecologic Oncology. International Federation of
Gynecology and Obstetrics. Int J Gynaecol Obstet 1995
Aug;50(2):215-6.

Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE,
Ling CC, Komaki R, Marcial VA, Thomas GM,
Lanciano R. Carcinoma of the cervix: patterns of care
studies: review of 1978, 1983, and 1988-1989 surveys.
Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1481-6. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Jul 30;
32(5):1535-7.

1993 Revised classification system for HIV infection and
expanded surveillance case definition for AIDS among
adolescents and adults. JAMA 1993;269(6):729-30.

Pao CC, Kao SM, Tang GC, Lee K, Si J, Ruan S.
Prevalence of human papillomavirus DNA sequences in
an area with very high incidence of cervical carcinoma.
Br J Cancer 1994 Oct;70(4):694-6.

Poka R, Juhasz B, Lampe L. Cervical cancer in young
women: a poorer prognosis? Int J Gynaecol Obstet 1994
Jul;46(1):33-7.

Robertson D, Fedorkow DM, Stuart GC, McGregor SE,
Duggan MA, Nation G. Age is prognostic variable in
cervical squamous cell carcinoma. Eur J Gynaecol Oncol
1993;14(4):283-91.

Rose PG, Fraire AE. Multiple primary gynecologic
neoplasms in a young HIV-positive patient. J Surg Oncol
1993 Aug;53(4):269-72.

Saint-Paul MT, Bremond A, Rochet Y. [Cervical cancer
before 35 years of age: epidemiological and prognostic
aspects. Retrospective study of 46 cases of cervical
cancer before 35 years of age in a series of 449 cases in
stages IA2 and IV]. J Gynecol Obstet Biol Reprod (Paris)
1993;22(7):737-42.  (Fre).

Schiffman MH, Brinton LA. The epidemiology of cervical
carcinogenesis. Cancer 1995;76(10 Suppl):1888-901.

Schlesselman JJ. Net effect of oral contraceptive use on the
risk of cancer in women in the United States. Obstet
Gynecol 1995 May;85(5 Pt 1):793-801.

Serur E, Fruchter RG, Maiman M, McGuire J, Arrastia CD,
Gibbon D. Age, substance abuse, and survival of patients
with cervical carcinoma. Cancer 1995 May 15;75(10):
2530-8.

Sparen P, Gustafsson L, Friberg LG, Ponten J, Bergstrom R,
Adami HO. Improved control of invasive cervical cancer
in Sweden over six decades by earlier clinical detection
and better treatment. J Clin Oncol 1995 Mar;13(3):   
715-25.

Stone KM, Zaidi A, Rosero-Bixby L, Oberle MW,  
Reynolds G, Larsen S, Nahmias AJ, Lee FK,    
Schachter J, Guinan ME. Sexual behavior, sexually
transmitted diseases, and risk of cervical cancer.
Epidemiology 1995 Jul;6(4):409-14.

Weiss LK, Kau TY, Sparks BT, Swanson GM. Trends in
cervical cancer incidence among young black and white
women in metropolitan Detroit. Cancer 1994 Apr 1;73(7):
1849-54.

Williams MA, Kenya PR, Mati JK, Thomas DB. Risk factors
for invasive cervical cancer in Kenyan women.           
Int J Epidemiol 1994 Oct;23(5):906-12.

Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of
cervical neoplasia? Results from a combined analysis of
24 studies. Int J Epidemiol 1994 Aug;23(4):682-90.

Zhang ZF, Graham S, Yu SZ, Marshall J, Zielezny M, Chen
YX, Sun M, Tang SL, Liao CS, Xu JL, et al.
Trichomonas vaginalis and cervical cancer. A prospective
study in China. Ann Epidemiol 1995 Jul;5(4):325-32.

Screening Patterns


Adami HO, Ponten J, Sparen P, Bergstrom R, Gustafsson L,
Friberg LG. Survival trend after invasive cervical cancer
diagnosis in Sweden before and after cytologic screening.
1960-1984. Cancer 1994 Jan 1;73(1):140-7.

Agarwal SS, Murthy NS, Sharma S, Sharma KC, Das DK.
Evaluation of a hospital based cytology screening
programme for reduction in life time risk of cervical
cancer. Neoplasma 1995;42(2):93-6.

Anderson LM, May DS. Has the use of cervical, breast, and
colorectal cancer screening increased in the United
States? Am J Public Health 1995 Jun;85(6):840-2.

Andrews HF, Kerner JF, Zauber AG, Mandelblatt J,  
Pittman J, Struening E. Using census and mortality data
to target small areas for breast, colorectal, and cervical
cancer screening. Am J Public Health 1994 Jan;84(1): 
56-61.

Ansell D, Lacey L, Whitman S, Chen E, Phillips C. A
nurse-delivered intervention to reduce barriers to breast
and
cervical cancer screening in Chicago inner city clinics.
Public Health Rep 1994 Jan-Feb;109(1):104-11.

Ashford AR, Neugut AI, Lantigua R, Gemson D, Bloch S,
Saxon J, Perez B. Attitudes towards cancer screening
among primary care physicians practicing in urban
minority communities [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1995;14:A337.

Austoker J. Cancer prevention in primary care. Screening for
cervical cancer. BMJ 1994 Jul 23;309(6949):241-8.  
Published erratum appears in BMJ 1994 Aug 13;
309(6952):452.

Azeem Majeed F, Cook DG, Anderson HR, Hilton S,   
Bunn S, Stones C. Using patient and general practice
characteristics to explain variations in cervical smear
uptake rates. Br Med J 1994;308(6939):1272-6.

Bailie R, Barron P, Learmonth G. Towards a rational
cervical cytology screening strategy. Case study of a
peri-urban settlement. S Afr Med J 1995 Jan;85(1):30-3.

Banner RO, DeCambra H, Enos R, Gotay C, Hammond
OW, Hedlung N, Issell BF, Matsunaga DS, Tsark JA. A
breast and cervical cancer project in a native Hawaiian
community: Wai'anae cancer research project. Prev Med
1995 Sep;24(5):447-53.

Berman BA, Bastani R, Nisenbaum R, Henneman CA,
Marcus AC. Cervical cancer screening among a low-income
multiethnic population of women. J Womens
Health 1994;3(1):33-43.

Bjorge T, Gunbjorud AB, Langmark F, Skare GB, Thoresen
SO. Cervical mass screening in Norway--510,000 smears
a year. Cancer Detect Prev 1994;18(6):463-70.

Bonaldi A, Crescini C, Giarolo MA, Baldone T, Artuso A,
Pezzica E. Results of an 'active call system' for early
detection of cervical carcinoma by postage of
personalized invitations to Pap smears. Cervix Low
Female Genital Tract 1993;11(2):53-7.

Boon ME, Beck S, Wijsman-Grootendorst A. Involving the
general practitioner in screening for cervical cancer.
Cytopathology 1994 Apr;5(2):69-75.

Bradley SM, Friedman EH. Cervical cytology screening: a
comparison of uptake among 'Asian' and 'non-Asian'
women in Oldham. J Public Health Med 1993;15(1):   
46-51.

Breast and cervical cancer screening among underserved
women. Baseline survey results from six states. The
National Cancer Institute Cancer Screening Consortium
for Underserved Women. Arch Fam Med 1995 Jul;4(7):
617-24.

Burger RA, Monk BJ, Van Nostrand KM, Greep N, Anton-Culver
H, Manetta A. Single-visit program for cervical
cancer prevention in a high-risk population.           
Obstet Gynecol 1995 Oct;86(4 Pt 1):491-8.

Burnett CB, Steakley CS, Tefft MC. Low-income, minority
women. Barriers to cancer screening. Ann N Y Acad Sci
1995 Sep 30;768:277-80.

Byles JE, Redman S, Sanson-Fisher RW, Boyle CA.
Effectiveness of two direct-mail strategies to encourage
women to have cervical (Pap) smears. Health Promot Int
1995;10(1):5-16.

Calle EE, Flanders WD, Thun MJ, Martin LM.
Demographic predictors of mammography and Pap smear
screening in US women. Am J Public Health 1993;83(1):
53-69.

Carey P, Gjerdingen DK. Follow-up of abnormal
Papanicolaou smears among women of different races.   
J Fam Pract 1993 Dec;37(6):583-7.

Chang AR. Some aspects of cervical screening in southern
New Zealand; the situation before implementation of the
national cervical cancer prevention programme.
Cytopathology 1993;4(2):67-76.

Chavez LR, Hubbell FA, McMullin JM, Martinez RG,
Mishra SI. Structure and meaning in models of breast and
cervical cancer risk factors: a comparison of perceptions
among Latinas, Anglo women, and physicians.         
Med Anthropol Q 1995 Mar;9(1):40-74.  Comments in:
Med Anthropol Q 1995 Mar;9(1):75-9; Med Anthropol Q
1995 Mar;9(1):77-9.

Chen F, Trapido EJ, Davis K. Differences in stage at
presentation of breast and gynecologic cancers among
whites, blacks, and Hispanics. Cancer 1994 Jun 1;73(11):
2838-42.

Crombie IK, Orbell S, Johnston G, Robertson AJ,     
Kenicer M. Women's experiences at cervical screening.    
Scott Med J 1995;40(3):81-2.

Davis DT, Bustamante A, Brown CP, Wolde-Tsadik G,
Savage EW, Cheng X, Howland L. The urban church
and cancer control: a source of social influence in
minority communities. Public Health Rep 1994 Jul-Aug;
109(4):500-6.

Dhamija S, Sehgal A, Luthra UK, Sehgal K. Factors
associated with awareness and knowledge of cervical
cancer in a community: implication for health education
programmes in developing countries. J R Soc Health
1993 Aug;113(4):184-6.

Dignan M, Michielutte R, Wells HB, Bahnson J. The Forsyth
County Cervical Cancer Prevention Project--I. Cervical
cancer screening for black women. Health Educ Res 1994
Dec;9(4):411-20.

Dignan M, Sharp P, Blinson K, Michielutte R, Konen J,  
Bell R, Lane C. Development of a cervical cancer
education program for native American women in North
Carolina. J Cancer Educ 1995 Winter;9(4):235-42.

Franks P, Clancy CM. Physician gender bias in clinical
decisionmaking: screening for cancer in primary care.
Med Care 1993 Mar;31(3):213-8.

Gilbert TJ, Sugarman JR, Cobb N. Abnormal Papanicolaou
smears and colposcopic follow-up among American
Indian and Alaska Native women in the Pacific northwest.
J Am Board Fam Pract 1995 May-Jun;8(3):183-8.

Goldman DA, Simpson DM. Survey of El Paso physicians'
breast and cervical cancer screening attitudes and
practices. J Community Health 1994 Apr;19(2):75-85.

Gregg J, Curry RH. Explanatory models for cancer among
African-American women at two Atlanta neighborhood
health centers: the implications for a cancer screening
program. Soc Sci Med 1994 Aug;39(4):519-26.

Hakama M. Potential contribution of screening to cancer
mortality reduction. Cancer Detect Prev 1993;17(4-5):
513-20.

Harris JM Jr. Papanicolaou smear recommendations, patient
complaints, and patient satisfaction in managed-care
medical organizations. Med Care 1995 Mar;33(3):272-9.

Himmelstein DU, Woolhandler S. Care denied: US residents
who are unable to obtain needed medical services.      
Am J Public Health 1995;85(3):341-4.

Hojgaard Nielsen N, Jensen H. Screening for cancer of the
uterine cervix in Greenland. APMIS 1993;101(4):290-4.

Holland BK, Foster JD, Louria DB. Cervical cancer and
health care resources in Newark, New Jersey, 1970 to
1988. Am J Public Health 1993 Jan;83(1):45-8.

Howe HL, Lehnherr M, Qualls RY. Using central
cancer-registry data to monitor progress in early detection
of
breast and cervical cancer (Illinois, United States).
Cancer Causes Control 1995 Mar;6(2):155-63.

Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM,
Meigs JW, Merino MJ, Flannery JT, Polednak AP. The
screening histories of women with invasive cervical
cancer, Connecticut. Am J Public Health 1995 Jun;85(6):
791-4.  Comment in: Am J Public Health 1995 Jun;85(6):
762-3.

Jayant K, Rao RS, Nene BM, Dale PS. Early diagnosis of
cervical cancers. Our experience at the Rural Cancer
Registry, Barshi, India. Indian J Cancer 1994 Jun;31(2):
59-63.

Jayant K, Rao RS, Nene BM, Dale PS. Improved stage at
diagnosis of cervical cancer with increased cancer
awareness in a rural Indian population. Int J Cancer 1995
Oct 9;63(2):161-3.

Kang SH, Bloom JR, Romano PS. Cancer screening among
African-American women: their use of tests and social
support. Am J Public Health 1994 Jan;84(1):101-3.

Kaplan CP, Bastani R, Marcus A, Breslow L, Nasseri K,
Chen L. Low-income women with cervical abnormalities:
individual and system factors affecting follow-up.           
J Womens Health 1995;4(2):179-88.

Katz SJ, Hofer TP. Socioeconomic disparities in preventive
care persist despite universal coverage. Breast and
cervical cancer screening in Ontario and the United
States. JAMA 1994 Aug 17;272(7):530-4.

Klassen AC, Celentano DD, Weisman CS. Cervical cancer
screening in hospitals: the efficacy of legislation in
Maryland. Am J Public Health 1993 Sep;83(9):1316-20.

Kottke TE, Trapp MA, Fores MM, Kelly AW, Jung SH,
Novotny PJ, Panser LA. Cancer screening behaviors and
attitudes of women in southeastern Minnesota. JAMA
1995 Apr 12;273(14):1099-105.

Lamont DW, Symonds RP, Brodie MM, Nwabineli NJ, Gillis
CR. Age, socio-economic status and survival from cancer
of cervix in the West of Scotland 1980-87. Br J Cancer
1993 Feb;67(2):351-7.  Comment in: Br J Cancer 1993
Jul;68(1):213.

Lantz PM, Stencil D, Lippert MT, Beversdorf S, Jaros L,
Remington PL. Breast and cervical cancer screening in a
low-income managed care sample: the efficacy of
physician letters and phone calls. Am J Public Health
1995 Jun;85(6):834-6.  Published erratum appears in  
Am J Public Health 1995 Aug;85(8 Pt 1):1063.

Leslie NS. Role of the nurse practitioner in breast and
cervical cancer prevention. Cancer Nurs 1995 Aug;18(4):
251-7.

Levi F, La Vecchia C, Randimbison L, Te VC. Incidence,
mortality and survival from invasive cervical cancer in
Vaud, Switzerland, 1974-1991. Ann Oncol 1994 Oct;
5(8):747-52.

Lewis D, Mitchell H. An evaluation of cervical screening in
general practice. Med J Aust 1994 May 16;160(10):  
628-32.

Lobell M, Bay C, Rhoads K, Keske B. Barriers to cancer
screening in Hispanic women [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1994;13:A466.

London L. Pap smear coverage among rural workers. S Afr
Med J 1993;83(3):172-6.

Lubitz RM, Litzelman DK, Dittus RS, Tierney WM. Is
obesity a barrier to physician screening for cervical
cancer? Am J Med 1995 May;98(5):491-6.

Mandelblatt J, Traxler M, Lakin P, Kanetsky P, Kao R.
Targeting breast and cervical cancer screening to elderly
poor black women: who will participate? The Harlem
Study Team. Prev Med 1993 Jan;22(1):20-33.

Mandelblatt J, Traxler M, Lakin P, Kanetsky P, Thomas L,
Chauhan P, Matseoane S, Ramsey E. Breast and cervical
cancer screening of poor, elderly, black women: clinical
results and implications. Harlem Study Team. Am J Prev
Med 1993 May-Jun;9(3):133-8.

Mandelblatt J, Traxler M, Lakin P, Thomas L, Chauhan P,
Matseoane S, Kanetsky P. A nurse practitioner
intervention to increase breast and cervical cancer
screening for poor, elderly black women. The Harlem
Study Team. J Gen Intern Med 1993 Apr;8(4):173-8.

Matsubara M. [Clinical significance of magnetic resonance
imaging (MRI) in evaluation of the extension of uterine
cervical cancer]. Nippon Sanka Fujinka Gakkai Zasshi
1993 Oct;45(10):1115-22.  (Jpn).

McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine,
and cervical cancer in the elderly woman. Clin Geriatr
Med 1993 Feb;9(1):115-30.

Meshack AF. For health's sake: cervical and breast cancer
screening [dissertation]. [Houston]: Univ. of Texas
Health Science Center at Houston School of Public
Health; 1993. 152 p.  Available from: University
Microfilms International, Ann Arbor, MI; AAD94-01777.

Michielutte R, Dignan M, Bahnson J, Wells HB. The Forsyth
County Cervical Cancer Prevention Project--II.
Compliance with screening follow-up of abnormal
cervical smears. Health Educ Res 1994 Dec;9(4):421-32.

Michielutte R, Sharp PC, Dignan MB, Blinson K. Cultural
issues in the development of cancer control programs for
American Indian populations. J Health Care Poor
Underserved 1994;5(4):280-96.

Modiano M, Buller D, Meister J, de Zapien J, Lash S,
Villar-Werstler P, Santa Cruz V. Lay health educators
(promotoras) improve cancer awareness and screening in
minority population: the juntos contra el cancer model. 
Paper presented at: 17th Annual Meeting of the American
Society of Preventive Oncology; 1993 Mar 20-23;
Tucson, AZ.

Munoz N, Bosch FX, de Sanjose SD, Shah KV. The role of
HPV in the etiology of cervical cancer. Mutat Res 1994;
305(2):293-301.

Murray M, McMillan C. Social and behavioural predictors of
women's cancer screening practices in Northern Ireland.
J Public Health Med 1993 Jun;15(2):147-53.

Murthy NS, Agarwal SS, Prabhakar AK, Sharma S, Das DK.
Estimation of reduction of life-time risk of cervical cancer
through one life-time screening. Neoplasma 1993;
40(4):255-8.

Naish J, Brown J, Denton B. Intercultural consultations:
investigation of factors that deter non-English speaking
women from attending their general practitioners for
cervical screening. BMJ 1994 Oct 29;309(6962):1126-8. 
Comment in: BMJ 1995 Jan 21;310(6973):194.

Orbell S, Crombie I, Robertson A, Johnston G, Kenicer M.
Assessing the effectiveness of a screening campaign: who
is missed by 80% cervical screening coverage? J R Soc
Med 1995 Jul;88(7):389-94.

Orr ST, Celentano DD, Hill G, Erozan YS, Shediac M,
Correa-Villasenor A, Matanoski G. Use of laboratory
reports to assess cervical cancer screening in a
community. Am J Prev Med 1994 Jul-Aug;10(4):235-7.

Palm BT, Kant AC, van den Bosch WJ, Vooijs GP,         
van Weel C. Preliminary results of a general practice
based call system for cervical cancer screening in The
Netherlands. Br J Gen Pract 1993 Dec;43(377):503-6.

Popovic D, Komaromi M, Popovic M. [Attitudes of spouses
toward examinations for the early detection of cervical
and breast carcinoma]. Med Pregl 1993;46(3-4):128-32. 
(Scr).

Pritchard DA, Straton JA, Hyndman J. Cervical screening in
general practice. Aust J Public Health 1995 Apr;19(2):
167-72.  Comment in: Aust J Public Health 1995 Apr;
19(2):115-7.

Results from the National Breast and Cervical Cancer Early
Detection Program, October 31, 1991-September 30,
1993. MMWR Morb Mortal Wkly Rep 1994 Jul 29;
43(29):530-4.

Rudolph A, Kahan V, Bordeu M. Cervical cancer prevention
project for inner city black and Latina women. Public
Health Rep 1993 Mar-Apr;108(2):156-60.

Seibt AC. Information sources influencing urban
Mexican-American women's cancer screening participation
[dissertation]. [Houston]: Univ. of Texas Health Science
Center at Houston School of Public Health; 1993. 237 p. 
Available from: University Microfilms International, Ann
Arbor, MI; AAD94-22050.

Seow A, Lee HP. Prevalence and determinants of cervical
cancer screening: a community-based study in Singapore.
Ann Acad Med Singapore 1994 May;23(3):342-7.

Seow A, Wong ML, Smith WC, Lee HP. Beliefs and
attitudes as determinants of cervical cancer screening: a
community-based study in Singapore. Prev Med 1995
Mar;24(2):134-41.

Sheridan-Leos N. Women's Health Loteria: a new cervical
cancer education tool for Hispanic females. Oncol Nurs
Forum 1995 May;22(4):697-701.

Slater DN. Multifactorial audit of invasive cervical cancer:
key lessons for the National Screening Programme. J Clin
Pathol 1995 May;48(5):405-7.

Slater DN, Milner PC, Radley H. Audit of deaths from
cervical cancer: proposal for an essential component of
the National Screening Programme. J Clin Pathol 1994
Jan;47(1):27-8.  Comment in: J Clin Pathol 1994 Sep;
47(9):867.

Smith MK. Implementing annual cancer screenings for
elderly women. J Gerontol Nurs 1995 Jul;21(7):12-7.

Stillwater B, Echavarria VA, Lanier AP. Pilot test of a
cervical cancer prevention video developed for Alaska
Native women. Public Health Rep 1995 Mar-Apr;110(2):
211-4.

Straton JA, Holman CD, Edwards BM. Cervical cancer
screening in Western Australia in 1992: progress since
1983. Med J Aust 1993 Nov 15;159(10):657-61.

Straton JA, Sutherland GJ, Hyndman JC. Cervical cancer
screening for hospital inpatients: report of an intervention
study. Aust J Public Health 1995 Jun;19(3):288-93.

Suarez L, Lloyd L, Weiss N, Rainbolt T, Pulley L. Effect of
social networks on cancer-screening behavior of older
Mexican-American women. J Natl Cancer Inst 1994;
86(10):775-9.

Summers A, Fullard B. Improving the coverage and quality
of cervical screening: women's views. J Public Health
Med 1995;17(3):277-81.

Swaddiwudhipong W, Chaovakiratipong C, Nguntra P,
Mahasakpan P, Lerdlukanavonge P, Koonchote S. Effect
of a mobile unit on changes in knowledge and use of
cervical cancer screening among rural Thai women. Int J
Epidemiol 1995 Jun;24(3):493-8.

Thomas SM, Fick AC. Women's health: early detection and
screening practices for breast and cervical cancer.          
J La State Med Soc 1994 Apr;146(4):152-8.

Watring W, Binstock M, Hackett J, Pretorius G,     
Anguiano H, Hyatt J, Bredt A. Cervical cancer screening
in a large HMO: effects of evidence-based clinical
practice guideline (CPG) on pap smear utilization
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:
A473.

Watson EJ. Decision-making style, motivation, and use of
papanicolaou screening tests in women age 35 and older
[dissertation]. [Columbia]: Univ. of South Carolina; 1993.

292 p.  Available from: University Microfilms
International, Ann Arbor, MI; AAD93-22004.

Webb J. Health promotion. Cervical screening update.   
Nurs Times 1994 Oct 26-Nov 1;90(43):37.

Weinrich S, Coker AL, Weinrich M, Eleazer GP, Greene
FL. Predictors of Pap smear screening in
socioeconomically disadvantaged elderly women.           
J Am Geriatr Soc 1995 Mar;43(3):267-70.

White GE. Older women's attitudes to cervical screening and
cervical cancer: a New Zealand experience. J Adv Nurs
1995 Apr;21(4):659-66.

White JE, Begg L, Fishman NW, Guthrie B, Fagan JK.
Increasing cervical cancer screening among minority
elderly. Education and on-site services increase
screening. J Gerontol Nurs 1993 May;19(5):28-34.

Whitman S, Lacey L, Ansell D, Chen EH, Dell J, Phillips
CW. Do chart reviews and interviews provide the same
information about breast and cervical cancer screening?
Int J Epidemiol 1993 Jun;22(3):393-7.

Whitman S, Lacey L, Ansell D, Dell J, Chen E, Phillips CW.
An intervention to increase breast and cervical cancer
screening in low-income African-American women.  
Fam Community Health 1994 Apr;17(1):56-63.

Wilcox LS, Mosher WD. Factors associated with obtaining
health screening among women of reproductive age.
Public Health Rep 1993 Jan-Feb;108(1):76-86.

Yajima A, Yaegashi N, Sato S. Cervical cancer control in
Japan. Arch STD HIV Res 1994;8(1-2):89-99.

Yancey AK, Tanjasiri SP, Klein M, Tunder J. Increased
cancer screening behavior in women of color by
culturally sensitive video exposure. Prev Med 1995 Mar;
24(2):142-8.

Yancey AK, Walden L. Stimulating cancer screening among
Latinas and African-American women. A community case
study. J Cancer Educ 1994;9(1):46-52.

Yi JK. Factors associated with cervical cancer screening
behavior among Vietnamese women. J Community Health
1994 Jun;19(3):189-200.

Screening


Allen KA, Zaleski MS, Cohen MB. Laboratory use of the
diagnosis reactive/reparative in gynecologic smears:
impact of CLIA '88. Mod Pathol 1995 Apr;8(3):266-9.

Aponte-Cipriani SL, Teplitz C, Rorat E, Savino A, Jacobs
AJ. Cervical smears prepared by an automated device
versus the conventional method. A comparative analysis.
Acta Cytol 1995 Jul-Aug;39(4):623-30.

Ashfaq R, Liang Y, Saboorian MH. Evaluation of
PAPNET(TM) system for rescreening of negative
cervical smears. Diagn Cytopathol 1995;13(1):31-6.

Awen C, Hathway S, Eddy W, Voskuil R, Janes C,
Hutchinson M. Efficacy of ThinPrep (R) preparation of
cervical smears: a 1,000-case, investigator-sponsored
study. Diagn Cytopathol 1994;11(1):33-7.

Baldauf JJ, Dreyfus M, Lehmann M, Ritter J, Philippe E.
Cervical cancer screening with cervicography and
cytology. Eur J Obstet Gynecol Reprod Biol 1995 Jan;
58(1):33-9.

Boon ME, Schut JJ, Benita EM, Kok LP. Confocal optical
sectioning and three-dimensional reconstruction of
carcinoma fragments in Pap smears using sophisticated
image data processing. Diagn Cytopathol 1994;10(3):
268-75.

Bur M, Knowles K, Pekow P, Corral O, Donovan J.
Comparison of ThinPrep preparations with conventional
cervicovaginal smears. Practical considerations.        
Acta Cytol 1995 Jul-Aug;39(4):631-42.

Burkman RT, Ward R, Balchandani K, Kini S. A continuous
quality improvement project to improve the quality of
cervical Papanicolaou smears. Obstet Gynecol 1994;
84(3):470-5.

Carothers A, McGoogan E, Vooijs P, Bird C, Colquhoun M,
Eason P, McKie M, Nieuwenhuis F, Pitt P, Rutovitz D,
Stark M, Tucker J, Van Orsouw A. A collaborative trial
of a semi-automatic system for slide preparation and
screening in cervical cytopathology. Anal Cell Pathol
1994;7(4):261-74.

Chudleigh MF. Hazard analysis of a computer based medical
diagnostic system. Comput Methods Programs Biomed
1994 Jul;44(1):45-54.

Hailey DM, Lea AR. New technologies in cervical cancer
screening--realities for a national program [abstract].
Annu Meet Int Soc Technol Assess Health Care 1994:
[Abstract No. 044].

Hutchinson ML, Isenstein LM, Goodman A, Hurley AA,
Douglass KL, Mui KK, Patten FW, Zahniser DJ.
Homogeneous sampling accounts for the increased
diagnostic accuracy using the ThinPrep Processor. Am J
Clin Pathol 1994 Feb;101(2):215-9.  Comment in: Am J
Clin Pathol 1994 Feb;101(2):121-2.

Koss LG, Lin E, Schreiber K, Elgert P, Mango L.
Evaluation of the PAPNET cytologic screening system for
quality control of cervical smears. Am J Clin Pathol 1994
Feb;101(2):220-9.

Laverty CR, Thurloe JK, Redman NL, Farnsworth A. An
Australian trial of ThinPrep: a new cytopreparatory
technique. Cytopathology 1995 Jun;6(3):140-8.

Sherman ME, Mango LJ, Kelly D, Paull G, Ludin V,
Copeland C, Solomon D, Schiffman MH. PAPNET
analysis of reportedly negative smears preceding the
diagnosis of a high-grade squamous intraepithelial lesion
or carcinoma. Mod Pathol 1994 Jun;7(5):578-81.

Slagel DD, Zaleski S, Cohen MB. Efficacy of automated
cervical cytology screening. Diagn Cytopathol 1995;
13(1):26-30.

Wilbur DC, Cibas ES, Merritt S, James LP, Berger BM,
Bonfiglio TA. ThinPrep Processor. Clinical trials
demonstrate an increased detection rate of abnormal
cervical cytologic specimens. Am J Clin Pathol 1994
Feb;101(2):209-14.  Comments in: Am J Clin Pathol
1994 Feb;101(2):121-2; Am J Clin Pathol 1994 Oct;
102(4):557-8.

Prevention


Alvarez RD, Helm CW, Edwards RP, Naumann RW,
Partridge EE, Shingleton HM, McGee JA, Hall JB,
Higgins RV, Malone JM Jr. Prospective randomized trial
of LLETZ versus laser ablation in patients with cervical
intraepithelial neoplasia. Gynecol Oncol 1994 Feb;52(2):
175-9.

Andersen ES, Pedersen B, Nielsen K. Laser conization: the
results of treatment of cervical intraepithelial neoplasia.
Gynecol Oncol 1994 Aug;54(2):201-4.

Backe J, Roos T, Kaesemann H, Martius J, Ott M. [Local
therapy and adjuvant interferon therapy in genital
papilloma virus infections]. Gynakol Geburtshilfliche
Rundsch 1995;35(2):79-84.  (Ger).

Bergstrom R, Adami HO, Gustafsson L, Ponten J, Sparen P.
Detection of preinvasive cancer of the cervix and the
subsequent reduction in invasive cancer. J Natl Cancer
Inst 1993 Jul 7;85(13):1050-7.  Comment in: J Natl
Cancer Inst 1993 Jul 7;85(13):1018-9.

Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read
MD. Efficacy and safety of large-loop excision of the
transformation zone. Lancet 1994 Jan 1;343(8888):32-4.

Brady JL, Fish ANJ, Woolas RP, Brown CL, Oram DH.
Large loop diathermy of the transformation zone: is 'see
and treat' an acceptable option for the management of
women with abnormal cervical smears? J Obstet Gynecol
1994;14(1):44-9.

Chen RD. [Chemoprevention of cervical cancer--intervention
study of cervical precancerous lesions by retinamide II
and riboflavin]. Chung Hua Chung Liu Tsa Chih 1993
Jul;15(4):272-4.  (Chi).

Chen RD, Ding AH, Han R. [A study on chemoprevention of
retinamide II from cervical precancerous lesions]. Chung
Hua Yu Fang I Hsueh Tsa Chih 1994 Mar;28(2):75-7. 
(Chi).

Chen RJ, Lee EF, Shih JC. Does the loop electrosurgical
excision procedure adversely affect the histopathological
interpretation of cervical conization specimens? Acta
Obstet Gynecol Scand 1994 Oct;73(9):726-9.

Childers JM, Chu J, Voigt LF, Feigl P, Tamimi HK,
Franklin EW, Alberts DS, Meyskens FL Jr.
Chemoprevention of cervical cancer with folic acid: a
phase III Southwest Oncology Group Intergroup study.
Cancer Epidemiol Biomarkers Prev 1995 Mar;4(2):155-9.

Harper DM, Roach MS. Cervical intraepithelial neoplasia in
pregnancy. J Fam Pract 1996 Jan;42(1):79-83.

Lie AK, Skjeldestad FE, Hagen B, Haugen OA. Occurrence
of human papillomavirus infection in cervical
intraepithelial neoplasia. A retrospective histopathological
study of 317 cases treated by laser conization. APMIS
1995 Oct;103(10):693-8.

Meyskens F, Surwit E, Childers J, Moon T, Shell M,   
Davis J, Alberts DS. Phase III randomized trial of
trans-retinoic acid to prevent progression of cervical
intraepithelial neoplasia (CIN): would new biomarkers
have helped along the way? Paper presented at: CCPC-93: 2nd
International Cancer Chemo Prevention
Conference; 1993 Apr 28-30; Berlin, Germany.

Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis
JR, Dorr RT, Johnson CS, Alberts DS. Enhancement of
regression of cervical intraepithelial neoplasia II
(moderate dysplasia) with topically applied
all-trans-retinoic acid: a randomized trial. J Natl Cancer
Inst 1994
Apr 6;86(7):539-43.  Comment in: J Natl Cancer Inst
1994 Apr 6;86(7):476-7.

Meyskens FL Jr, Surwit E, Moon TE, Davis J, Alberts DS.
A placebo-controlled, randomized phase III trial of locally
applied beta-trans-retinoic acid (vitamin A acid, RA) in
cervical intraepithelial neoplasia (CIN): favorable effect
on CIN II (moderate dysplasia) [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1993;12:A465.

Mitchell MF, Hittelman WK, Lotan R, Nishioka K,
Tortolero-Luna G , Richards-Kortum R, Wharton JT,
Hong WK. Chemoprevention trials and surrogate end
point biomarkers in the cervix. Cancer 1995;          
76(10 Suppl):1956-77.

Mitchell MF, Hittelman WN, Hong WK, Lotan R,
Schottenfeld D. The natural history of cervical
intraepithelial neoplasia: an argument for intermediate
endpoint biomarkers. Cancer Epidemiol Biomarkers Prev
1994 Oct-Nov;3(7):619-26.

Puig-Tintore LM, Jou P. Laser or conization for treatment of
CIN III long-term results. Paper presented at: European
Society of Gynaecological Oncology 8th International
Meeting: Prevention, early detection, diagnosis,
management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Wright TC Jr, Richart RM. Loop excision of the uterine
cervix. Curr Opin Obstet Gynecol 1995;7(1):30-4.

MANAGEMENT OF LOW-STAGE CERVICAL
CANCER (FIGO I-IIA)

Pathology and Prognostic factors


Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell
carcinoma of the cervix. A clinicopathologic study of 26
patients. Cancer 1994 Feb 1;73(3):672-7.

al-Nafussi AI, Hughes DE. Histological features of CIN3 and
their value in predicting invasive microinvasive squamous
carcinoma. J Clin Pathol 1994 Sep;47(9):799-804.

al-Nafussi AI, Klys HS, Rebello G, Kelly C, Kerr G,   
Cowie V. The assessment of proliferating cell nuclear
antigen (PCNA) immunostaining in the uterine cervix and
cervical squamous neoplasia. Int J Gynecol Cancer 1993;
3(3):154-8.

al-Saleh W, Delvenne P, Arrese JE, Nikkels AF, Pierard GE,
Boniver J. Inverse modulation of intraepithelial
Langerhans' cells and stromal macrophage/dendrocyte
populations in human papillomavirus-associated squamous
intraepithelial lesions of the cervix. Virchows Arch 1995;
427(1):41-8.

Allen DG, Roovers JPW, Van Lindert ACM, Heintz APM.
Early stage cervical cancer: a multivariate analysis of
histopathological prognostic factors. Aust N Z J Obstet
Gynaecol 1994;34(5):553-6.

Arai T, Nakano T, Oka K. Local control prediction by
histologic grading or radiation effects with drill biopsy
specimens for uterine cervical cancer. Int J Radiat Oncol
Biol Phys 1993 Nov 15;27(4):811-6.

Attanoos R, Nahar K, Bigrigg A, Roberts S, Newcombe RG,
Ismail SM. Primary adenocarcinoma of the cervix. A
clinicopathologic study of prognostic variables in 55
cases. Int J Gynecol Cancer 1995;5(3):179-86.

Beynon DWG, Lopes A, Robertson G, Daras V, Monaghan
JM. Squamous cell carcinoma antigen: pretreatment
levels as an indicator of advanced or metastatic disease.
Int J Gynecol Cancer 1994;4(3):206-10.

Bichel P, Jakobsen A, Nielsen K, Holund B, Visfeldt J.
Prediction of lymph node metastases in patients with early
squamous cell carcinoma of the cervix uteri by
histopathological grading and flow cytometry. Eur J
Cancer 1993;29A(3):337-40.

Bolli JA, Doering DL, Bosscher JR, Day TG Jr, Rao CV,
Owens K, Kelly B, Goldsmith J. Squamous cell
carcinoma antigen: clinical utility in squamous cell
carcinoma of the uterine cervix. Gynecol Oncol 1994
Nov;55(2):169-73.

Bremer GL, Tiebosch AT, van der Putten HW, de Haan J,
Arends JW. Basement membranes in cervical cancer:
relationship to pelvic lymph node metastasis and
prognosis. Gynecol Oncol 1995 Jun;57(3):351-5.

Burke TW. Clinical and pathological risk factors in stage I
cervical cancer. Clin Consult Obstet Gynecol 1995;7(2):
118-25.

Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH,    
Chard T. The prognostic significance of urinary beta core
fragment in premenopausal women with carcinoma of the
cervix. Gynecol Oncol 1994 Nov;55(2):271-6.

Chen CA, Wu CC, Chen TM, Lui LT, Chang CF, Hsieh
CY. Cell kinetics and radiosensitivity of cervical
squamous cell carcinoma. Cancer Lett 1994 Jul 29;82(2):
135-40.

Chou CY, Wang ST, Kuo HC, Tzeng CC, Yao BL. Serum
level of squamous cell carcinoma antigen and tumor size
are useful to identify preoperatively patients at high risk
of cervical cancer. Cancer 1994 Nov 1;74(9):2497-501.

Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker
AW, Lurain JR. Flow cytometric evaluation of early
invasive cervical cancer. Obstet Gynecol 1993 Mar;81(3):
367-71.

Costa MJ, Walls J, Trelford JD. c-erbB-2 oncoprotein
overexpression in uterine cervix carcinoma with glandular
differentiation. A frequent event but not an independent
prognostic marker because it occurs late in the disease.
Am J Clin Pathol 1995 Dec;104(6):634-42.

Davidson SE, Ngan R, Wilks DP, Moore JV, West CML. A
comparison of four methods for assessing tumour
vascularity in carcinoma of the cervix. Int J Oncol 1994;
5(3):639-45.

Duk JM, Groenier KH, ten Hoor KA, Aalders JG, de Bruijn
HW. SCC-antigen, a new prognostic factor in cervical
cancer [abstract]. Proc Annu Meet Am Assoc Cancer Res
1995;36:A1456.

Elliott P. Lymph node metastases, cell type, age, HPV status
and type, neoadjuvant chemotherapy and treatment
failures in cervical cancer. Int J Gynaecol Obstet 1995
Jul;49 Suppl:S17-25.

Fujimoto I, Umezawa S, Hirai Y, Hasumi K. Behavioral
analysis of microinvasive carcinoma of uterine cervix
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1994;
35:A1216.

Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic
factors and relapse patterns in early-stage cervical
carcinoma after brachytherapy and radical hysterectomy.
Gynecol Oncol 1994 Jun;53(3):314-9.

Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J,
Wilcox FL. Prognostic value of epidermal growth factor
receptor expression in cervical carcinoma. J Clin Pathol
1993 Feb;46(2):149-53.

Helm CW, Kinney WK, Keeney G, Lawrence WD, Frank
TS, Gore H, Reynolds RK, Soong SJ, Partridge EE,
Roberts J, Podratz K, Shingleton HM. A matched study
of surgically treated stage IB adenosquamous carcinoma
and adenocarcinoma of the uterine cervix. Int J Gynecol
Cancer 1993;3(4):245-9.

Himmelmann A, Ferno M, Langstrom-Einarsson E, 
Stendahl U, Trope C, Willen R. The influence of risk
factors and treatment on survival in invasive squamous
cervical carcinoma [abstract]. Br J Radiol 1993;66 Suppl:
50.

Ikenberg H, Sauerbrei W, Schottmuller U, Spitz C,
Pfleiderer A. Human papillomavirus DNA in cervical
carcinoma--correlation with clinical data and influence on
prognosis. Int J Cancer 1994 Nov 1;59(3):322-6.

Im DD, Duska LR, Rosenshein NB. Adequacy of conization
margins in adenocarcinoma in situ of the cervix as a
predictor of residual disease. Gynecol Oncol 1995 Nov;
59(2):179-82.

Jelen I, Valente PT, Gautreaux L, Clark GM.
Deoxyribonucleic acid ploidy and S-phase fraction are not
significant prognostic factors for patients with cervical
cancer. Am J Obstet Gynecol 1994 Dec;171(6):1511-6;
discussion 1516-8.

Kainz C, Gitsch G, Tempfer C, Heinzl H, Koelbl H,
Breitecker G, Reinthaller A. Vascular space invasion and
inflammatory stromal reaction as prognostic factors in
patients with surgically treated cervical cancer stage IB to
IIB. Anticancer Res 1994 Sep-Oct;14(5B):2245-8.

Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G,
Reinthaller A. Mutant p53 in patients with invasive
cervical cancer stages IB to IIB. Gynecol Oncol 1995
May;57(2):212-4.

Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G,
Reinthaller A, Breitenecker G. Prognostic value of CD44
splice variants in human stage III cervical cancer. Eur J
Cancer 1995 Sep;31A(10):1706-9.

Kainz C, Speiser P, Wanner C, Obermair A, Tempfer C,
Sliutz G, Reinthaller A, Breitenecker G. Prognostic value
of tumour microvessel density in cancer of the uterine
cervix stage IB to IIB. Anticancer Res 1995 Jul-Aug;
15(4):1549-51.

Kainz C, Zeisler H, Kohlberger P, Gitsch G, Heinzl H,
Breitenecker G, Reinthaller A. Prognostic value of
cytokeratins and carcinoembryonic antigen expression in
primary surgically treated cervical cancer. Anticancer Res
1994 Mar-Apr;14(2B):667-71.

Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T,   
To N, Akazawa K, Nakano H. Histopathologic prognostic
factors in stage IIb cervical carcinoma treated with radical
hysterectomy and pelvic-node dissection - an analysis
with mathematical statistics. Int J Gynecol Cancer 1993;
3(4):219-25.

Kaspar HG, Dinh TV, Doherty MG, Hannigan EV,    
Kumar D. Clinical implications of tumor volume
measurement in stage I adenocarcinoma of the cervix.
Obstet Gynecol 1993 Feb;81(2):296-300.

Kenter GG, Cornelisse CJ, Jiwa NM, Aartsen EJ,   
Hermans J, Mooi W, Heintz AP, Fleuren GJ. Human
papillomavirus type 16 in tumor tissue of low-stage
squamous carcinoma of the uterine cervix in relation to
ploidy grade and prognosis. Cancer 1993 Jan 15;71(2):
397-401.

Kim YT, Nam JH, Mok JE. The use of PCR with consensus
primer sets for the detection of human papilloma viruses
in archival cervical cancer specimens [abstract].       
Proc Annu Meet Am Soc Clin Oncol 1993;12:A733.

Kobayashi H, Fujishiro S, Terao T. Biochemical markers as
a predictor for lymph node involvement in patients with
cervical cancer of the uterus. Int J Oncol 1994;4(5):
1053-9.

Koechli OR, Sevin BU, Nadji M, Lu Y, Averette HE.
Multivariate analysis of prognostic factors of early stage
cervical cancer in patients undergoing radical
hysterectomy [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1993;12:A807.

Kohno Y, Iwanari O, Kitao M. Prognostic importance of
histologic vascular density in cervical cancer treated with
hypertensive intraarterial chemotherapy. Cancer 1993 
Oct 15;72(8):2394-400.

Konski A, Domenico D, Irving D, Tyrkus M, Neisler J,
Phibbs G, Bishop K, Mah J, Eggleston W. Flow
cytometric DNA content analysis of paraffin-embedded
tissue derived from cervical carcinoma. Int J Radiat
Oncol Biol Phys 1994 Nov 15;30(4):839-43.

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Trope CG,
Pettersen EO. No prognostic impact of flow-cytometric
measured DNA ploidy and S-phase fraction in cancer of
the uterine cervix: a prospective study of 465 patients.
Gynecol Oncol 1995 Apr;57(1):79-85.

Lai CH, Chang HC, Chang TC, Hsueh S, Tang SG.
Prognostic factors and impacts of adjuvant therapy in
early-stage cervical carcinoma with pelvic node
metastases. Gynecol Oncol 1993 Dec;51(3):390-6.

Lai CH, Hsueh S, Huang MY, Chang MF, Soong YK. The
uses and limitations of DNA flow cytometry in stage IB
or II cervical carcinoma. Cancer 1993 Dec 15;72(12):
3655-62.

Landoni F, Bocciolone L, Perego P, Maneo A, Bratina G,
Mangioni C. Cancer of the cervix, FIGO stages IB and
IIA: patterns of local growth and paracervical extension.
Int J Gynecol Cancer 1995;5(5):329-34.

Lara PC, Rey-Baltar D, Rivera D, Apolinario R, Alarcon I,
Rodriguez T, Hernandez MA, Gonzalez G, Ruiz A,
Clavo B, Lopez-Bonilla A, Falcon Vizcaino O.
[Squamous cell antigen (SCC-Ag) and cervical cancer.
Modifications induced by radiation]. Neoplasia 1995;
12(3):91-5.  (Spa).

Leung KM, Chan WY, Hui PK. Invasive squamous cell
carcinoma and cervical intraepithelial neoplasia III of
uterine cervix. Morphologic differences other than
stromal invasion. Am J Clin Pathol 1994 Apr;101(4):
508-13.

Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts
SA, Chadwick C, Wilks DP, Potten CS, Hendry JH,
Hunter RD, West CM. Apoptosis, intrinsic
radiosensitivity and prediction of radiotherapy response in
cervical carcinoma. Radiother Oncol 1995 Oct;37(1):1-9.

Li XY, Jiao SZ. [Significance of DNA content and S-phase
fraction in cervical adenocarcinoma]. Chung Kuo Chung
Liu Lin Chuang 1995;22(2):81-3.  (Chi).

Maassen V, Dieckhoff R, Baltzer J, Kindermann G. [Risk of
hematogenous metastasis of cancer of the uterine cervix].
Geburtshilfe Frauenheilkd 1994 Dec;54(12):656-61. 
(Ger).

Mariani L, Iacovelli A, Vincenzoni C, Diotallevi FF,  
Atlante M, Lombardi A. Cervical carcinoma in young
patients: clinical and pathological variables. Int J
Gynaecol Obstet 1993 Apr;41(1):61-6.

Minagawa Y, Kigawa J, Kanamori Y, Itamochi H,  
Terakawa N. Tumor cell kinetics in elderly patients with
cervical cancer. Obstet Gynecol 1993 Apr;81(4):610-4.

Ngan HY, Cheng GT, Yeung WS, Wong LC, Ma HK. The
prognostic value of TPA and SCC in squamous cell
carcinoma of the cervix. Gynecol Oncol 1994 Jan;52(1):
63-8.

Nguyen HN, Sevin BU, Averette HE, Ganjei P, Perras J,
Ramos R, Angioli R, Donato D, Penalver M. The role of
DNA index as a prognostic factor in early cervical
carcinoma. Gynecol Oncol 1993 Jul;50(1):54-9.

Nguyen HN, Sevin BU, Averette HE, Ramos R, Ganjei P,
Perras J. Evidence of tumor heterogeneity in cervical
cancers and lymph node metastases as determined by flow
cytometry. Cancer 1993 Apr 15;71(8):2543-50.

Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression
is associated with poor prognosis in squamous cell
carcinoma of the cervix. Cancer 1994 Feb 1;73(3):   
664-71.

Rose BR, Thompson CH, Simpson JM, Jarrett CS, Elliott
PM, Tattersall MH, Dalrymple C, Cossart YE. Human
papillomavirus deoxyribonucleic acid as a prognostic
indicator in early-stage cervical cancer: a possible role
for type 18. Am J Obstet Gynecol 1995 Nov;173(5):1461-8.

Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE.
Serum squamous cell carcinoma antigen levels in invasive
cervical cancer: prediction of response and recurrence.
Am J Obstet Gynecol 1993 Mar;168(3 Pt 1):942-6.

Schlenger K, Hockel M, Mitze M, Schaffer U, Weikel W,
Knapstein PG, Lambert A. Tumor vascularity--a novel
prognostic factor in advanced cervical carcinoma.
Gynecol Oncol 1995 Oct;59(1):57-66.

Schwickert G, Walenta S, Sundfor K, Rofstad EK,
Mueller-Klieser W. Correlation of high lactate levels in
human
cervical cancer with incidence of metastasis. Cancer Res
1995 Nov 1;55(21):4757-9.

Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli
OR, Averette HE. Prognostic factors of early stage
cervical cancer treated by radical hysterectomy. Cancer
1995;76(10 Suppl):1978-86.

Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell
AH, Jones WB, Winchester DP, Clive RE. Is there really
a difference in survival of women with squamous cell
carcinoma, adenocarcinoma, and adenosquamous cell
carcinoma of the cervix? Cancer 1995;76(10 Suppl):
1948-55.

Sproston AR, Roberts SA, Davidson SE, Hunter RD, West
CM. Serum tumour markers in carcinoma of the uterine
cervix and outcome following radiotherapy. Br J Cancer
1995 Dec;72(6):1536-40.

Stock RJ, Zaino R, Bundy BN, Askin FB, Woodward J,
Fetter B, Paulson JA, DiSaia PJ, Stehman FB. Evaluation
and comparison of histopathologic grading systems of
epithelial carcinoma of the uterine cervix: Gynecologic
Oncology Group studies. Int J Gynecol Pathol 1994 Apr;
13(2):99-108.

Tang GJ, Sun CF, Lin FJ, Tsao KC. The role of flow
cytometry in non-resected cervical carcinoma. Br J Radiol
1995 Mar;68(807):283-90.

Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA,
Milosevic MF, Rawlings GA, Banerjee D, Pintilie M,
Wilson GD. Proliferation measurements with flow
cytometry Tpot in cancer of the uterine cervix:
correlation between two laboratories and preliminary
clinical results. Int J Radiat Oncol Biol Phys 1995 Jul 30;
32(5):1319-29.  Comment in: Int J Radiat Oncol Biol
Phys 1995 Jul 30;32(5):1539-41.

Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann
CO, Horowitz IR, Icenogle JP, Reeves WC. Human
papillomavirus and disease-free survival in FIGO stage Ib
cervical cancer. J Infect Dis 1995 Nov;172(5):1184-90.

van Bommel PF, Kenemans P, Helmerhorst TJ, Gallee MP,
Ivanyi D. Expression of cytokeratin 10, 13, and
involucrin as prognostic factors in low stage squamous
cell carcinoma of the uterine cervix. Cancer 1994 Oct 15;
74(8):2314-20.

van Bommel PF, van den Brule AJ, Helmerhorst TJ, Gallee
MP, Gaarenstroom KN, Walboomers JM, Meijer CJ,
Kenemans P. HPV DNA presence and HPV genotypes as
prognostic factors in low-stage squamous cell cervical
cancer. Gynecol Oncol 1993 Mar;48(3):333-7.

Werner-Wasik M, Schmid CH, Bornstein L, Ball HG, Smith
DM, Madoc-Jones H. Prognostic factors for local and
distant recurrence in stage I and II cervical carcinoma. 
Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1309-17.

Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK,
Milas L, Allen PK, Meyn RE Jr. ASTRO Research
Fellowship: apoptosis as a predictor of tumor response to
radiation in stage IB cervical carcinoma. American
Society for Therapeutic Radiology and Oncology. Int J
Radiat Oncol Biol Phys 1995 Jul 30;32(5):1487-93.

Wiggins DL, Granai CO, Steinhoff MM, Calabresi P. Tumor
angiogenesis as a prognostic factor in cervical carcinoma.
Gynecol Oncol 1995 Mar;56(3):353-6.

Wilailak S, Tangtrakul S, Srisupundit S, Bullangpoti S,
Linasmita V, Bhamarapravati Y. Prognostic factors
associated with recurrence in stage IB cervical carcinoma
after radical hysterectomy and pelvic lymphadenectomy. 
J Med Assoc Thai 1993 Jan;76 Suppl 1:74-7.

Willen R, Himmelmann A, Langstrom-Einarsson E,     
Ferno M, Ranstam J, Baldetorp B, Skjaerris J,       
Prien-Larsen J, Trope C, Stendahl U. Prospective
malignancy grading, flow cytometry DNA-measurements
and adjuvant chemotherapy for invasive squamous cell
carcinoma of the uterine cervix. Anticancer Res 1993 
Jul-Aug;13(4):1187-96.

Wong YF, Chung TK, Cheung TH, Lam SK, Xu YG, 
Chang AM. Frequent ras gene mutations in squamous cell
cervical cancer. Cancer Lett 1995 Aug 16;95(1-2):29-32.

Yoshioka T, Inoue Y, Hoshiai H, Noda K. [Prognostic
factors in uterine cervical and corpus cancer]. Gan To
Kagaku Ryoho 1995 Sep;22(10):1417-22.  (Jpn).

Zhang WH. [Adenocarcinoma of the uterine cervix. An
analysis of 121 cases]. Chung Hua Chung Liu Tsa Chih
1993 Jan;15(1):61-4.  (Chi).

Zolzer F, Alberti W, Pelzer T, Lamberti G, Hulskamp FH,
Streffer C. Changes in S-phase fraction and micronucleus
frequency as prognostic factors in radiotherapy of
cervical carcinoma. Radiother Oncol 1995 Aug;36(2):
128-32.

Imaging


Arimoto T. Significance of computed tomography-measured
volume in the prognosis of cervical carcinoma. Cancer
1993 Oct 15;72(8):2383-8.

Bautz W, Merl T, Kersting-Sommerhoff B. [Computerized
tomography staging of carcinomas of the uterus].
Radiologe 1994 Jul;34(7):370-6.  (Ger).

Beyersdorff D, Bahnsen J, Frischbier HJ. Nodal involvement
in cancer of the uterine cervix: value of lymphography
and MRI. Eur J Gynaecol Oncol 1995;16(4):274-7.

Bragg DG, Hricak H. Imaging in gynecologic malignancies.
Cancer 1993 Feb 15;71(4 Suppl):1648-51.

Carter JR, Lau M, Twiggs LB. A comparison of vascular
pulsatility and resistive indices in gynecological tumor
detection using transvaginal ultrasound. Vasc Surg 1995;
29(1):29-35.

Collins CD, Constant O, Fryatt I, Blake PR, Parsons CA.
Relationship of computed tomography tumour volume to
patient survival in carcinoma of the cervix treated by
radical radiotherapy. Br J Radiol 1994 Mar;67(795): 
252-6.

Dudarev AL, Vinokurov VL, Shelkoplias EN, Goritskaia IV.
[Magnetic resonance tomography in oncologic
gynecology]. Vestn Rentgenol Radiol 1993 Sep-Oct;(5):
14-5.  (Rus).

Ebner F, Tamussino K, Kressel HY. Magnetic resonance
imaging in cervical carcinoma: diagnosis, staging, and
follow-up. Magn Reson Q 1994 Mar;10(1):22-42.

Fernando IN, Moskovic E, Fryatt I, Glaholm J, Blake PR. Is
there still a role for lymphography in the management of
early stage carcinoma of the cervix? Br J Radiol 1994
Nov;67(803):1052-6.

Fischetti SG, Politi G, Lomeo E, Garozzo G, Di Leo S,
Nuciforo G. [Carcinoma of the uterine cervical canal.
Staging and biometric assessment with magnetic
resonance]. Radiol Med (Torino) 1994 Oct;88(4):445-52. 
(Ita).

Fujita T, Ito K, Choji T, Honma Y, Nakaki H, Uchisako H,
Tanaka N, Kuramitsu T, Hatanaka M, Matsumoto T,    
et al. [Usefulness of 2D FLASH multislice dynamic MR
imaging for evaluation of parametrial invasion in cervical
carcinoma]. Nippon Igaku Hoshasen Gakkai Zasshi 1993
Apr 25;53(4):472-4.  (Jpn).
Genolet PM, Hanggi W, Dreher E. [Evaluation of tumor
extension in invasive cancer of the uterine cervix.

Diagnostic evaluation of cervix cancer]. Gynakol
Geburtshilfliche Rundsch 1993;33(3):180-4.  (Fre).

Gochev G, Totsev N, Vasilev D, Simeonova L, Ianev N,
Elenchev L. [The potentials of computed axial
tomography (CAT) in the diagnosis of carcinoma of the
cervix uteri]. Akush Ginekol (Sofiia) 1994;33(3):25-6. 
(Bul).

Hanabayashi T, Imai A, Itoh N, Tamaya T. Enhanced
magnetic resonance imaging evaluation for spread of
cervical carcinoma. Int J Gynaecol Obstet 1993 Dec;
43(3):297-304.

Hawnaur JM, Johnson RJ, Buckley CH, Tindall V,
Isherwood I. Staging, volume estimation and assessment
of nodal status in carcinoma of the cervix: comparison of
magnetic resonance imaging with surgical findings.   
Clin Radiol 1994 Jul;49(7):443-52.

Houvenaeghel G, Delpero JR, Rosello R, Resbeut M,   
Viens P, Jacquemier J, Noirclerc M, Guerinel G. Results
of a prospective study with comparison of clinical,
endosonographic, computed tomography, magnetic
resonance imaging and pathologic staging of advanced
gynecologic carcinoma and recurrence. Surg Gynecol
Obstet 1993 Sep;177(3):231-6.

Houvenaeghel G, Martino M, Resbeut M, Rosello R,    
Perez T, Delpero JR, Jacquemier J, Guerinel G. Pelvic
staging of advanced and recurrent gynecologic cancers:
contribution of endosonography. Gynecol Oncol 1994
Dec;55(3 Pt 1):393-400.

Hricak H. [Magnetic resonance imaging of the female
pelvis]. Lijec Vjesn 1994 May-Jun;116(5-6):149-54. 
(Scr).

Hricak H, Quivey JM, Campos Z, Gildengorin V,
Hindmarsh T, Bis KG, Stern JL, Phillips TL. Carcinoma
of the cervix: predictive value of clinical and magnetic
resonance (MR) imaging assessment of prognostic
factors. Int J Radiat Oncol Biol Phys 1993 Nov 15;27(4):
791-801.  Comment in: Int J Radiat Oncol Biol Phys 1993
Nov 15;27(4):981-3.

Hricak H, Swift PS, Campos Z, Quivey JM, Gildengorin V,
Goranson H. Irradiation of the cervix uteri: value of
unenhanced and contrast-enhanced MR imaging.
Radiology 1993 Nov;189(2):381-8.

Hsieh CY, Wu CC, Chen TM, Chen CA, Chen CL,     
Wang JF, Chang CF, Hsieh FJ. Clinical significance of
intratumoral blood flow in cervical carcinoma assessed by
color Doppler ultrasound. Cancer 1995 May 15;75(10):
2518-22.

Kaji Y, Sugimura K, Kitao M, Ishida T. Histopathology of
uterine cervical carcinoma: diagnostic comparison of
endorectal surface coil and standard body coil MRI.       
J Comput Assist Tomogr 1994 Sep-Oct;18(5):785-92.

Kawakami K, Fushiki M, Sho K, Matsui A, Suyama S,
Murata K, Morita R. MR evaluation of the uterine
cervical cancer before, during and after radiation therapy
[abstract].  In: ICRO'93 - International Congress of
Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 328.

Kim KH, Lee BH, Do YS, Chin SY, Park SY, Kim BG, 
Jang JJ. Stage IIb cervical carcinoma: MR evaluation of
effect of intraarterial chemotherapy. Radiology 1994 Jul;
192(1):61-5.

Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB,  
Lee JY, Han MC. Preoperative staging of uterine cervical
carcinoma: comparison of CT and MRI in 99 patients.    
J Comput Assist Tomogr 1993 Jul-Aug;17(4):633-40.

Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical
carcinoma: evaluation of pelvic lymph node metastasis
with MR imaging. Radiology 1994 Mar;190(3):807-11.

Kitagaki H. [MR imaging-evaluation of therapeutic effect of
radiotherapy for uterine cervix cancer]. Nippon Igaku
Hoshasen Gakkai Zasshi 1995 Mar;55(4):215-21.  (Jpn).

Lien HH, Blomlie V, Iversen T, Trope C, Sundfor K, 
Abeler VM. Clinical stage I carcinoma of the cervix.
Value of MR imaging in determining invasion into the
parametrium. Acta Radiol 1993 Mar;34(2):130-2.

Mamsen A, Ledertoug S, Horlyck A, Knudsen HJ,
Rasmussen KL, Nyland MH, Jakobsen A. The possible
role of ultrasound in early cervical cancer. Gynecol Oncol
1995 Feb;56(2):187-90.

Marano P, Summaria V, Smaniotto D, Danza FM, Speca S,
Valentini AL, Greggi S, Lancia M, Cellini N.
[Experience with the combined diagnosis and therapy of
locally advanced carcinoma of the uterine cervix (stage
FIGO IIB-III). Transrectal ultrasonography and CT in the
staging and in follow-up after therapy. Preliminary
results]. Radiol Med (Torino) 1993 Nov;86(5):630-8. 
(Ita).

Martin AJ, Poon CS, Thomas GM, Kapusta LR, Shaw PA,
Henkelman RM. MR evaluation of cervical cancer in
hysterectomy specimens: correlation of quantitative T2
measurement and histology. J Magn Reson Imaging 1994
Nov-Dec;4(6):779-86.

Mayr NA, Tali ET, Yuh WT, Brown BP, Wen BC, Buller
RE, Anderson B, Hussey DH. Cervical cancer:
application of MR imaging in radiation therapy.
Radiology 1993 Nov;189(2):601-8.

Mezrich R. Magnetic resonance imaging applications in
uterine cervical cancer. Magn Reson Imaging Clin N Am
1994 May;2(2):211-43.

Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE,
Ling CC, Komaki R, Marcial VA, Thomas GM,
Lanciano R. Carcinoma of the cervix: patterns of care
studies: review of 1978, 1983, and 1988-1989 surveys.
Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1481-6. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Jul 30;
32(5):1535-7.

Monzen Y, Mori H, Matsumoto A, Yoshida S, Wakisaka M,
Komatsu E, Tashiro M, Hori Y. [Uterine cervical cancer:
usefulness of MR imaging after the initial radiation
therapy]. Nippon Igaku Hoshasen Gakkai Zasshi 1995
Sep;55(11):745-50.  (Jpn).

Moore DH. Evaluation and staging of cervical carcinoma.
Clin Consult Obstet Gynecol 1995;7(2):111-7.

Omigbodun AO, Thomas JO, Adewole IF. Cytologic
detection of urinary bladder involvement in cervical
cancer. Int J Gynecol Cancer 1994;4(6):401-3.

Pendlebury SC, Cahill S, Crandon AJ, Bull CA. Role of
bipedal lymphangiogram in radiation treatment planning
for cervix cancer. Int J Radiat Oncol Biol Phys 1993  
Nov 15;27(4):959-62.

Pirhonen JP, Grenman SA, Bredbacka AB, Bahado-Singh
RO, Salmi TA. Effects of external radiotherapy on uterine
blood flow in patients with advanced cervical carcinoma
assessed by color Doppler ultrasonography. Cancer 1995;
76(1):67-71.

Poka R, Szluha K, Hernadi Z, Juhasz B, Lampe L. Are
pre-operative lymphographic results reflected in the
survival
of stage Ib and IIa cervical cancer? J Obstet Gynecol
1994;14(5):352-4.

Rutgers JL, Mattox TF, Vargas MP. Angiogenesis in uterine
cervical squamous cell carcinoma. Int J Gynecol Pathol
1995;14(2):114-8.

Schmitz MJ, Nahhas WA, Clark MA, Brown M. Stage IB
carcinoma of the cervix: are all staging tests and
procedures necessary? Eur J Gynaecol Oncol 1994;
15(3):199-204.

Schnall MD. Magnetic resonance evaluation of uterine
malignancies. Semin Ultrasound CT MR 1994 Feb;15(1):
27-37.

Shepherd SF, Collins CD, Fryatt IJ, Parsons CA, Blake PR.
Computerized axial tomographic scan measurements as
prognostic indicators in patients with cervical carcinoma.
Br J Radiol 1995 Jun;68(810):600-3.

Sironi S, De Cobelli F, Scarfone G, Colombo E, Bolis G,
Ferrari A, DelMaschio A. Carcinoma of the cervix: value
of plain and gadolinium-enhanced MR imaging in
assessing degree of invasiveness. Radiology 1993 Sep;
188(3):797-801.

Stummvoll W, Ruschitzka G, Hammer J. [Color doppler
ultrasonography of uterine vessels during radiotherapy of
advanced cervix cancers]. Gynakol Geburtshilfliche
Rundsch 1994;34(2):102-5.  (Ger).

Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical
carcinoma: computed tomography and magnetic
resonance imaging for preoperative staging.           
Obstet Gynecol 1995 Jul;86(1):43-50.

Toita T, Nakano M, Higashi M, Sakumoto K, Kanazawa K.
Prognostic value of cervical size and pelvic lymph node
status assessed by computed tomography for patients with
uterine cervical cancer treated by radical radiation
therapy. Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):
843-9.

Varpula M, Kilholma P, Klemi P. CT and ultra low field
(0.02 T) MR imaging of uterine cervical carcinoma.  
Acta Radiol 1994 Jul;35(4):361-6.

Varpula MJ. Ultra low field (0.02 t) magnetic resonance
imaging of the female pelvis [dissertation]. Turku,
Finland: Turun Yliopisto; 1993. 132 p.

Vijaykumar DK, Prahlad S, Chaturvedi HK. Ultrasound
evaluation of pelvic nodes in cervical carcinoma. Eur J
Gynaecol Oncol 1995;16(3):224-7.

Weber TM, Sostman HD, Spritzer CE, Ballard RL, Meyer
GA, Clark-Pearson DL, Soper JT. Cervical carcinoma:
determination of recurrent tumor extent versus radiation
changes with MR imaging. Radiology 1995 Jan;194(1):
135-9.

Westhofen M, Reichel C, Nadjmi D. [Colour Doppler
imaging in the indication of cervical lymph node surgery].
Otorinolaringologia 1994;4(5-6):285-91.  (Ger).

Wong WL, Studholme C, Lewis P, Raju KS, Beaney RP,
Tonge K, Nunnan T, Hawkes DJ, Pemberton J.
Combined MR, CT and PET imaging in oncological
patients [abstract]. Br J Radiol 1993;66 Suppl:33-4.


Surgical Assessment and Resection of 
Lymph Nodes


Altintas A, Vardar MA, Evruke C, Aridogan N. Is it
essential to perform complete paraaortic lymph node
dissection if no metastases have been shown in the lower
part of the aorta? Eur J Gynaecol Oncol 1995;16(2):  
120-2.

Benedetti-Panici P, Greggi S, Scambia G, Maneschi F,
Baiocchi G, Amoroso MA, Rabitti C, Mancuso S.
Anatomical study of para-aortic and pelvic lymph nodes
in gynecologic malignancies. Paper presented at:
European Society of Gynaecological Oncology 8th
International Meeting: Prevention, early detection,
diagnosis, management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Benedetti-Panici P, Maneschi F, Scambia G, Greggi S,
Mancuso S. Anatomic abnormalities of the
retroperitoneum encountered during aortic and pelvic
lymphadenectomy. Am J Obstet Gynecol 1994 Jan; 
170(1 Pt 1):111-6.

Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of
frozen section for lymph node metastasis in patients
undergoing radical hysterectomy for carcinoma of the
cervix. Gynecol Oncol 1993 Oct;51(1):50-3.

Fowler JM, Carter JR, Carlson JW, Maslonkowski R,  
Byers LJ, Carson LF, Twiggs LB. Lymph node yield
from laparoscopic lymphadenectomy in cervical cancer: a
comparative study. Gynecol Oncol 1993 Nov;51(2):  
187-92.

Girardi F, Haas J. The importance of the histologic
processing of pelvic lymph nodes in the treatment of
cervical cancer. Int J Gynecol Cancer 1993;3(1):12-7.

Girardi F, Pickel H, Winter R. Pelvic and parametrial lymph
nodes in the quality control of the surgical treatment of
cervical cancer. Gynecol Oncol 1993 Sep;50(3):330-3.

Hacker NF, Wain GV, Nicklin JL. Resection of bulky
positive lymph nodes in patients with cervical carcinoma.
Int J Gynecol Cancer 1995;5(4):250-6.

Hackett TE, Olt G, Sorosky JI, Podczaski E, Harrison TA,
Mortel R. Surgical predictors of para-aortic metastases in
early-stage cervical carcinoma. Gynecol Oncol 1995 Oct;
59(1):15-9.

Hording U, Ravn V, Knudsen J, Visfeldt J. The use of
polymerase chain reaction to detect metastatic cancer cells
within lymph nodes stage I cervical carcinoma. Int J
Gynecol Pathol 1995;14(4):339-43.

Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz
KC. Surgical treatment of patients with stages IB and IIA
carcinoma of the cervix and palpably positive pelvic
lymph nodes. Gynecol Oncol 1995 May;57(2):145-9.

Lanciano RM, Corn BW. The role of surgical staging for
cervical cancer. Semin Radiat Oncol 1994;4(1):46-51.

Park JS, Chee YH, Namkoong SE, Han SK, Kim TE, Lee
HY, Kim SJ. Human papillomavirus detection in cervical
carcinoma tissues and paraaortic lymph nodes by the
polymerase chain reaction. Gynecol Oncol 1994 Jun;
53(3):344-51.

Patsner B. Extraperitoneal staging lymphadenectomy for
locally advanced cervical cancer. Effective, cost-effective
and minimally invasive. Eur J Gynaecol Oncol 1994;
15(6):460-3.

Potter ME, Spencer S, Soong SJ, Hatch KD. The influence
of staging laparotomy for cervical cancer on patterns of
recurrence and survival. Int J Gynecol Cancer 1993;3(3):
169-74.

Renolleau C, Laroussinie MP, Mosseri V, Fenton J,          
de la Rochefordiere A, Clough KB, Hamelin JP, Durand
JC. [Pelvic lymph node invasion in cancer of the uterine
cervix]. Bull Cancer (Paris) 1995;82(5):377-83.  (Fre).

Romanini C, Garzetti GG. Role of pelvic and paraaortic
lymphadenectomy in radical surgery for early stage
cervical carcinoma: a randomized clinical study. Ital J
Gynaecol Obstet 1993;5(4):159-64.

Rose BR, Thompson CH, Jiang XM, Tattersall MH, Elliott
PM, Dalrymple C, Cossart YE. Detection of human
papillomavirus type 16 E6/E7 transcripts in histologically
cancer-free pelvic lymph nodes of patients with cervical
carcinoma. Gynecol Oncol 1994 Feb;52(2):212-7.

Satoh C. [A clinical and pathological study on paraaortic
lymph node metastasis in uterine cervical carcinoma].
Nippon Sanka Fujinka Gakkai Zasshi 1994 Dec;46(12):
1343-50.  (Jpn).

Schatten C, Vavra N, Nagele F, Barrada M, Aygun M,
Enzelsberger H, Sevelda P. [The prognostic effect of
scintigraphy-guided lymphadenectomy in therapy of stage
Ib cervix carcinoma]. Geburtshilfe Frauenheilkd 1995
Aug;55(8):441-6.  (Ger).


Diagnosis and Management of Stage IA1


Andersen ES, Husth M, Joergensen A, Nielsen K. Laser
conization for microinvasive carcinoma of the cervix.
Short-term results. Int J Gynecol Cancer 1993;3(3):183-5.

Andersen ES, Nielsen K, Pedersen B. The reliability of
preconization diagnostic evaluation in patients with
cervical intraepithelial neoplasia and microinvasive
carcinoma. Gynecol Oncol 1995 Oct;59(1):143-7.

Anderson MC. Invasive carcinoma of the cervix following
local destructive treatment for cervical intraepithelial
neoplasia. Br J Obstet Gynaecol 1993 Jul;100(7):657-63.

Girardi F, Burghardt E, Pickel H. Small FIGO stage IB
cervical cancer. Gynecol Oncol 1994 Dec;55(3 Pt 1):
427-32.

Hopkins MP, Morley GW. Microinvasive squamous cell
carcinoma of the cervix. J Reprod Med 1994 Sep;39(9):
671-3.

Jones WB, Mercer GO, Lewis JL Jr, Rubin SC, Hoskins WJ.
Early invasive carcinoma of the cervix. Gynecol Oncol
1993 Oct;51(1):26-32.

Kennedy AW, Belinson JL, Wirth S, Taylor J. The role of
the loop electrosurgical excision procedure in the
diagnosis and management of early invasive cervical
cancer. Int J Gynecol Cancer 1995;5(2):117-20.

Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz
KC. Identification of a low-risk subset of patients with
stage IB invasive squamous cancer of the cervix possibly
suited to less radical surgical treatment. Gynecol Oncol
1995 Apr;57(1):3-6.  Comment in: Gynecol Oncol 1995
Apr;57(1):1-2.

Morgan PR, Anderson MC, Buckley CH, Murdoch JB,
Lopes A, Duncan ID, Monaghan JM. The Royal College
of Obstetricians and Gynaecologists micro-invasive
carcinoma of the cervix study: preliminary results.       
Br J Obstet Gynaecol 1993 Jul;100(7):664-8.

Morris M, Mitchell MF, Silva EG, Copeland LJ, Gershenson
DM. Cervical conization as definitive therapy for early
invasive squamous carcinoma of the cervix. Gynecol
Oncol 1993 Nov;51(2):193-6.

Orlandi C, Costa S, Terzano P, Martinelli GN, Comerci G,
Guerra B, Martellini L. Presurgical assessment and
therapy of microinvasive carcinoma of the cervix.
Gynecol Oncol 1995 Nov;59(2):255-60.

Ostor AG. Studies on 200 cases of early squamous cell
carcinoma of the cervix. Int J Gynecol Pathol 1993 Jul;
12(3):193-207.

Ostor AG, Rome RM. Micro-invasive squamous cell
carcinoma of the cervix: a clinico-pathologic study of 200
cases with long-term follow-up. Int J Gynecol Cancer
1994;4(4):257-64.

Peng ZL. [Stage Ia cervical cancer]. Chung Hua Fu Chan Ko
Tsa Chih 1993 Jun;28(6):346-8, 381.  (Chi).

Rodriguez-Oliver A, Hernandez F, Rojas R, Gomez T,
Menjon S, Herruzo A. [Treatment and follow-up of
women with microinvasive carcinoma of cervix].
Oncologia 1994;17(7):31-5.  (Spa).

Ruiz Ortiz E, Gonzalez Lira G, Escudero de los Rios P,
Sebastian Mauricio R. [Microinvasive cervico-uterine
cancer. Diagnosis and treatment]. Ginecol Obstet Mex
1994 Aug;62:237-42.  (Spa).

Sugimori H, Iwasaka T. Cervical microcarcinoma:
differential diagnosis. Arch STD HIV Res 1994;8(1-2):
155-67.

Ueki M, Okamoto Y, Misaki O, Seiki Y, Kitsuki K, Ueda M,
Sugimoto O. Conservative therapy for microinvasive
carcinoma of the uterine cervix. Gynecol Oncol 1994
Apr;53(1):109-13.

Vavra N, Nagele F, Rosen A, Klein M, Barrada M,
Buxbaum P, Sevelda P. [Conisation in stage Ia cervix
cancer]. Geburtshilfe Frauenheilkd 1994 Jul;54(7):    
397-400.  (Ger).

Yaegashi N, Sato S, Inoue Y, Noda K, Yajima A.
Conservative surgical treatment in cervical cancer with 3
to 5 mm stromal invasion in the absence of confluent
invasion and lymph-vascular space involvement. Gynecol
Oncol 1994 Sep;54(3):333-7.


Primary Surgery, Including 
Treatment in Pregnancy


Alvarez RD, Gelder MS, Gore H, Soong SJ, Partridge EE.
Radical hysterectomy in the treatment of patients with
bulky early stage carcinoma of the cervix uteri. Surg
Gynecol Obstet 1993 Jun;176(6):539-42.

Anderson B, LaPolla J, Turner D, Chapman G, Buller R.
Ovarian transposition in cervical cancer. Gynecol Oncol
1993 May;49(2):206-14.

Averette HE, Nguyen HN, Donato DM, Penalver MA, Sevin
BU, Estape R, Little WA. Radical hysterectomy for
invasive cervical cancer. A 25-year prospective
experience with the Miami technique. Cancer 1993    
Feb 15;71(4 Suppl):1422-37.

Benedetti-Panici P, Scambia G, Baiocchi G, Maneschi F,
Greggi S, Mancuso S. Radical hysterectomy: a
randomized study comparing two techniques for resection
of the cardinal ligament. Gynecol Oncol 1993 Aug;50(2):
226-31.

Bidzinski M, Lemieszczuk B, Zielinski J. Evaluation of the
hormonal function and features of the ultrasound picture
of transposed ovary in cervical cancer patients after
surgery and pelvic irradiation. Eur J Gynaecol Oncol
1993;14 Suppl:77-80.

Bissett D, Lamont DW, Nwabineli NJ, Brodie MM,
Symonds RP. The treatment of stage I carcinoma of the
cervix in the west of Scotland 1980-1987. Br J Obstet
Gynaecol 1994 Jul;101(7):615-20.

Bosze P, Meszaros I, Palfalvi L, Ungar L. Perioperative
complications of 116 radical hysterectomies and pelvic
node dissections. Eur J Surg Oncol 1993 Dec;19(6):  
605-8.

Burke TW. Treatment options in stage IB cervical cancer:
radical hysterectomy and radiotherapy. Semin Radiat
Oncol 1994;4(1):34-40.

Carvalho JP, Souen JS, Carramao S da S, Yeu WL,    
Pinotti JA. Wertheim-Meigs radical hysterectomy.     
Rev Paul Med 1994 Apr-Jun;112(2):539-42.

Cheng J. [Clinical application of extraperitoneal ovarian
transposition in cervical cancer]. Chung Hua Fu Chan Ko
Tsa Chih 1993 Sep;28(9):542-4, 570.  (Chi).

Cobanoglu O, Gurkan Zorlu C, Kuscu E, Ergun Y, 
Aydogdu T, Gokmen O. Clinical experience of 115 early
stage cervical cancer. Paper presented at: European
Society of Gynaecological Oncology 8th International
Meeting: Prevention, early detection, diagnosis,
management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Connor JP, Morris PC, Alagoz T, Anderson B, Bottles K,
Buller RE. Intraoperative autologous blood collection and
autotransfusion in the surgical management of early
cancers of the uterine cervix. Obstet Gynecol 1995 Sep;
86(3):373-8.

Covens A, Rosen B, Gibbons A, Osborne R, Murphy J,
DePetrillo A, Lickrish G, Shaw P, Colgan T. Differences
in the morbidity of radical hysterectomy between
gynecological oncologists. Gynecol Oncol 1993 Oct;
51(1):39-45.

Debus-Thiede G, Maassen V, Dimpfl T, Klosterhalfen T,
Kindermann G. [Late disorders of bladder function after
Wertheim operation--an analysis of urodynamic
parameters with reference to surgical radicality].
Geburtshilfe Frauenheilkd 1993 Aug;53(8):525-31. 
(Ger).

Duggan B, Muderspach LI, Roman LD, Curtin JP, 
d'Ablaing G 3d, Morrow CP. Cervical cancer in
pregnancy: reporting on planned delay in therapy.  
Obstet Gynecol 1993 Oct;82(4 Pt 1):598-602.

Fanning J, Hilgers RD, Palabrica C. Surgical stapling
technique for radical hysterectomy. Gynecol Oncol 1994
Nov;55(2):179-84.

Feeney DD, Moore DH, Look KY, Stehman FB, Sutton GP.
The fate of the ovaries after radical hysterectomy and
ovarian transposition. Gynecol Oncol 1995 Jan;56(1):3-7. 
Comment in: Gynecol Oncol 1995 Jan;56(1):1-2.

Fotiou SK, Tserkezoglou AJ, Steinhauer G, Papailiou J,
Tavernarakis A. Pelvic lymphocysts after radical
hysterectomy and lymphadenectomy. Eur J Gynaecol
Oncol 1994;15(6):449-54.

Harrison TA, Sevin BU, Koechli O, Nguyen HN, Averette
HE, Penalver M, Donato DM, Nadji M. Adenosquamous
carcinoma of the cervix: prognosis in early stage disease
treated by radical hysterectomy. Gynecol Oncol 1993
Sep;50(3):310-5.

Jensen JK, Lucci JA 3d, DiSaia PJ, Manetta A, Berman ML.
To drain or not to drain: a retrospective study of
closed-suction drainage following radical hysterectomy with
pelvic lymphadenectomy. Gynecol Oncol 1993;51(1):  
46-9.

Kennedy AW, Peterson G, Tuason LJ, Belinson JL, Webster
KD. Radical hysterectomy for cervical cancer: the effect
of shorter length of stay on outcome. Cleve Clin J Med
1995 May-Jun;62(3):193-7.

Knudsen HJ, Rasmussen KL, Ledertoug S, Mamsen A,
Nyland MH, Jakobsen A. A comparison of survival and
side effects in two periods with a different approach to
radical hysterectomy as treatment of cervical cancer
stages Ib and IIa. Zentralbl Gynakol 1995;117(9):476-80.

Kralj B, Lukanovic A. Treatment of micturition disturbances
after radical hysterectomy due to changes of cystometric
curve. Paper presented at: European Society of
Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Lewandowski GS, Vaccarello L, Copeland LJ. Surgical
issues in the management of carcinoma of the cervix in
pregnancy. Surg Clin North Am 1995 Feb;75(1):89-100.

Magrina JF. Complications of irradiation and radical surgery
for gynecologic malignancies. Obstet Gynecol Surv 1993
Aug;48(8):571-5.

Matthews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN,
Stringer CA, Morris M, Silva EG. Stage I cervical
adenocarcinoma: prognostic evaluation of surgically
treated patients. Gynecol Oncol 1993 Apr;49(1):19-23.

McLellan R, Dillon MB, Woodruff JD, Heatley GJ, Fields
AL, Rosenshein NB. Long-term follow-up of stage I
cervical adenocarcinoma treated by radical surgery.
Gynecol Oncol 1994 Feb;52(2):253-9.

Monk BJ, Tewari K, Gamboa-Vujicic G, Burger RA,
Manetta A, Berman ML. Does perioperative blood
transfusion affect survival in patients with cervical cancer
treated with radical hysterectomy? Obstet Gynecol 1995
Mar;85(3):343-8.

Montz FJ, Holschneider CH, Solh S, Schuricht LC,     
Monk BJ. Small bowel obstruction following radical
hysterectomy: risk factors, incidence, and operative
findings. Gynecol Oncol 1994 Apr;53(1):114-20.

Morris PC, Haugen J, Tomjack J, Anderson B, Buller RE.
Blood transfusion and the risk of recurrence in stage IB
cervical cancer. Gynecol Oncol 1995 Jun;57(3):401-6.

Nevin J, Soeters R, Dehaeck K, Bloch B, Van Wyk L.
Advanced cervical carcinoma associated with pregnancy.
Int J Gynecol Cancer 1993;3(1):57-63.

Nwabineli NJ, Walsh DJ, Davis JA. Urinary drainage
following radical hysterectomy for cervical carcinoma - a
pilot comparison of urethral and suprapubic routes. Int J
Gynecol Cancer 1993;3(4):208-10.

O'Callaghan DJ, Dwyer PL. Clinical and urodynamic follow-up
of women with established urinary dysfunction after
radical hysterectomy. Aust N Z J Obstet Gynaecol 1994;
34(5):557-61.

Orr JW Jr, Orr PJ, Bolen DD, Holimon JL. Radical
hysterectomy: does the type of incision matter? Am J
Obstet Gynecol 1995 Aug;173(2):399-405; discussion
405-6.

Parker M, Bosscher J, Barnhill D, Park R. Ovarian
management during radical hysterectomy in the
premenopausal patient. Obstet Gynecol 1993 Aug;
82(2):187-90.  Comments in: Obstet Gynecol 1993
Dec;82(6):1042-3; Obstet Gynecol 1993 Dec;82(6):1043.

Pateisky N, Vavra N, Berkemeier H, Barrada M, Senker W,
Schatten C. [Isotope nephrogram in follow-up of radically
operated cervix cancers]. Geburtshilfe Frauenheilkd 1993
Aug;53(8):532-4.  (Ger).

Patsner B. Closed-suction drainage versus no drainage
following radical abdominal hysterectomy with pelvic
lymphadenectomy for stage IB cervical cancer. Gynecol
Oncol 1995 May;57(2):232-4.

Poka R, Hernadi Z, Lampe L. Invasive cervical carcinoma
associated with pregnancy. J Obstet Gynecol 1993;13(2):
91-4.

Sartori E, Fallo L, La Face B, Bianchi UA, Pecorelli S.
Extended radical hysterectomy in early-stage carcinoma
of the uterine cervix: tailoring the radicality. Int J
Gynecol Cancer 1995;5(2):143-7.

Schreuder HW, Vierhout ME, Veen HF. [Disabling
constipation following Wertheim's radical hysterectomy].
Ned Tijdschr Geneeskd 1993 May 22;137(21):1059-62. 
(Dut).

Sivanesaratnam V, Jayalakshmi P, Loo C. Surgical
management of early invasive cancer of the cervix
associated with pregnancy. Gynecol Oncol 1993 Jan;
48(1):68-75.

Sivanesaratnam V, Sen DK, Jayalakshmi P, Ong G. Radical
hysterectomy and pelvic lymphadenectomy for early
invasive cancer of the cervix - 14-year experience. Int J
Gynecol Cancer 1993;3(4):231-8.

Sorbe B, Graflund M, Linder A, Forslin L, Wallmo L,
Quarfort L, Johnson P. Treatment of cervical carcinoma
by Wertheim-Meigs surgery: long-term follow-up results
in a well-defined Swedish region. Int J Oncol 1995;6(4):
817-23.

Sorosky JI, Squatrito R, Ndubisi BU, Anderson B, Podczaski
ES, Mayr N, Buller RE. Stage I squamous cell cervical
carcinoma in pregnancy: planned delay in therapy
awaiting fetal maturity. Gynecol Oncol 1995 Nov;59(2):
207-10.

Steren A, Nguyen HN, Averette HE, Estape R, Angioli R,
Donato DM, Penalver MA, Sevin BU. Radical
hysterectomy for stage IB adenocarcinoma of the cervix:
the University of Miami experience. Gynecol Oncol 1993
Mar;48(3):355-9.

van der Vange N, Weverling GJ, Ketting BW, Ankum WM,
Samlal R, Lammes FB. The prognosis of cervical cancer
associated with pregnancy: a matched cohort study.
Obstet Gynecol 1995 Jun;85(6):1022-6.

Vierhout ME, Schreuder HWB, Veen HF. The relation
between colorectal and lower urinary tract dysfunction
following radical hysterectomy for carcinoma of the
cervix. Int Urogynecol J 1994;5(2):82-5.

Weerasekera DS, Gunawardena KK. A retrospective
evaluation of early carcinoma of the cervix treated
surgically in a Provincial General Hospital. Ceylon Med J
1994 Jun;39(2):75-7.

Wu YX, Qiu S, Meng J. [Careful dissection of the pelvic
plexus helps alleviate urinary retention following radical
hysterectomy]. Chunghua Chung Liu Tsa Chih 1994
Nov;16(6):465-8.  (Chi).

Yamawaki T, Tanaka H, Takeuchi S, Yanase H,    
Taniguchi H, Toyoda N. Autologous blood transfusion
using recombinant human erythropoietin in radical
hysterectomy. Asia Oceania J Obstet Gynaecol 1994 Jun;
20(2):147-53.

Zivkovic F, Ralph G, Tamussino K, Schied G, Walzl M.
Stress-overflow urinary incontinence after radical
hysterectomy and radiation therapy for cervical cancer.
Int Urogynecol J 1994;5(5):305-8.


Primary Radiotherapy


Acker JC, Marks LB. The lack of impact of pelvic irradiation
on small bowel mobility: implications for radiotherapy
treatment planning. Int J Radiat Oncol Biol Phys 1995  
Jul 30;32(5):1473-5.

Barillot I, Horiot JC, Cuisenier J, Pigneux J, Schraub S,
Rozan R, Pourquier H, Daly N, Vrousos C, Keiling R, 
et al. Carcinoma of the cervical stump: a review of 213
cases. Eur J Cancer 1993;29A(9):1231-6.

Barillot I, Horiot JC, Maingon P, Bone-Lepinoy MC,
Vaillant D, Feutray S. Maximum and mean bladder dose
defined from ultrasonography. Comparison with the
ICRU reference in gynaecological brachytherapy.
Radiother Oncol 1994 Mar;30(3):231-8.

Deshpande DD, Shrivastava SK, Nehru RM, Viswanathan
PS, Dinshaw KA. Treatment volume from total reference
air kerma (TRAK) in intracavitory applications and its
comparison with ICRU reference volume. Int J Radiat
Oncol Biol Phys 1994 Jan 15;28(2):499-504.

Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma
as an independent risk factor for disease recurrence in
patients with stage IB cervical carcinoma. Gynecol Oncol
1995 Oct;59(1):38-44.

Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time
course and incidence of late complications in patients
treated with radiation therapy for FIGO stage IB
carcinoma of the uterine cervix. Int J Radiat Oncol Biol
Phys 1995 Jul 30;32(5):1289-300.  Comment in: Int J
Radiat Oncol Biol Phys 1995 Jul 30;32(5):1531-4.

Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence
of tumor size and morphology on the outcome of patients
with FIGO stage IB squamous cell carcinoma of the
uterine cervix. Int J Radiat Oncol Biol Phys 1994 Apr 30;
29(1):9-16.

Grigsby PW, Georgiou A, Williamson JF, Perez CA.
Anatomic variation of gynecologic brachytherapy
prescription points. Int J Radiat Oncol Biol Phys 1993 
Oct 20;27(3):725-9.

Grigsby PW, Vest ML, Perez CA. Recurrent carcinoma of
the cervix exclusively in the paraaortic nodes following
radiation therapy. Int J Radiat Oncol Biol Phys 1994   
Jan 15;28(2):451-5.  Comment in: Int J Radiat Oncol Biol
Phys 1994 Sep 30;30(2):509.

Husseinzadeh N, Van Aken ML, Aron B. Ovarian
transposition in young patients with invasive cervical
cancer receiving radiation therapy. Int J Gynecol Cancer
1994;4(1):61-5.

Kato E, Morita K. [Treatment results of conformation
radiotherapy for stage I and II cervical cancer]. Nippon
Igaku Hoshasen Gakkai Zasshi 1995 Mar;55(4):240-6. 
(Jpn).

Kato E, Morita K. [2-axial conformational irradiation for
whole-pelvis irradiation of cervical cancer: improvement
and evaluation with DVH]. Nippon Igaku Hoshasen
Gakkai Zasshi 1994 Aug 25;54(9):897-907.  (Jpn).

Kim RY, McGinnis LS, Spencer SA, Meredith RF, Jennelle
RL, Salter MM. Conventional four-field pelvic
radiotherapy technique without computed tomography-treatment
planning in cancer of the cervix: potential
geographic miss and its impact on pelvic control. Int J
Radiat Oncol Biol Phys 1995 Jan 1;31(1):109-12.

Kim RY, McGinnis LS, Spencer SA, Meredith RF, Jennelle
RL, Salter MM. Conventional four-field pelvic
radiotherapy technique without CT treatment planning in
cancer of the cervix: potential geographic miss. Radiother
Oncol 1994 Feb;30(2):140-5.

Kleinerman RA, Boice JD Jr, Storm HH, Sparen P,
Andersen A, Pukkala E, Lynch CF, Hankey BF,
Flannery JT. Second primary cancer after treatment for
cervical cancer: an international cancer registries study.
Cancer 1995;76(3):442-52.

Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence
of treatment time on outcome for squamous cell cancer of
the uterine cervix treated with radiation: a
patterns-of-care
study. Int J Radiat Oncol Biol Phys 1993 Feb 15;25(3):
391-7.

Levenback C. Complications of radiotherapy for treatment of
cervix cancer. Clin Consult Obstet Gynecol 1995;7(2):
152-9.

Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson
DM. Hemorrhagic cystitis following radiotherapy for
stage Ib cancer of the cervix. Gynecol Oncol 1994 Nov;
55(2):206-10.

Lutgens LC, Schutte B, de Jong JM, Thunnissen FB. DNA
content as prognostic factor in cervix carcinoma stage
IB-III treated with radiotherapy. Gynecol Oncol 1994 Sep;
54(3):275-81.

McIntyre JF, Eifel PJ, Levenback C, Oswald MJ. Ureteral
stricture as a late complication of radiotherapy for stage
IB carcinoma of the uterine cervix. Cancer 1995 Feb 1;
75(3):836-43.

Meertens H, van Bunningen BN, Moonen LM, Steggerda
MJ, Blom AP, van den Berg AC. Brachytherapy.    
Annu Rep Neth Cancer Inst 1993:92.

Morita K, Kato E, Fuwa N, Ito Y. Conformational
radiotherapy for cervical cancer [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 414.

Nakano T, Arai T, Morita S, Oka K. Radiation therapy alone
for adenocarcinoma of the uterine cervix. Int J Radiat
Oncol Biol Phys 1995 Jul 30;32(5):1331-6.  Comment in:
Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1543-4.

Patton TJ, Mitchell MF, Atkinson EN, Eifel P, Gastorf L,
Yancey C, Miller D, Wharton JT. Parameters of small
bowel dysfunction in cervical cancer patients undergoing
radiotherapy. Int J Gynecol Cancer 1993;3(3):175-82.

Pearcey RG, Turner MJ. Inherent radiosensitivity and dna
ploidy as predictors of treatment response in patients with
carcinoma of the cervix [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 263.

Perez CA, Grigsby PW, Castro-Vita H, Lockett MA.
Carcinoma of the uterine cervix. I. Impact of prolongation
of overall treatment time and timing of brachytherapy on
outcome of radiation therapy. Int J Radiat Oncol Biol
Phys 1995 Jul 30;32(5):1275-88.  Comment in: Int J
Radiat Oncol Biol Phys 1995 Jul 30;32(5):1527-9.

Pernot M, Hoffstetter S, Peiffert D, Carolus JM,    
Guillemin F, Verhaeghe JL, Marchal C, Luporsi E,
Beckendorf V, Stines J, et al. [Statistical study of a
series
of 672 cases of carcinoma of the uterine cervix. Results
and complications according to age and modalities of
treatment]. Bull Cancer (Paris) 1995 Jul;82(7):568-81. 
(Fre).

Rotman M, Aziz H, Eifel PJ. Irradiation of pelvic and
para-aortic nodes in carcinoma of the cervix. Semin Radiat
Oncol 1994;4(1):23-9.

Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby
PW, Cooper J, John M. Prophylactic extended-field
irradiation of para-aortic lymph nodes in stages IIB and
bulky IB and IIA cervical carcinomas. Ten-year treatment
results of RTOG 79-20. JAMA 1995 Aug 2;274(5):   
387-93.  Comment in: JAMA 1995 Aug 2;274(5):427-8.

Schwarz R. [Results of radiotherapy of cervix cancer].
Zentralbl Gynakol 1993;115(12):537-40.  (Ger).

Sinistrero G, Sismondi P, Rumore A, Zola P. Analysis of
complications of cervix carcinoma treated by radiotherapy
using the Franco-Italian glossary. Radiother Oncol 1993
Mar;26(3):203-11.

Werner-Wasik M, Schmid CH, Bornstein LE,           
Madoc-Jones H. Increased risk of second malignant
neoplasms outside radiation fields in patients with cervical
carcinoma. Cancer 1995 May 1;75(9):2281-5.


Quality of Life Considerations


Bennetts A, Irwig L, Oldenburg B, Simpson JM, Mock P,
Boyes A, Adams K, Weisberg E, Shelley J. PEAPS-Q: a
questionnaire to measure the psychosocial effects of
having an abnormal pap smear. J Clin Epidemiol 1995;
48(10):1235-43.

Bruner DW, Lanciano R, Keegan M, Corn B, Martin E,
Hanks GE. Vaginal stenosis and sexual function following
intracavitary radiation for the treatment of cervical and
endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993
Nov 15;27(4):825-30.

Corney RH, Crowther ME, Everett H, Howells A, Shepherd
JH. Psychosexual dysfunction in women with
gynaecological cancer following radical pelvic surgery.
Br J Obstet Gynaecol 1993 Jan;100(1):73-8.

Cull A, Cowie VJ, Farquharson DI, Livingstone JR, Smart
GE, Elton RA. Early stage cervical cancer: psychosocial
and sexual outcomes of treatment. Br J Cancer 1993 Dec;
68(6):1216-20.

Flay LD, Matthews JH. The effects of radiotherapy and
surgery on the sexual function of women treated for
cervical cancer. Int J Radiat Oncol Biol Phys 1995      
Jan 15;31(2):399-404.

Krumm S, Lamberti J. Changes in sexual behavior following
radiation therapy for cervical cancer. J Psychosom Obstet
Gynaecol 1993 Mar;14(1):51-63.

Lalos A, Jacobsson L, Lalos O, Stendahl U. Experiences of
the male partner in cervical and endometrial cancer - a
prospective interview study. J Psychosom Obstet
Gynaecol 1995 Sep;16(3):153-65.

Lambley P. The role of psychological processes in the
aetiology and treatment of cervical cancer: a
biopsychological perspective. Br J Med Psychol 1993
Mar;66 Pt 1:43-60.  Published erratum appears in Br J
Med Psychol 1993 Sep;66(Pt 3):304.

Peipert JF, Wells CK, Schwartz PE, Feinstein AR.
Prognostic value of clinical variables in invasive cervical
cancer. Obstet Gynecol 1994 Nov;84(5):746-51.

Peipert JF, Wells CK, Schwartz PE, Feinstein AR. The
impact of symptoms and comorbidity on prognosis in
stage IB cervical cancer. Am J Obstet Gynecol 1993 Sep;
169(3):598-604.

Rollison B, Strang P. Pain, nausea and anxiety during
intra-uterine brachytherapy of cervical carcinomas. Support
Care Cancer 1995 May;3(3):205-7.

Speca M, Robinson JW, Goodey E, Frizzell B. Patients
evaluate a quality of life scale: whose life is it anyway?
Cancer Pract 1994 Sep-Oct;2(5):365-70.

Thranov I, Klee M. Sexuality among gynecologic cancer
patients--a cross-sectional study. Gynecol Oncol 1994
Jan;52(1):14-9.  Comment in: Gynecol Oncol 1994 Jan;
52(1):10-3.

Werngren-Elgstrom M, Lidman D. Lymphoedema of the
lower extremities after surgery and radiotherapy for
cancer of the cervix. Scand J Plast Reconstr Surg Hand
Surg 1994 Dec;28(4):289-93.



New Surgical Approaches


Bolla M, Sarrazin R, Salvat J, Berland E, Schmidt MH,
Rolachon I. [Feasibility of retroperitoneal pelvic lymph
node exploration in cervix-carcinoma treated by
radio-surgery association or a definitive radiotherapy. A
retrospective study of 52 cases]. Bull Cancer Radiother
1995;82(3):326-31.  (Fre).

Childers JM, Nasseri A. Minimal access surgery in
gynecologic cancer: we can, but should we? Curr Opin
Obstet Gynecol 1995 Feb;7(1):57-62.

Childers JM, Surwit EA. Current status of operative
laparoscopy in gynecologic oncology. Oncology
(Huntingt) 1993 Nov;7(11):47-51; discussion 53-4, 57.

Clough KB, Renolleau C, Durand JC. [Should laparoscopic
lymphadenectomy modify the therapeutic protocols for
cancer of the cervix?] J Gynecol Obstet Biol Reprod
(Paris) 1994;23(6):671-5.  (Fre).

Dargent D, Roy M, Keita N, Mathevet P, Adeleine P. The
schauta operation: its place in the management of cervical
cancer in 1993. Paper presented at: 24th Annual Meeting
of the Society of Gynecologic Oncologists; 1993        
Feb 7-10; Palm Desert, CA.
Delgado G, Potkul RK, Dolan JR. Retroperitoneal radical
hysterectomy. Gynecol Oncol 1995 Feb;56(2):191-4.

Fidalgo de Matos CJ, Querleu D, Leblanc E. [Pelvic
endoscopic lymphadenectomy in the assessment of early
cancer of the uterine neck: survey of 25 French hospital
centers]. Rev Med Brux 1993 Jun;14(6):163-8.  (Fre).

Gallup DG, King LA, Messing MJ, Talledo OE. Paraaortic
lymph node sampling by means of an extraperitoneal
approach with a supraumbilical transverse sunrise
incision. Am J Obstet Gynecol 1993 Aug;169(2 Pt 1):
307-11; discussion 311-2.

Hatch KD, Hallum AV 3d, Surwit EA, Childers JM. The
role of laparoscopy in gynecologic oncology. Cancer
1995;76(10 Suppl):2113-6.

Kadar N. Laparoscopic resection of fixed and enlarged aortic
lymph nodes in patients with advanced cervix cancer.
Gynaecol Endosc 1993;2(4):217-21.

Kadar N. Laparoscopic vaginal radical hysterectomy: an
operative technique and its evolution. Gynaecol Endosc
1994;3(2):109-22.

Kadar N, Pelosi MA. Can cervical cancer be adequately
staged by laparoscopic aortic lymphadenectomy?
Gynaecol Endosc 1994;3(4):213-6.

Kadar N, Reich H. Laparoscopically assisted radical Schauta
hysterectomy and bilateral laparoscopic pelvic
lymphadenectomy for the treatment of bulky stage IB
carcinoma of the cervix. Gynaecol Endosc 1993;2(3):
135-42.

Lee CL, Huang KG, Lai YM, Lai CH, Soong YK. Ureteral
injury during laparoscopically assisted radical vaginal
hysterectomy. Hum Reprod 1995;10(8):2047-9.

Lichtenegger W. The vaginal radical operation of cervical
cancer. J Obstet Gynaecol 1995;21(2):179-84.

Mage G, Canis M, Pouly JL, Wattiez A, Glowaczower E,
Raiga J, Bruhat M. [Wertheim hysterectomy].            
Ref Gynecol Obstet 1994;2(Spec Iss):140-8.  (Fre).

Magrina JF, Serrano L, Cornella JL. Laparoscopic
lymphadenectomy and radical or modified radical vaginal
hysterectomy for endometrial and cervical carcinoma:
preliminary experience. J Gynecol Surg 1995;11(3):  
147-51.

Massi G, Savino L, Susini T. Schauta-Amreich vaginal
hysterectomy and Wertheim-Meigs abdominal
hysterectomy in the treatment of cervical cancer: a
retrospective analysis. Am J Obstet Gynecol 1993 Mar;
168(3 Pt 1):928-34.  Comment in: Am J Obstet Gynecol
1994 Jul;171(1):287-8.

Nezhat CR, Nezhat FR, Burrell MO, Ramirez CE, 
Welander C, Carrodeguas J, Nezhat CH. Laparoscopic
radical hysterectomy and laparoscopically assisted vaginal
radical hysterectomy with pelvic and paraaortic node
dissection. J Gynecol Surg 1993 Summer;9(2):105-20.

Plante M, Roy M. The use of operative laparoscopy in
determining eligibility for pelvic exenteration in patients
with recurrent cervical cancer. Gynecol Oncol 1995 Dec;
59(3):401-4.

Querleu D. Laparoscopic paraaortic node sampling in
gynecologic oncology: a preliminary experience. 
Gynecol Oncol 1993 Apr;49(1):24-9.

Querleu D. Laparoscopically assisted radical vaginal
hysterectomy. Gynecol Oncol 1993 Nov;51(2):248-54.

Querleu D, Leblanc E, Castelain B, Elhage A. [Celioscopic
pelvic and para-aortic lymphadenectomy]. Chirurgie
1993-94;119(4):208-11.  (Fre).

Stitt JC, Elg SA. Laparoscopic lymph node dissection in the
evaluation and management of patients with pelvic
malignancy. Mil Med 1995 Sep;160(9):462-4.

Su TH, Wang KG, Yang YC, Hong BK, Huang SH.
Laparoscopic para-aortic lymph node sampling in the
staging of invasive cervical carcinoma: including a
comparative study of 21 laparotomy cases. Int J Gynaecol
Obstet 1995;49(3):311-8.

Wattiez A, Raymond F, Canis M, Chapron C, Pouly JL,
Mage G, Bruhat MA. [External iliac lymphadenectomy
by celioscopy: surgical technique]. Ann Chir 1993;47(6):
523-8.  (Fre).

Wurtz A, Porte H, Gambiez L, Jaillard-Thery S,     
Chambon JP, Mazeman E. [Value of iliac direct-view
retroperitoneoscopy (or extraperitoneal pelvioscopy) in
the assessment of lymph node invasion by pelvic cancer].
Ann Chir 1995;49(5):383-9.  (Fre).

Adjuvant Therapy After Hysterectomy


Atkovar G, Uzel O, Ozsahin M, Koca S, Sahinler I,    
Okkan S, Uzel R. Postoperative radiotherapy in
carcinoma of the cervix: treatment results and prognostic
factors. Radiother Oncol 1995 Jun;35(3):198-205.

Chatani M, Matayoshi Y, Masaki N, Narumi Y, Teshima T,
Inoue T. Prophylactic irradiation of para-aortic lymph
nodes in carcinoma of the uterine cervix. A prospective
randomized study. Strahlenther Onkol 1995 Nov;171(11):
655-60.

Fang FM, Yeh CY, Lai YL, Chiou JF, Chang KH.
Radiotherapy following simple hysterectomy in patients
with invasive carcinoma of the uterine cervix. J Formos
Med Assoc 1993 May;92(5):420-5.

Foley M, Lenehan P, Murphy J, Kelehan P. Adjuvant
radiotherapy reduces the incidence of central pelvic
failure following radical hysterectomy for large cervical
tumors. Paper presented at: European Society of
Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Frigerio L, Busci L, Rabaiotti E, Mariani A. Adjunctive
radiotherapy after radical hysterectomy in high risk early
stage cervical carcinoma. Assessment of morbidity and
recurrences. Eur J Gynaecol Oncol 1994;15(2):132-7.

Gadducci A, Fabrini MG, Bonuccelli A, Fanucchi A,
Perutelli A, Facchini V. Recurrence patterns in patients
with early stage cervical cancer treated with radical
hysterectomy and external pelvic irradiation. Anticancer
Res 1995 May-Jun;15(3):1071-7.

Inoue T, Morita K. Long-term observation of patients treated
by postoperative extended-field irradiation for nodal
metastases from cervical carcinoma stages IB, IIA, and
IIB. Gynecol Oncol 1995 Jul;58(1):4-10.  Comment in:
Gynecol Oncol 1995 Jul;58(1):1-3.

Killackey MA, Boardman L, Carroll DS. Adjuvant
chemotherapy and radiation in patients with poor
prognostic stage Ib/IIa cervical cancer. Gynecol Oncol
1993 Jun;49(3):377-9.  Comment in: Gynecol Oncol 1995
Jan;56(1):147.

Li QD, Liu EC, Zhang BL. [Treatment of stage I and II
cervical carcinoma by non-radical operation with or
without radiation]. Chung Kuo Chung Liu Lin Chuang
1995;22(9):654-7.  (Chi).

Mitsuhashi N, Takahashi M, Yamakawa M, Nozaki M,
Takahashi T, Sakurai H, Maebayashi K, Hayakawa K,
Niibe H. Results of postoperative radiation therapy for
patients with carcinoma of the uterine cervix: evaluation
of intravaginal cone boost with an electron beam.
Gynecol Oncol 1995 Jun;57(3):321-6.

Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS,
Manetta A, DiSaia PJ, Berman ML. Extent of disease as
an indication for pelvic radiation following radical
hysterectomy and bilateral pelvic lymph node dissection
in the treatment of stage IB and IIA cervical carcinoma.
Gynecol Oncol 1994 Jul;54(1):4-9.  Comment in:
Gynecol Oncol 1994 Jul;54(1):1-3.

Pedulla F, Centurioni MG, Foglia G, Ferrari I, Orsatti M,
Vitale V, Ragni N. Treatment of FIGO stage Ib cervical
carcinoma with nodal involvement. Eur J Gynaecol Oncol
1994;15(1):59-64.

Perez CA, Grigsby PW, Camel HM, Galakatos AE,    
Mutch D, Lockett MA. Irradiation alone or combined
with surgery in stage IB, IIA, and IIB carcinoma of
uterine cervix: update of a nonrandomized comparison.
Int J Radiat Oncol Biol Phys 1995 Feb 15;31(4):703-16. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Feb 15;
31(4):1007-8.

Robertson DI, Paslawski D, Duggan MA, Stuart GC, Nation
JG. Estrogen and progesterone receptor, human
papillomavirus, and DNA ploidy analysis in invasive
carcinoma of the cervix in pregnancy. Am J Clin Pathol
1993 Jul;100(1):18-21.

Roman LD, Morris M, Mitchell MF, Eifel PJ, Burke TW,
Atkinson EN. Prognostic factors for patients undergoing
simple hysterectomy in the presence of invasive cancer of
the cervix. Gynecol Oncol 1993 Aug;50(2):179-84.

Stitt JA. Use of postoperative irradiation for carcinoma of
the cervix. Semin Radiat Oncol 1994;4(1):41-5.

Stock RG, Chen AS, Flickinger JC, Kalnicki S, Seski J.
Node-positive cervical cancer: impact of pelvic irradiation
and patterns of failure. Int J Radiat Oncol Biol Phys 1995
Jan 1;31(1):31-6.

Sutton G, Bundy B, Delgado G, Sevin B, Creasman W,
Major F, Zaino R. Evaluation of pelvic radiotherapy
following radical hysterectomy in patients with clinical
stage IB squamous carcinoma of the cervix: a study of the
Gynecologic Oncology Group. Paper presented at: 24th
Annual Meeting of the Society of Gynecologic
Oncologists; 1993 Feb 7-10; Palm Desert, CA.

Takamura A, Mizoe J, Arimoto T, Kamada T, Shirato H,
Matsuoka Y, Tomita M, Irie G. Is postoperative
radiotherapy beneficial in the management of stage I-II
squamous-cell carcinoma of the uterine cervix with
negative metastatic nodes and positive parametrial
involvement? A retrospective review of 70 patients. Asia
Oceania J Obstet Gynaecol 1993 Jun;19(2):145-51.

Toita T, Takizawa Y, Sueyama H, Yamaguchi K, Kushi A,
Ogawa K, Hara R, Nakano M, Higashi M, Sakumoto K,
et al. [Role of postoperative irradiation for carcinoma of
the uterine cervix: multivariate analysis of prognostic
factors and patterns of failure]. Nippon Igaku Hoshasen
Gakkai Zasshi 1994 Feb 25;54(2):163-70.  (Jpn).

Zanetta G, Colombo A, Maneo A, Colombo M, Nava S,
Landoni F, Mangioni C. Postoperative treatments for
stage Ib-IIa cervical carcinoma with lymph node
metastases after primary surgery: complications and
efficacy of three different methods. Ital J Gynaecol Obstet
1995;7(2):45-50.

Zanetta G, Colombo A, Milani R, Placa F, Mangioni C.
Long-term results of sequential postoperative treatment
with vincristine, bleomycin, mitomycin C, cis-platin and
radiotherapy after surgery for high-risk patients with
cervical carcinoma stage IB-IIA. Int J Gynecol Cancer
1995;5(1):40-4.


Adjuvant Surgery After Radiotherapy


Cabrera J, Tirapegui E, Fluxa L, Fernandez M, Perez C,
Mucientes F, Klaassen R, Poloni O, Boggiano G. [Results
of combined treatment of early cervicouterine cancer].
Rev Chil Obstet Ginecol 1994;59(2):128-34.  (Spa).

Fras AP. Residual carcinoma of the uterine cervix after
low-dose preoperative intracavitary irradiation. Radiol
Oncol 1995;29(1):15-8.

Gerdin E, Cnattingius S, Johnson P. Complications after
radiotherapy and radical hysterectomy in early-stage
cervical carcinoma. Acta Obstet Gynecol Scand 1995
Aug;74(7):554-61.

Monk BJ, Solh S, Johnson MT, Montz FJ. Radical
hysterectomy after pelvic irradiation in patients with high
risk cervical cancer or uterine sarcoma: morbidity and
outcome. Eur J Gynaecol Oncol 1993;14(6):506-11.

Perez CA, Grigsby PW, Camel HM, Galakatos AE,    
Mutch D, Lockett MA. Irradiation alone or combined
with surgery in stage IB, IIA, and IIB carcinoma of
uterine cervix: update of a nonrandomized comparison.
Int J Radiat Oncol Biol Phys 1995 Feb 15;31(4):703-16. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Feb 15;
31(4):1007-8.

Pernot M, Hoffstetter S, Peiffert D, Carolus JM,    
Guillemin F, Verhaeghe JL, Marchal C, Luporsi E,
Beckendorf V, Stines J, et al. [Statistical study of a
series
of 672 cases of carcinoma of the uterine cervix. Results
and complications according to age and modalities of
treatment]. Bull Cancer (Paris) 1995 Jul;82(7):568-81. 
(Fre).

Poka R, Szluha K, Hernadi Z, Juhasz B, Lampe L. Analysis
of survival in stage Ib and IIa cervical cancer treated with
or without preoperative local radiotherapy. Eur J
Gynaecol Oncol 1995;16(3):208-11.

Scalliet P, Kramar A, Lambin P, Bouzy J, Haie-Meder C,
Gerbaulet A, Chassagne D. Prospective registration vs
retrospective assessment of side-effects and
complications: comparison of two series of patients
treated at Institut Gustave Roussy for uterine cervix
carcinoma [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 196.

Srisupundit S, Tangtrakul S, Linasmita V, Bullangpoti S,
Kraiphibul P, Pojchanugool L. Combined radiotherapy
and hysterectomy in the treatment of high risk stage II
invasive carcinoma of the uterine cervix. Gan To Kagaku
Ryoho 1995 Aug;22 Suppl 3:256-61.


MANAGEMENT OF ADVANCED-STAGE AND
RECURRENT CERVICAL CANCER

Radiotherapy


Antonadou D, Synodinou M, Katsoulis M, Synodinos D,  
Zis I, Throuvalas N. Evaluation of preoperative versus
post-operative combined RT in early carcinoma of the
uterine cervix [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 416.

Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B,
Simpson P, Hill M, Ali M. Heuristically derived tumor
burden score as a prognostic factor for stage IIIB
carcinoma of the cervix. Int J Radiat Oncol Biol Phys
1995 Feb 15;31(4):743-51.

Ash D, Bates T. Report on the clinical effects of
inadvertent radiation underdosage in 1045 patients. Clin
Oncol (R Coll Radiol) 1994;6(4):214-26.

Baldini B, Lastruccl L, Moncini D, Santoni R, Savino L,
Susini T, Taddei GL. Radiation therapy followed by
surgery in the treatment of 83 patients with clinical stage
IIB cervical carcinoma. Paper presented at: European
Society of Gynaecological Oncology 8th International
Meeting: Prevention, early detection, diagnosis,
management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Biswal BM, Mohanti BK, Rath GK, Kumar L, Kriplani A,
Ganesh T, Takkar D, Kumar S. Results of radical
radiotherapy in carcinoma of the uterine cervix stage I-III.
Clin Oncol (R Coll Radiol) 1994;6(6):356-60.

Carl UM, Bahnsen J, Wiegel T. Radiation therapy of
para-aortic lymph nodes in cancer of the uterine cervix.    
Acta Oncol 1993;32(1):63-7.

Choy D, Wong LC, Sham J, Ngan HY, Ma HK. Dose-tumor
response of carcinoma of cervix: an analysis of 594
patients treated by radiotherapy. Gynecol Oncol 1993
Jun;49(3):311-7.

Corn BW, Hanlon AL, Pajak TF, Owen J, Hanks GE.
Technically accurate intracavitary insertions improve
pelvic control and survival among patients with locally
advanced carcinoma of the uterine cervix. Gynecol Oncol
1994 Jun;53(3):294-300.

De Neve W, Van den Heuvel F, Coghe M, Verellen D, De
Beukeleer M, Roelstraete A, De Roover P, Thon L,
Storme G. Interactive use of on-line portal imaging in
pelvic radiation. Int J Radiat Oncol Biol Phys 1993     
Feb 15;25(3):517-24.

Eifel PJ, Thoms WW Jr, Smith TL, Morris M, Oswald MJ.
The relationship between brachytherapy dose and
outcome in patients with bulky endocervical tumors
treated with radiation alone. Int J Radiat Oncol Biol Phys
1994 Jan 1;28(1):113-8.

Eisbruch A, Williamson JF, Dickson DR, Grigsby PW, Perez
CA. Estimation of tissue volume irradiated by
intracavitary implants. Int J Radiat Oncol Biol Phys 1993
Mar 15;25(4):733-44.  Comment in: Int J Radiat Oncol
Biol Phys 1994 Apr 30;29(1):217-8.

Fine BA, Hempling RE, Piver MS, Baker TR, McAuley M,
Driscoll D. Severe radiation morbidity in carcinoma of
the cervix: impact of pretherapy surgical staging and
previous surgery. Int J Radiat Oncol Biol Phys 1995   
Feb 15;31(4):717-23.  Comment in: Int J Radiat Oncol
Biol Phys 1995 Feb 15;31(4):1009-10.

Formenti SC, Meyerowitz BE, Ell K, Muderspach L,
Groshen S, Leedham B, Klement V, Morrow PC.
Inadequate adherence to radiotherapy in Latina
immigrants with carcinoma of the cervix. Potential impact
on disease free survival. Cancer 1995 Mar 1;75(5): 
1135-40.

Fyles AW, Pintilie M, Kirkbride P, Levin W, Manchul LA,
Rawlings GA. Prognostic factors in patients with cervix
cancer treated by radiation therapy: results of a multiple
regression analysis. Radiother Oncol 1995 May;35(2):
107-17.

Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A,
Randrianarivello H, Chassagne D. Overall treatment time
in advanced cervical carcinomas: a critical parameter in
treatment outcome. Int J Radiat Oncol Biol Phys 1993
Dec 1;27(5):1051-6.

Hanba K, Nakano T, Hukuhisa K, Morita S, Arai T. Long-term
prognosis for patients with cervical cancer treated
with intracavitary irradiation [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 274.

Harrington KJ, Lambert HE, Kelly SA, Lai PS, Price GD.
Prostaglandin-induced cervical dilatation prior to
intracavitary radiotherapy for carcinoma of the cervix: a
pilot study. Int J Gynecol Cancer 1994;4(6):404-7.

Hopkins MP, Morley GW. Prognostic factors in advanced
stage squamous cell cancer of the cervix. Cancer 1993
Oct 15;72(8):2389-93.

Horiot JC, Barillot I, Pigneux J, Schraub S, Pourquier H,
Daly N, Bolla M, Rozan R. Carcinoma of the uterine
cervix treated with radiotherapy alone: prognostic factors
and prevention of complications [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 415.

Komaki R, Brickner TJ, Hanlon AL, Owen JB, Hanks GE.
Long-term results of treatment of cervical carcinoma in
the United States in 1973, 1978, and 1983: Patterns of
Care Study (PCS). Int J Radiat Oncol Biol Phys 1995 
Feb 15;31(4):973-82.

Lanciano R, Corn B, Martin E, Schultheiss T, Hogan WM,
Rosenblum N. Perioperative morbidity of intracavitary
gynecologic brachytherapy. Int J Radiat Oncol Biol Phys
1994 Jul 30;29(5):969-74.

Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence
of treatment time on outcome for squamous cell cancer of
the uterine cervix treated with radiation: a
patterns-of-care
study. Int J Radiat Oncol Biol Phys 1993 Feb 15;25(3):
391-7.

Ma DM. [Outcome and complications of treatment by
intracavitary afterloading radiotherapy in 143 patients
with cervical cancer]. Chung Hua Fu Chan Ko Tsa Chih
1993 Nov;28(11):646-8, 699.  (Chi).

Marcial VA, Komaki R. Altered fractionation and
extended-field irradiation of carcinoma of the cervix.
Cancer 1995;76(10 Suppl):2152-8.

Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M,
Takahashi T, Sakurai H, Hayakawa K, Niibe H.
Evaluation of external beam therapy and three
brachytherapy fractions for carcinoma of the uterine
cervix. Int J Radiat Oncol Biol Phys 1994 Jul 30;29(5):
975-82.  Comment in: Int J Radiat Oncol Biol Phys 1994
Jul 30;29(5):1195-7.

Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M,
Takahashi T, Sakurai H, Maebayashi K, Hayakawa K,
Niibe H. Squamous cell carcinoma of the uterine cervix:
radiation therapy for patients aged 70 years and older.
Radiology 1995 Jan;194(1):141-5.

Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE,
Ling CC, Komaki R, Marcial VA, Thomas GM,
Lanciano R. Carcinoma of the cervix: patterns of care
studies: review of 1978, 1983, and 1988-1989 surveys.
Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1481-6. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Jul 30;
32(5):1535-7.

Morita K, Kato E, Fuwa N, Ito Y. Conformational
radiotherapy for cervical cancer [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 414.

Natali M, Chiarlone R, Siccardi C, Luzi G, Marziano C.
Radiotherapy exclusive in the carcinoma of the uterine
cervix. Paper presented at: European Society of
Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Pedersen D, Bentzen SM, Overgaard J. Continuous or
split-course combined external and intracavitary
radiotherapy of locally advanced carcinoma of the uterine
cervix. Acta Oncol 1994;33(5):547-55.

Pedersen D, Bentzen SM, Overgaard J. Early and late
radiotherapeutic morbidity in 442 consecutive patients
with locally advanced carcinoma of the uterine cervix. 
Int J Radiat Oncol Biol Phys 1994 Jul 30;29(5):941-52. 
Comment in: Int J Radiat Oncol Biol Phys 1995 Mar 30;
31(5):1349-51.

Pedersen D, Bentzen SM, Overgaard J. Reporting
radiotherapeutic complications in patients with uterine
cervical cancer. The importance of latency and
classification system. Radiother Oncol 1993 Aug;28(2):
134-41.

Pedersen D, Sogaard H, Overgaard J, Bentzen SM.
Prognostic value of pretreatment factors in patients with
locally advanced carcinoma of the uterine cervix treated
by radiotherapy alone. Acta Oncol 1995;34(6):787-95.

Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann
TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA.
The adverse effect of treatment prolongation in cervical
carcinoma. Int J Radiat Oncol Biol Phys 1995 Jul 30;
32(5):1301-7.  Comment in: Int J Radiat Oncol Biol Phys
1995 Jul 30;32(5):1527-9.

Prasad KN, Pradhan S, Datta NR. Urinary tract infection in
patients of gynecological malignancies undergoing
external pelvic radiotherapy. Gynecol Oncol 1995 Jun;
57(3):380-2.

Senanayake LF, Sun SL, Collis C, Tate AT, Skeggs DB,
Davy TJ. Conformation therapy using a computer
controlled telecobalt unit for advanced cervical
carcinoma. Clin Oncol (R Coll Radiol) 1994;6(5):308-13.

Sismondi P, Zola P, Sinistrero G, Rumore A, Katsaros D.
Cervical cancer treatment complications: the Italian
multicenter study. Paper presented at: European Society
of Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Smart GP. Isometric wedge shielding for pelvic boost
external beam therapy after Curietron treatments.
Australas Phys Eng Sci Med 1994 Dec;17(4):221-5.

Snijders-Keilholz A, van Acht M, de Vroome H, Hermans J,
Trimbos JB, Leer JW. Pelvic failure rate and radiation
toxicity in relation to total dose of radiation alone for
the
treatment of cancer of the uterine cervix. Clin Oncol    
(R Coll Radiol) 1993;5(1):6-10.

To WW, Ngan HY, Wong LC, Choy DT, Ma HK. Use of
prophylactic antibiotics in patients with carcinoma of the
cervix receiving intracavitary radium insertion. Eur J
Gynaecol Oncol 1993;14(3):197-201.

Toita T, Takizawa Y, Nakano M, Sueyama H, Kushi A,
Kakihana Y, Ogawa K, Hara R, Higashi M, Sakumoto K,
et al. Radical radiation therapy for adenocarcinoma of the
uterine cervix. Strahlenther Onkol 1994 May;170(5): 
277-80.

Vedula R. Implication of uterine configuration on dosimetry
to point A using the Amersham afterloading system. Int J
Radiat Oncol Biol Phys 1993 Mar 15;25(4):721-31.

Vermund H. Evolution of brachytherapy in the treatment of
uterine cervical carcinoma: a review. Endocuriether
Hyperthermia Oncol 1995;11(1):1-8.

Vermund H, Alqaisi ME, Chenier T, Christie KI, Semer DA,
Wiley AL Jr. Interstitial and intracavitary brachytherapy
in carcinoma of the uterine cervix. Endocuriether
Hyperthermia Oncol 1995;11(1):43-55.

Xiang EW. Long term results of 60Co HDR after-loading in
the treatment of cervical cancer. Chung Hua Chung Liu
Tsa Chih 1993;15(2):114-7.

Yeoh E, Horowitz M, Russo A, Muecke T, Ahmad A,  
Robb T, Chatterton B. A retrospective study of the effects
of pelvic irradiation for carcinoma of the cervix on
gastrointestinal function. Int J Radiat Oncol Biol Phys
1993 May 20;26(2):229-37.


High- or Low-Dose Rate Brachytherapy


Arterbery VE. High-dose rate brachytherapy for carcinoma
of the cervix. Curr Opin Oncol 1993 Nov;5(6):1005-9.

Boothby R, Clark K, Forbes A, Wheppelemann B,   
Castaldo T. Use of nasopharyngeal (NP) tube as an
endocervical sleeve for high dose remote afterloading
(HDR) in patients with cervical cancer [abstract].      
Proc Annu Meet Am Soc Clin Oncol 1994;13:A838.

Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. A
prospective randomized study concerning the point A
dose in high-dose rate intracavitary therapy for carcinoma
of the uterine cervix. The final results. Strahlenther Onkol
1994 Nov;170(11):636-42.

Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. [A
prospective randomized study concerning the point A
dose in high-dose rate intracavitary therapy for carcinoma
of the uterine cervix]. Rinsho Hoshasen 1994;39(10):
1155-60.  (Jpn).

Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T.
Long term follow-up results of high-dose rate remote
afterloading intracavitary radiation therapy for carcinoma
of the uterine cervix. Strahlenther Onkol 1994 May;
170(5):269-76.

Chiou JF, Liu MT, Lai YL, Chang KH. High-dose-rate
afterloading brachytherapy in carcinoma of the uterine
cervix. J Formos Med Assoc 1993 Feb;92(2):165-73.

Cikaric S. HDR brachytherapy of cervix carcinoma applied
to 272 younger and 119 older than 60 years patients:
comparison of 5-year results and complications [abstract]. 
In: ICRO'93 - International Congress of Radiation
Oncology - Preprinted abstracts and programme; 1993
Jun 21-25; Kyoto, Japan. [place unknown]: International
Society for Radiation Oncology; 1993. p. 275.

Corn BW, Galvin JM, Soffen EM, Henze G, Schwaibold F.
Positional stability of sources during low-dose-rate
brachytherapy for cervical carcinoma. Int J Radiat Oncol
Biol Phys 1993 Jun 15;26(3):513-8.

Dinshaw KA, Shrivastava SK, Deore SM. Influence of dose-rate
on clinical end points: analysis using l-Q model
[abstract].  In: ICRO'93 - International Congress of
Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 99.

Fushiki M, Suyama S, Kawakami K, Takahashi M,     
Matsui A, Sho K, Yabumoto E, Morita R. Previous
treatment results and new patterns of care for
radiotherapy of the uterine cervical cancer [abstract].  In:
ICRO'93 - International Congress of Radiation Oncology
- Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 415.

Gerbaulet A, Lartigau E. Low dose rate and high dose rate
brachytherapy [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 96.

Grigsby PW, Slessinger ED, Teague SP, Williamson JF,
Perez CA. Clinical evaluation of an interstitial remote
afterloading device for multichannel intracavitary
irradiation. Int J Radiat Oncol Biol Phys 1995 Feb 15;
31(4):875-81.

Haie-Meder C, Kramar A, Lambin P, Lancar R, Scalliet P,
Bouzy J, Gerbaulet A. Analysis of complications in a
prospective randomized trial comparing two
brachytherapy low dose rates in cervical carcinoma. Int J
Radiat Oncol Biol Phys 1994 Jul 30;29(5):953-60. 
Comments in: Int J Radiat Oncol Biol Phys 1994 Jul 30;
29(5):1195-7; Int J Radiat Oncol Biol Phys 1995 Mar 30;
31(5):1349-51.

Hammer J, Zoidl JP, Altendorfer C, Seewald DH, Track C,
Stummvoll W, Labeck W. Combined external and high
dose rate intracavitary radiotherapy in the primary
treatment of cancer of the uterine cervix. Radiother Oncol
1993 Apr;27(1):66-8.

Herrmann T, Christen N, Alheit HD. [Gynecologic
brachytherapy--from low-dose-rate to high-tech].
Strahlenther Onkol 1993 Mar;169(3):141-51.  (Ger).

Hsu WL, Wu CJ, Jen YM, Yen SH, Lin KT, Ger LP, Kim
RY. Twice-per-day fractionated high versus continuous
low dose rate intracavitary therapy in the radical
treatment of cervical cancer: a nonrandomized
comparison of treatment results. Int J Radiat Oncol Biol
Phys 1995 Jul 30;32(5):1425-31.

Hunter R. Clinical experience of changing dose rate
[abstract]. Eur J Cancer 1993;29A Suppl 6:S36.

Ito H, Kutuki S, Nishiguchi I, Kuribayashi T, Nakayama T,
Takemasa K, Uematsu M, Ando Y, Ogawa K.
[Radiotherapy for cervical cancer patients with high-dose
rate brachytherapy: application of shielded colpostats].
Nippon Igaku Hoshasen Gakkai Zasshi 1994 Jan 25;
54(1):46-54.  (Jpn).

Ito H, Kutuki S, Nishiguchi I, Shigematsu N, Kuribayashi T,
Uematsu M, Nakayama T, Ka WJ, Takemasa K, Ando Y,
et al. Radiotherapy for cervical cancer with high-dose rate
brachytherapy--correlation between tumor size, dose and
failure. Radiother Oncol 1994 Jun;31(3):240-7.

Itoh H, Ogawa K. [Radiotherapy for cervical cancer patients;
modification of dose distribution by shielded colpostats].
Rinsho Hoshasen 1994;39(6):673-84.  (Jpn).

Jones G, Lukka H, O'Brien B. High dose rate versus low
dose rate brachytherapy for squamous cell carcinoma of
the cervix: an economic analysis. Br J Radiol 1994 Nov;
67(803):1113-20.

Kim RY, Meyer JT, Plott WE, Spencer SA, Meredith RF,
Jennelle RL, Salter MM. Major geometric variations
between multiple high-dose-rate applications of
brachytherapy in cancer of the cervix: frequency and
types of variation. Radiology 1995 May;195(2):419-22.

Kutsutani-Nakamura Y, Furukawa S, Tabushi K, Nakano T,
Ishii T, Arai T. Relationship of time dose and
fractionation in fractionated high dose rate and low dose
rate regimens for intracavitary brachytherapy of the
cervix [abstract].  In: ICRO'93 - International Congress
of Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 377.

Lambin P, Gerbaulet A, Kramar A, Scalliet P,              
Haie-Meder C, Malaise EP, Chassagne D. Phase III trial
comparing two low dose rates in brachytherapy of cervix
carcinoma: report at two years. Int J Radiat Oncol Biol
Phys 1993 Feb 15;25(3):405-12.

Lambin P, Gerbaulet A, Kramar A, Scalliet P,              
Haie-Meder C, Michel G, Prade M, Bouzy J,      
Malaise EP, Chassagne D. A comparison of early effects
with two dose rates in brachytherapy of cervix carcinoma
in a prospective randomised trial. Eur J Cancer 1994;
30A(3):312-20.

Lancar R, Kramar A, Haie-Meder C, Lambin P, Bouzy J,
Scalliet P, Gerbaulet A. [Method for evaluating long term
complications. A study from a phase III trial comparing
two low dose rates in gynecologic brachytherapy].     
Bull Cancer (Paris) 1994 Jul;81(7):632-7.  (Fre).

Le Pechoux C, Akine Y, Sumi M, Tokuuye K, Ikeda H,
Yajima M, Yamada T, Tanemura K, Tsunematsu R,
Ohmi K, et al. High dose rate brachytherapy for
carcinoma of the uterine cervix: comparison of two
different fractionation regimens. Int J Radiat Oncol Biol
Phys 1995 Feb 15;31(4):735-41.  Comment in: Int J
Radiat Oncol Biol Phys 1995 Feb 15;31(4):1011-3.

Lou HK. [Afterloading intracavitary irradiation therapy for
cancer of uterine cervix]. Chung Hua Fu Chan Ko Tsa
Chih 1993 Nov;28(11):649-50, 699.  (Chi).

Mayer A, Nemeth G, Nemeskeri C, Thalacker U.
[Preoperative low-dose-rate versus high-dose-rate
brachytherapy in stage IB cervix cancer. An efficacy
study]. Strahlenther Onkol 1993 Dec;169(12):716-20. 
(Ger).

Meden H, Busch M, Bartels U, Tsikuras P, Rath W,
Duhmke E, Kuhn W. Experience with a new flexible
applicator system for intracavitary radiotherapy of
cervical cancer. Onkologie 1994;17(6):604-7.

Nag S, Abitbol AA, Anderson LL, Blasko JC, Flores A,
Harrison LB, Hilaris BS, Martinez AA, Mehta MP,  
Nori D, et al. Consensus guidelines for high dose rate
remote brachytherapy in cervical, endometrial, and
endobronchial tumors. Clinical Research Committee,
American Endocurietherapy Society. Int J Radiat Oncol
Biol Phys 1993 Dec 1;27(5):1241-4.

Nair MT, Cheng MC, Barker A, Rouse BS. High dose rate
(HDR) brachytherapy technique: for carcinoma of uterine
cervix using Nucletron applicators. Med Dosim 1995
Fall;20(3):201-7.

Niel CG, Koper PC, Visser AG, Sipkema D, Levendag PC.
Optimizing brachytherapy for locally advanced cervical
cancer. Int J Radiat Oncol Biol Phys 1994 Jul 1;29(4):
873-7.

Noyes WR, Peters NE, Thomadsen BR, Fowler JF, Buchler
DA, Stitt JA, Kinsella TJ. Impact of optimized treatment
planning for tandem and ring, and tandem and ovoids,
using high dose rate brachytherapy for cervical cancer.
Int J Radiat Oncol Biol Phys 1995 Jan 1;31(1):79-86.

Ogino I, Kitamura T, Okamoto N, Yamasita K, Aikawa Y,
Okajima H, Matsubara S. Late rectal complication
following high dose rate intracavitary brachytherapy in
cancer of the cervix. Int J Radiat Oncol Biol Phys 1995
Feb 15;31(4):725-34.

Okawa T, Sakata S, Kita-Okawa M, Kaneyasu Y, Inoue T,
Ikida H, Takekawa Y, Nakano T, Wada S, Fushiki M,  
et al. Comparison between high dose-rate and low dose-rate
brachytherapy for cervix cancer: Japanese experience
of treatment results and complication (1975-1985)
[abstract].  In: ICRO'93 - International Congress of
Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 274.

Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low
dose rate vs. high dose rate brachytherapy in the
treatment of carcinoma of the uterine cervix: a clinical
trial. Int J Radiat Oncol Biol Phys 1994 Jan 15;28(2):
335-41.

Paul B, Baveja R, Mishra SP, Bhandari V, Kumar S,   
Ghosh R. Analysis of MDR-brachytherapy failures in
treatment of carcinoma cervix uteri [abstract]. Br J Radiol
1993;66 Suppl:52.

Sarkaria JN, Petereit DG, Stitt JA, Hartman T, Chappell R,
Thomadsen BR, Buchler DA, Fowler JF, Kinsella TJ. A
comparison of the efficacy and complication rates of low
dose-rate versus high dose-rate brachytherapy in the
treatment of uterine cervical carcinoma. Int J Radiat
Oncol Biol Phys 1994 Aug 30;30(1):75-82; discussion
247.

Selke P, Roman TN, Souhami L, Freeman CR, Clark BG,
Evans MD, Pla C, Podgorsak EB. Treatment results of
high dose rate brachytherapy in patients with carcinoma
of the cervix. Int J Radiat Oncol Biol Phys 1993 Nov 15;
27(4):803-9.

Teshima T, Inoue T, Ikeda H, Miyata Y, Nishiyama K,
Inoue T, Murayama S, Yamasaki H, Kozuka T. High-dose rate
and low-dose rate intracavitary therapy for
carcinoma of the uterine cervix. Final results of Osaka
University Hospital. Cancer 1993 Oct 15;72(8):2409-14.

Teshima T, Inoue T, Inoue T, Ikeda H, Sasaki S,   
Yamazaki H, Ohtani M, Murayama S, Kozuka T. High-dose rate
intracavitary therapy for cervical cancer with a
microSelectron: a preliminary report. Radiat Med 1993
Nov-Dec;11(6):237-41.

Teshima T, Inoue T, Inoue T, Ikeda H, Yamazaki H,  
Ohtani M, Sasaki S, Murayama S, Kozuka T. Mid-dose
rate intracavitary therapy for cervical cancer with a
Selectron: a preliminary report. Radiat Med 1993     
Nov-Dec;11(6):242-6.

Thranov IR, Engelholm SA, Knudsen JB. [Optimization of
radiotherapy of cervical cancer. Introduction of an
external radiotherapy based on CT and low-dosage
afterload technique at the Rikshospitalet]. Ugeskr Laeger
1995 May 1;157(18):2569-73.  (Dan).

Uno T, Itami J, Shiina T, Kato H, Sakai M, Arimizu N.
High-dose rate intracavitary irradiation for carcinoma of
the uterine cervix: risk factors for rectal and bladder
complication [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 273.

Wang XE. [Long-term results of 60Co HDR after-loading in
the treatment of cervical cancer]. Chung Hua Chung Liu
Tsa Chih 1993 Mar;15(2):114-7.  (Chi).

Wright J, Jones G, Whelan T, Lukka H. Patient preference
for high or low dose rate brachytherapy in carcinoma of
the cervix. Radiother Oncol 1994 Dec;33(3):187-94.

Yamazaki H, Inoue T, Ikeda H, Tang JT, Murayama S,
Teshima T, Otani M, Kozuka T. High-dose-rate remote
afterloading intestinal radiotherapy employing the
template technique for recurrent cancer in the pelvic area.
Strahlenther Onkol 1993 Aug;169(8):481-5.


Presurgical Neoadjuvant Chemotherapy or
Concomittant Chemotherapy with Radiotherapy


Bloss JD, Lucci JA 3rd, DiSaia PJ, Manetta A, Schiano MA,
Ramsinghani N, Berman ML. A phase II trial of
neoadjuvant chemotherapy prior to radical hysterectomy
and/or radiation therapy in the management of advanced
carcinoma of the uterine cervix. Gynecol Oncol 1995 Oct;
59(1):105-10.

Brunet J, Alonso C, Llanos M, Lacasta A, Fuentes J,
Mendoza LA, Badia JM, Delgado E, Ojeda B.
Chemotherapy and radiotherapy in locally advanced
cervical cancer. Acta Oncol 1995;34(7):941-4.

Burholt DR, Werts ED, Paljug WR, Polizotto SL, Yann VM.
Response of cervical carcinoma cells to radiation-platinum
combination [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1994;35:A3854.

Cardenas J, Olguin A, Figueroa F, Pena J, Becerra F, 
Huizar R. A randomized trial of chemotherapy followed
by radiotherapy vs radiotherapy alone in stage IIIB
cervical carcinoma: preliminary results. Paper presented
at: 4th International Congress on Anticancer
Chemotherapy; 1993 Feb 2-5; Paris, France.

Chadha M, Jacobs AJ, Stenson R. Chemotherapy rapidly
alternating with accelerated radiotherapy for advanced
carcinoma of the uterine cervix. Int J Gynecol Cancer
1995;5(4):257-61.

Chauvergne J, Lhomme C, Rohart J, Heron JF, Ayme Y,
Goupil A, Fargeot P, David M. [Neoadjuvant
chemotherapy of stage IIb or III cancers of the uterine
cervix. Long-term results of a multicenter randomized
trial of 151 patients]. Bull Cancer (Paris) 1993 Dec;
80(12):1069-79.  (Fre).

Chiara S, Bruzzone M, Merlini L, Bruzzi P, Rosso R,
Franzone P, Orsatti M, Vitale V, Foglia G, Odicino F,  
et al. Randomized study comparing chemotherapy plus
radiotherapy versus radiotherapy alone in FIGO stage
IIB-III cervical carcinoma. GONO (North-West Oncologic
Cooperative Group). Am J Clin Oncol 1994 Aug;17(4):
294-7.

Clark BG, Souhami L, Roman TN, Evans MD, Pla C. Rectal
complications in patients with carcinoma of the cervix
treated with concomitant cisplatin and external beam
irradiation with high dose rate brachytherapy: a
dosimetric analysis. Int J Radiat Oncol Biol Phys 1994
Mar 30;28(5):1243-50.  Comment in: Int J Radiat Oncol
Biol Phys 1994 Mar 30;28(5):1271-2.

Cole DJ, Jones AC. The treatment of locally advanced
carcinoma of the cervix with radiation, 5-fluorouracil and
mitomycin C [abstract]. Br J Radiol 1993;66 Suppl:52.

Colin PH. Concomitant chemotherapy and radiotherapy:
theoretical basis and clinical experience. Anticancer Res
1994;14(6A):2357-61.

De Dycker RP. Pelvic arterial chemotherapy in cervical
cancer. Reg Cancer Treat 1994;7(1):43-6.

de la Garza J, Castaneda N, Ramirez JL, Lara F, Mota A,
Guadarrama A. Ifosfamide + mesna + 5 fluorouracil +
radiotherapy: early results in patients with untreated stage
IIIB-IV cervical cancer. Paper presented at: 4th
International Congress on Anticancer Chemotherapy;
1993 Feb 2-5; Paris, France.

de la Garza J, Castaneda N, Ramirez JL, Lara F, Mota A,
Guadarrama A. Neoadjuvant chemotherapy with
ifosfamide + mesna + 5-fluorouracil + radiotherapy.
Preliminary results in patients (pts) with untreated stage
IIIB-IV cervical cancer [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1993;12:A835.

De Santis V, Maffeo A, Graziano R, Frezza P, Ferrari E,
Gallo MS. Mitomycin C/5FU and radiation therapy for
locally advanced uterine cervical cancer. Paper presented
at: European Society of Gynaecological Oncology 8th
International Meeting: Prevention, early detection,
diagnosis, management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Delanian S, Housset M, Maulard-Durdux C, Taurelle R,
Lecuru F, Baillet F. [Simultaneous radiochemotherapy in
locally advanced cancers of the cervix: a preliminary
study]. Bull Cancer (Paris) 1995;82(5):371-6.  (Fre).

Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman
WT. Neoadjuvant chemotherapy with vincristine and
cisplatin followed by radical hysterectomy and pelvic
lymphadenectomy for FIGO stage IB bulky cervical
cancer: a Gynecologic Oncology Group pilot study.
Gynecol Oncol 1995 Jun;57(3):412-6.

Erazo A, Cervantes G, Ortega B, Torrecillas L. A phase II
trial of ifosfamide (I), mesna (M) and cisplatin (C)
chemotherapy (CT) as neoadjuvant or palliative treatment
for cervical cancer [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1993;12:A850.

Erazo A, Torrecillas L, Cervantes G, Ortega B. A phase II
trial of Neo-Adjuvant chemotherapy (CT) with Ifosfamide
(I), Mesna and Cisplatin (C) in stage IIA-IIIB cervical
cancer.  In: Banzet P, Holland  JF, Khayat D, Weil M,
editors. Cancer treatment: an update. Presentations given
at the 4th International Congress on Anticancer
Chemotherapy; 1993 Feb 2-5; Paris, France. Paris:
Springer-Verlag; 1994. p. 485-7.

Fushiki H, Fujimura M, Yamakawa Y, Izumi R. [Early
evaluation of intra-arterial chemotherapeutic effects for
carcinoma of the uterine cervix]. Nippon Gan Chiryo
Gakkai Shi 1995;30(9):1659-77.  (Jpn).

Gamucci T, Zeuli M, Calabresi F, Conti L, Gandolfo L,
Mariani A, Lombardi G. Preoperative chemotherapy for
cervicocarcinoma: clinical and biological evaluation
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;
14:A740.

Gerson R, Tellez-Bernal E, Figueroa J, Chacon H,     
Roman E, Torres Lobaton A, Garcia Gonzalez H, 
Lazaro M, Martinez L, Aguero E. Carboplatin plus
radiotherapy in advanced cervical cancer phase II study
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;
12:A881.

Glaubitz M, Gunter HH, Luck HJ, Hahn T, Meerpohl HG,
Achterrath W, Kuhnle H. Results of carboplatin and
ifosfamide combination chemotherapy in the treatment of
cervical cancer. Paper presented at: European Society of
Gynaecological Oncology 8th International Meeting:
Prevention, early detection, diagnosis, management and
follow-up of gynaecological malignancies; 1993 Jun 9-12;
Barcelona, Spain.

Harima K, Harima Y, Tanaka Y, Tateyama I, Hashii K.
Preoperative chemoembolization therapy for uterine
carcinoma [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 288.

Hashii K, Tateyama I, Mori T, Harima K, Harima Y,
Fujisawa I. [Evaluation of preoperative intraarterial
chemotherapy using CDDP with TAE for advanced
cervical cancers. With reference to the Pt tissue
concentration and the histological antineoplastic effect in
the uterine cervix and the pelvic lymph nodes]. Nippon
Gan Chiryo Gakkai Shi 1994;29(11):1885-97.  (Jpn).

Hoshino T, Suzuki Y, Adachi T, Takayama M. [Intraarterial
infusion therapy with OK-432 and G-CSF for cervical
cancer: evaluation and discussion]. Nippon Gan Chiryo
Gakkai Shi 1994;29(4):720-5.  (Jpn).

Husseinzadeh N, Shrake P, DeEulis T, Rowley K, Aron B.
Chemotherapy and extended-field radiation therapy to
para-aortic area in patients with histologically proven
metastatic cervical cancer to para-aortic nodes: a phase II
pilot study. Gynecol Oncol 1994 Mar;52(3):326-31.

Ishigaki T, Nagata Y, Okajima K, Mitsumori M, Fujiwara K,
Ohya N, Otsu S, Shibata T, Hiraoka M, Abe M.
Transcatheter arterial infusion therapy for uterine cervical
cancer [abstract].  In: ICRO'93 - International Congress
of Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 288.

Itoh N, Morishita S, Sawairi M, Hanabayashi T, Mori H,
Yamawaki Y, Tamaya T. Neoadjuvant intra-arterial
infusion chemotherapy by Cisplatin-containing
combination regimens for patients with locally advanced
uterine cervical cancer.  In: Einhorn J, Nord CE,  
Norrby SR, editors. Recent advances in chemotherapy.
Proceedings of the18th International Congress of
Chemotherapy; 1993 Jun 27-Jul 2; Stockholm, Sweden.
Washington (DC): American Society for Microbiology;
1993. p. 1007-8.

Jennings TS, Dottino PR, Stock R, Beddoe AM, Rahaman J.
Concomitant interferon alpha-2b (IFN alpha), cisplatin
(DDP), and irradiation (RT) for locally advanced cervical
cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol
1995;14:A743.

Jones WB. New approaches to high-risk cervical cancer.
Advanced cervical cancer. Cancer 1993 Feb 15;       
71(4 Suppl):1451-9.

Katsaros D, Zola P, Sinistrero G, Bergamino T, Rumore A,
Ferrero A, Bau MG, Sismondi P. Weekly cisplatin
induction chemotherapy in high-risk cervical cancer
patients with bulky tumor: a phase II study. Int J Oncol
1995;6(5):1033-8.

Kigawa J, Minagawa Y, Ishihara H, Itamochi H, Tei S,
Terakawa N. The role of neoadjuvant intra-arterial
infusion chemotherapy for advanced cervical cancer
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:
A865.

Kim SJ. Multimodal treatment for the locally advanced stage
IB, IIA, IIB patients of cervical cancer. Int J Gynaecol
Obstet 1995 Jul;49 Suppl:S49-57.

Kumar L, Biswal BM, Kumar S, Kriplani A, Rath GK.
Randomized phase III study of neo-adjuvant
chemotherapy (CT) + radiotherapy (RT) vs RT alone in
locally advanced cervical cancer (CA CX) [abstract].
Proc Annu Meet Am Soc Clin Oncol 1994;13:A819.

Kumar L, Kaushal R, Nandy M, Biswal BM, Kumar S,
Kriplani A, Singh R, Rath GK, Kochupillai V.
Chemotherapy followed by radiotherapy versus
radiotherapy alone in locally advanced cervical cancer: a
randomized study. Gynecol Oncol 1994 Sep;54(3):    
307-15.

Kumar L, Nandy M, Biswal BM, Kumar S, Kriplani A,
Singh R, Rath GK, Kochupillai V. Induction
chemotherapy in locally advanced cervical cancer: a
randomized study. G Ital Oncol 1995;15(1):39-42.

Liao GW. [Treatment of advanced cervix carcinoma with
hypogastric artery infusion chemotherapy plus
radiotherapy]. Chung Kuo Chung Liu Lin Chuang 1994;
21(8):592-4.  (Chi).

Lin JC, Ho ES, Jan JS, Yang CH, Hsu WP. Concomitant
chemoradiotherapy for advanced epidermoid carcinoma
of the uterine cervix: a preliminary report. Chung Hua I
Hsueh Tsa Chih (Taipei) 1994 Jul;54(1):26-32.

Lippman SM, Kavanagh JJ, Paredes M, Delgadillo F, Hong
WK, Figuerda F, Olguin A, Freedman RS, Massimini G,
Holdener EE, et al. 13-cis-retinoic acid (13CRA),
interferon-alpha 2a (IFN-a2a) and radiotherapy for locally
advanced cancer of the cervix [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1993;12:A816.

Lorvidhaya V, Tonusin A, Sukthomya W, Changwiwit W,
Nimmolrat A. Induction chemotherapy and irradiation in
advanced carcinoma of the cervix. Gan To Kagaku Ryoho
1995 Aug;22 Suppl 3:244-51.

Louvet C, Moreau S, de Gramont A, Varette C,   
Demuynck B, Beerblock K, Marpeau L, Zylberait D,
Pigne A, Soubrane D, Zylberait D, Krulik M. Bleomycin,
Ifosfamide and Carboplatin in advanced uterine cervix
carcinoma: preliminary results.  In: Banzet P, Holland JF,
Khayat D, Weil M, editors. Cancer treatment: an update.
Presentations given at the 4th International Congress on
Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France.
Paris: Springer-Verlag; 1994. p. 488-91.

Macia M, Novo A, Ces J, Gonzalez M, Huidobro C,    
Yuste J, Diab T. Neoadjuvant and salvage chemotherapy
with cisplatin (CDDP) and 5-fluorouracil (5-FU) in
cervical carcinoma. Eur J Gynaecol Oncol 1993;14(3):
192-6.

Malfetano J, Keys H, Kredentser D, Cunningham M,
Kotlove D, Weiss L. Weekly cisplatin and radical
radiation therapy for advanced, recurrent, and poor
prognosis cervical carcinoma. Cancer 1993 Jun 1;
71(11):3703-6.

Maneschi F, Benedetti-Panici P, Scambia G, Salerno MG,
D'Agostino G, Mancuso S. Menstrual and hormone
patterns in women treated with high-dose cisplatin and
bleomycin. Gynecol Oncol 1994 Sep;54(3):345-8.

Maruyama Y, Bowen MG, Van Nagell JR, Gallion HH,
DePriest P, Wierzbicki J. A feasibility study of 252Cf
neutron brachytherapy, cisplatin + 5-FU chemo-adjuvant
and accelerated hyperfractionated radiotherapy for
advanced cervical cancer. Int J Radiat Oncol Biol Phys
1994 Jun 15;29(3):529-34.

Moja LM, Maseela T. Neo-adjuvant chemotherapy in
carcinoma of the cervix-bulky disease. Paper presented
at: European Society of Gynaecological Oncology 8th
International Meeting: Prevention, early detection,
diagnosis, management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Morris M, Eifel PJ, Burke TW, McNamara MM, 
Levenback C, Kavanagh JJ, Gershenson DM. Treatment
of locally advanced cervical cancer with concurrent
radiation and intra-arterial chemotherapy. Gynecol Oncol
1995 Apr;57(1):72-8.

Nagata Y, Ishigaki T, Okajima K, Fujiwara K, Kinashi T,
Mitumori M, Ooya N, Kitakabu Y, Hiraoka M, Abe M,
et al. Transcatheter arterial infusion therapy combined
with radical hysterectomy in the treatment of advanced
cervical cancer. Cardiovasc Intervent Radiol 1993     
Jan-Feb;16(1):14-8; discussion 18-20.

Namkoong SE, Park JS, Kim JW, Bae SN, Han GT, Lee JM,
Jung JK, Kim SJ. Comparative study of the patients with
locally advanced stages I and II cervical cancer treated by
radical surgery with and without preoperative adjuvant
chemotherapy. Gynecol Oncol 1995 Oct;59(1):136-42.

Narimatsu A, Kobayashi M, Ito T. [Neoadjuvant
chemotherapy with intra-arterial infusion (CDDP, MMC,
PEP, AT-II) in the treatment of stage III cervical cancer].
Nippon Gan Chiryo Gakkai Shi 1994;29(12):1948-55. 
(Jpn).

Nevin J, Bloch B, Van Wijk L, Soeters R, Dehaeck K,    
Ball H, Denny L. Primary chemotherapy with bleomycin,
ifosfamide and cisplatinum (BIP) followed by
radiotherapy in the treatment of advanced cervical cancer.
A pilot study. Eur J Gynaecol Oncol 1995;16(1):30-5.

Ohsugi F, Yamada T, Tada S. [Low-dose consecutive
intra-arterial infusion of CDDP to treat advanced cervical
carcinoma: usefulness of a vascular access device with
alteration of intrapelvic blood flow]. Nippon Igaku
Hoshasen Gakkai Zasshi 1995 May;55(6):380-9.  (Jpn).

Okawa T, Niibe H, Arai T, Sekiba K, Noda K, Takeuchi S,
Hashimoto S, Ogawa N. Effect of LC9018 combined with
radiation therapy on carcinoma of the uterine cervix. A
phase III, multicenter, randomized, controlled study.
Cancer 1993 Sep 15;72(6):1949-54.

Paladini D, Raspagliesi F, Fontanelli R, Ntousias V. Radical
surgery after induction chemotherapy in locally advanced
cervical cancer. A feasibility study. Int J Gynecol Cancer
1995;5(4):296-300.

Panici P, Greggi S, Scambia G, Salerno MG, Battaglia F,
Amoroso M, Mancuso S. Responsiveness to neoadjuvant
chemotherapy (NAC) as a major prognostic factor in
locally advanced cervical cancer (LACC). Paper
presented at: European Society of Gynaecological
Oncology 8th International Meeting: Prevention, early
detection, diagnosis, management and follow-up of
gynaecological malignancies; 1993 Jun 9-12; Barcelona,
Spain.

Panici PB, Greggi S, Scambia G, Battaglia F, Amoroso M,
Salerno MG, Mancuso S. Response to neoadjuvant
chemotherapy (NAC) as a major prognostic factor in
locally advanced cervical cancer (LACC) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1995;14:A792.

Panici PB, Greggi S, Scambia G, Maneschi F, Salerno MG,
Amoroso M, Rabitti C, Mancuso S. Neoadjuvant
chemotherapy (NAC) followed by radical surgery (RS) in
locally advanced cervical cancer (LACC): a multivariate
survival analysis (MSA). Paper presented at: 4th
International Congress on Anticancer Chemotherapy;
1993 Feb 2-5; Paris, France.

Paredes Espinoza M, Lippman SM, Kavanagh JJ, Delgadillo
Madrueno F, Paredes Casillas P, Banuelos Acosta O,
Alvarez Marquez V, Buenrostro Ahued MA, de Alba
Ayala I, Arias Castro G. [Treatment of 32 cervico-uterine
cancer patients with 13-cis-retinoic acid and interferon
alpha]. Rev Invest Clin 1994 Mar-Apr;46(2):105-11. 
(Spa).

Parham G, Hicks M. Retroperitoneal lymphadenectomy
followed by concomitant chemoradiation and tailored
surgical debulking: a pilot multimodality protocol for
advanced cervical and vaginal cancer [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1995;14:A809.

Park SY, Kim BG, Kim JH, Lee JH, Lee ED, Lee KH, Park
KB, Lee BH, Kim KH. Phase I/II study of neoadjuvant
intraarterial chemotherapy with mitomycin-C, vincristine,
and cisplatin in patients with stage IIb bulky cervical
carcinoma. Cancer 1995;76(5):814-23.

Park SY, Kim BG, Kim JI, Lee JH, Lee ED, Lee KH, Park
KP, Lee BH, Kim KH, Hong WS. Neoadjuvant intra-arterial
chemotherapy in patients with stage IIB bulky
cervical carcinoma [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1994;13:A849.

Park TK, Lee SK, Kim SN, Hwang TS, Kim GE, Suh CO,
Loh JK. Combined chemotherapy and radiation for bulky
stages I-II cervical cancer: comparison of concurrent and
sequential regimens. Gynecol Oncol 1993 Aug;50(2):
196-201.

Pearcey RG, Stuart GC, MacLean GD, Nation JG, Arthur K,
Lukka H, Jeffrey J, James K, Brundage M. Phase II
study to evaluate the toxicity and efficacy of concurrent
cisplatin and radiation therapy in the treatment of patients
with locally advanced squamous cell carcinoma of the
cervix. Gynecol Oncol 1995 Jul;58(1):34-41.

Potish RA, Twiggs LB. On the lack of demonstrated clinical
benefit of neoadjuvant cisplatinum therapy for cervical
cancer. Int J Radiat Oncol Biol Phys 1993 Nov 15;27(4):
975-9.

Rabinovich M, Vallejo C, Perez J, Cuevas MA,  
Machiavelli M, Lacava J, Leone B, Focaccia G,   
Suttora G, Romero A, et al. Neoadjuvant chemotherapy
(NCH) with ifosfamide (IFX) and cisplatin (P) in
advanced cervical carcinoma (ACC) [abstract].         
Proc Annu Meet Am Soc Clin Oncol 1993;12:A836.

Resbeut M, Cowen D, Viens P, Noirclerc M, Perez T,
Gouvernet J, Delpero JR, Gamerre M, Boubli L,
Houvenaeghel G. Concomitant chemoradiation prior to
surgery in the treatment of advanced cervical carcinoma.
Gynecol Oncol 1994 Jul;54(1):68-75.

Resbeut M, Noirclerc M, Gravis G, d'Ercole C, Pechikoff P,
Hovenaeghel G, Delpero JR, Blache JL, Viens P.
Concomitant chemotherapy and radiotherapy in the
treatment of advanced cervix carcinomas.  In: Banzet P,
Holland JF, Khayat D, Weil M, editors. Cancer
treatment: an update. Presentations given at the 4th
International Congress on Anticancer Chemotherapy;
1993 Feb 2-5; Paris, France. Paris: Springer-Verlag;
1994. p. 476-8.

Resbeut M, Noirclerc M, Viens P, d'Ercole C,
Houvenaeghel G, Boubli L, Gamerre M, Delpero JR.
[Simultaneous radiotherapy and chemotherapy in the
treatment of advanced cancer of the cervix uteri]. Bull
Cancer (Paris) 1993 Nov;80(11):984-93.  (Fre).

Roberts WS, Lapolla JP, Greenberg H, Berman C,
McDonald T. Continuous intra-arterial cisplatin combined
with radiotherapy in locally advanced squamous
carcinoma of the cervix: a Gynecologic Oncology Group
pilot study. Int J Gynecol Cancer 1995;5(5):335-40.

Sardi J, Giaroli A, Sananes C, Ferreyra M, Bastardas M,  
Di Paola GR. [Evaluation of a randomized prospective
trial with a new therapeutic approach for stage IIIB
carcinoma of the cervix uteri]. Prensa Med Argent 1994;
81(3):236-48.  (Spa).

Sardi J, Sananes C, Giaroli A, Bayo J, Rueda NG, Vighi S,
Guardado N, Paniceres G, Snaidas L, Vico C, et al.
Results of a prospective randomized trial with
neoadjuvant chemotherapy in stage IB, bulky, squamous
carcinoma of the cervix. Gynecol Oncol 1993 May;49(2):
156-65.  Comment in: Gynecol Oncol 1993 May;49(2):
153-5.

Scambia G, Benedetti Panici P, Foti E, Amoroso M,   
Salerno G, Ferrandina G, Battaglia F, Greggi S,          
De Gaetano A, Puglia G, et al. Squamous cell carcinoma
antigen: prognostic significance and role in the
monitoring of neoadjuvant chemotherapy response in
cervical cancer. J Clin Oncol 1994 Nov;12(11):2309-16.

Scarabelli C, Zarrelli A, Gallo A, Visentin MC. Multimodal
treatment with neoadjuvant intraarterial chemotherapy and
radical surgery in patients with stage IIIB-IVA cervical
cancer: a preliminary study. Cancer 1995;76(6):1019-26.

Shimamoto T, Tateyama H, Kohso T, Hamada M.
Neoadjuvant chemotherapy using a platinum, vincristine
and peplomycin (CVP) combination in patients with
carcinoma of the uterine cervix. Asia Oceania J Obstet
Gynaecol 1993 Sep;19(3):261-9.

Shimizu Y, Umezawa S, Hasumi K. Neoadjuvant
chemotherapy followed by radical surgery for bulky
adenocarcinoma of the uterine cervix [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1995;14:A804.

Skoog LA, Waggoner SE, Williams SF, Rotmensch J,
Heimann R, Fleming GF. Response to cisplatin (P),
continuous infusion (CIV) 5-fluorouracil (5-FU), and
leucovorin (L) (PFL) neoadjuvant chemotherapy in
carcinoma of the uterine cervix [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1995;14:A802.

Souhami L, Seymour R, Roman TN, Stanimir GW,  
Trudeau M, Clark BG, Freeman CR. Weekly cisplatin
plus external beam radiotherapy and high dose rate
brachytherapy in patients with locally advanced
carcinoma of the cervix. Int J Radiat Oncol Biol Phys
1993 Nov 15;27(4):871-8.

Souhami L, Trudeau M, Seymour R, Roman T, Stanimir G,
Clark B, Freeman C. Synchronous chemoradiation in
advanced carcinoma of the cervix.  In: Salmon SE,
editor. Adjuvant therapy of cancer VII. Proceedings of
the 7th International Conference on the Adjuvant Therapy
of Cancer; 1993 Mar 10-13; Tucson, AZ. Philadelphia:
J.B. Lippincott Co.; 1993. p. 377-82.

Stehman FB, Bundy BN. Carcinoma of the cervix treated
with chemotherapy and radiation therapy. Cooperative
studies in the Gynecologic Oncology Group. Cancer 1993
Feb 15;71(4 Suppl):1697-701.

Sueyama H, Nakano M, Sakumoto K, Toita T, Takizawa Y,
Moromizato H, Kakihana Y, Kushi A, Moromizato H,
Higashi M, et al. Intra-arterial chemotherapy with
cisplatin followed by radical radiotherapy for locally
advanced cervical cancer. Gynecol Oncol 1995 Dec;
59(3):327-32.

Sueyama H, Nakano M, Toita T, Takizawa Y,    
Moromizato H, Kakihana Y, Kushi A, Sasaki K,  
Higashi M, Kanazawa K, Sekiya T. [Intra-arterial
chemotherapy with cisplatin followed by radical
radiotherapy for locally advanced cervical cancer].
Rinsho Hoshasen 1994;39(6):691-8.  (Jpn).

Takashima H, Hosokawa N, Hino I, Sato K, Kojima K,
Ohkawa M, Tanabe M, Jinbo T, Hando T, Seo H.
[Results of radiotherapy for stage III uterine cervical
carcinomas and preliminary study of combined
radiotherapy and transarterial infusion chemotherapy].
Nippon Igaku Hoshasen Gakkai Zasshi 1994 Nov 25;
54(13):1270-6.  (Jpn).

Tattersall MH, Lorvidhaya V, Vootiprux V, Cheirsilpa A,
Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen
MS, et al. Randomized trial of epirubicin and cisplatin
chemotherapy followed by pelvic radiation in locally
advanced cervical cancer. Cervical Cancer Study Group
of the Asian Oceanian Clinical Oncology Association.    
J Clin Oncol 1995 Feb;13(2):444-51.  Comment in: J Clin
Oncol 1995 Aug;13(8):2141-2.

Tchan Kyu Park, Sung Ki Lee, Soo Nyung Kim, Tai Sik
Hwang, Gwi Eon Kim, Chang Ok Suh, Juhn Kyu Loh.
Combined chemotherapy and radiation for bulky stages  
I-II cervical cancer: comparison of concurrent and
sequential regimens. Gynecol Oncol 1993;50(2):196-201.

Villena-Heinsen C, Mink D, Lung-Kurt S, Kramann B, 
Kujat C, Schnabel K, Schmidt W. Preoperative
intraarterial chemotherapy for bulky cervical carcinoma
in stage IB - IIB. Reg Cancer Treat 1994;7(1):17-21.

Wadler S, Beitler JJ, Rubin JS, Haynes H, McGill F,
Rozenblit A, Goldberg G, Cohen C, Speyer J,  
Runowicz C. Pilot trial of cisplatin, radiation, and
WR2721 in carcinoma of the uterine cervix: a New York
Gynecologic Oncology Group study. J Clin Oncol 1993
Aug;11(8):1511-6.

Wadler S, Haynes H, Beitler JJ, Goldberg G, Holland JF,
Hochster H, Bruckner H, Mandeli J, Smith H,  
Runowicz C. Management of hypocalcemic effects of
WR2721 administered on a daily times five schedule with
cisplatin and radiation therapy. The New York
Gynecologic Oncology Group. J Clin Oncol 1993
Aug;11(8):1517-22.  Comment in: J Clin Oncol 1994
Jan;12(1):232.

Xiao XH. [Operation combined with chemotherapy for 63
cases of cervical carcinoma in the Xinjiang Kashi area].
Chung Hua Fu Chan Ko Tsa Chih 1993 Oct;28(10):  
610-2, 636.  (Chi).

Yacoub SF, Shaeffer J, el-Mahdi AM, Faris L, Zhu A.
Nuclear morphometry as a predictor of response to
neoadjuvant chemotherapy plus radiotherapy in locally
advanced cervical cancer. Gynecol Oncol 1994 Sep;
54(3):327-32.

Zanetta G, Colombo A, Maneo A, Colombo M, Nava S,
Landoni F, Mangioni C. Postoperative treatments for
stage Ib-IIa cervical carcinoma with lymph node
metastases after primary surgery: complications and
efficacy of three different methods. Ital J Gynaecol Obstet
1995;7(2):45-50.

Zanetta G, Colombo A, Milani R, Placa F, Mangioni C.
Long-term results of sequential postoperative treatment
with vincristine, bleomycin, mitomycin C, cis-platin and
radiotherapy after surgery for high-risk patients with
cervical carcinoma stage IB-IIA. Int J Gynecol Cancer
1995;5(1):40-4.

Zanetta G, Landoni F, Colombo A, Pellegrino A, Maneo A,
Leventis C. Three-year results after neoadjuvant
chemotherapy, radical surgery, and radiotherapy in
locally advanced cervical carcinoma. Obstet Gynecol
1993 Sep;82(3):447-50.


Potential Improvements in Radiobiology


Acharya DK. Role of metronidazole in radiation therapy (a
review of 717 cancer cases). Indian J Med Sci 1994 May;
48(5):111-6.

Balmukhanov S, Abdrahmanov J, Philippenko V, Mustafin J,
Aidarhanov A, Shibanova A. Intratumoral sensibilization:
a new strategy in radiation therapy [abstract].  In:
ICRO'93 - International Congress of Radiation Oncology
- Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 401.

Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW. Patterns
and variability of tumor oxygenation in human soft tissue
sarcomas, cervical carcinomas, and lymph node
metastases. Int J Radiat Oncol Biol Phys 1995 Jul 15;
32(4):1121-5.

Chapman JD, Parliament MB. Can individual tumor
oxygenation status be measured and does it predict
treatment response [abstract]?  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 133.

Chougule A. Linear quadratic model compared with TDF
and TSD concepts for malignancy of cervix uteri treated
with twice daily fractionated schedules. Strahlenther
Onkol 1994 Jan;170(1):30-5.

Chougule AA, Supe SJ. Hyperfractionated radiotherapy of
carcinoma of the uterine cervix and predictivity of
empirical models. Indian J Radiol Imaging 1994;4(2):
109-13.

Dusenbery K, McGuire W, Carson L, Potish R, Fowler J,
Twiggs L. Recombinant human erythropoietin (R-huepo)
increases hemoglobin during radiation therapy for cervix
cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol
1993;12:A828.

Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler
JM, Twiggs LB, Potish RA. Erythropoietin increases
hemoglobin during radiation therapy for cervical cancer.
Int J Radiat Oncol Biol Phys 1994 Jul 30;29(5):1079-84.

Feldmann HJ, Seegenschmiedt MH, Molls M. Hyperthermia
--its actual role in radiation oncology. Part III: Clinical
rationale and results in deep seated tumors. Strahlenther
Onkol 1995 May;171(5):251-64.

Geard CR, Jones JM. Radiation and taxol effects on
synchronized human cervical carcinoma cells. Int J Radiat
Oncol Biol Phys 1994 Jun 15;29(3):565-9.

Herskovic TM, Pineda A, Pereira M, Behnam K, Murthy S,
Piesla T, Ashford P. Hyperfractionated template treatment
of cancer of cervix using the MicroSelectron high dose
rate remote afterloader. Endocuriether Hyperthermia
Oncol 1995;11(2):97-9.

Hockel M, Knoop C, Schlenger K, Vorndran B,   
Baussmann E, Mitze M, Knapstein PG, Vaupel P.
Intratumoral pO2 predicts survival in advanced cancer of
the uterine cervix. Radiother Oncol 1993 Jan;26(1):45-50.

Hockel M, Vorndran B, Schlenger K, Baussmann E,
Knapstein PG. Tumor oxygenation: a new predictive
parameter in locally advanced cancer of the uterine
cervix. Gynecol Oncol 1993 Nov;51(2):141-9.  Comment
in: Gynecol Oncol 1993 Nov;51(2):139-40.

Komaki R, Pajak TF, Marcial VA, Rotman M, Grigsby PW,
Leibel SA, Eifel PJ. Twice-daily fractionation of external
irradiation with brachytherapy in bulky carcinoma of the
cervix. Phase I/II study of the Radiation Therapy
Oncology Group 88-05. Cancer 1994 May 15;73(10):
2619-25.

Li RY. [Intracavitary microwave hyperthermia combined
with external irradiation in the treatment of cervical
carcinoma]. Chung Kuo Chung Liu Lin Chuang 1993;
20(1):32-5.  (Chi).

Marcial VA, Marcial LV. Radiation therapy of cervical
cancer. New developments. Cancer 1993 Feb 15;     
71(4 Suppl):1438-45.

Maruyama Y, Bowen MG, Van Nagell JR, Gallion HH,
DePriest P, Wierzbicki J. A feasibility study of 252Cf
neutron brachytherapy, cisplatin + 5-FU chemo-adjuvant
and accelerated hyperfractionated radiotherapy for
advanced cervical cancer. Int J Radiat Oncol Biol Phys
1994 Jun 15;29(3):529-34.

Maruyama Y, van Nagell JR, Yoneda J, Gallion HH,
DePriest P, Feola JM, Wierzbicki J. Schedule in Cf-252
neutron brachytherapy: complications after delayed
implant therapy for cervical cancer in a phase II trial. 
Am J Clin Oncol 1993 Apr;16(2):168-74.

Matthews RH, Ercal N, Murrell HJ. Transvaginal electron
beam cone used in treating an advanced squamous cell
carcinoma of the cervix. Mo Med 1993 Apr;90(4):    
188-90.

Minarik L, Hall EJ. Taxol in combination with acute and low
dose rate irradiation. Radiother Oncol 1994 Aug;32(2):
124-8.  Comment in: Radiother Oncol 1994 Aug;32(2):
95-7.

Mitsuhashi N, Takahashi I, Takahashi M, Hayakawa K,
Niibe H. Clinical study of radioprotective effects of
amifostine (YM-08310, WR-2721) on long-term outcome
for patients with cervical cancer. Int J Radiat Oncol Biol
Phys 1993 Jun 15;26(3):407-11.

Overgaard J. Clinical evaluation of nitroimidazoles as
modifiers of hypoxia in solid tumors. Oncol Res 1994;
6(10-11):509-18.

Robertson J, Johnston C, Eisbruch A, Reynolds K,    
Roberts J, Lawrence T. A phase I/II study of
bromodeoxyuridine (BRDU) and radiation therapy (RT)
for locally advanced cervix cancer [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1995;14:A481.

Rodriguez M, Sevin BU, Perras J, Nguyen HN, Pham C,
Steren AJ, Koechli OR, Averette HE. Paclitaxel: a
radiation sensitizer of human cervical cancer cells.
Gynecol Oncol 1995 May;57(2):165-9.

Rubin JS, Wadler S, Beitler JJ, Haynes H, Rozenblit A,
McGill F, Goldberg G, Runowicz C. Audiological
findings in a Phase I protocol investigating the effect of
WR 2721, high-dose cisplatin and radiation therapy in
patients with locally advanced cervical carcinoma.         
J Laryngol Otol 1995 Aug;109(8):744-7.

Rui-Ying Li, et al. Intracavitary hyperthermia combined with
radiation in the treatment of uterine cervix cancer
[abstract].  In: ICRO'93 - International Congress of
Radiation Oncology - Preprinted abstracts and
programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 337.

Runsen L, Tiezhuang Y, LingYu Y, Manchang L,   
Guoying P, Yonghui S, Ding Jeo L. Hyperthermia in
combination with radiation in the treatment for carcinoma
of the urine cervix [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 336.

Stehman FB, Bundy BN. Carcinoma of the cervix treated
with chemotherapy and radiation therapy. Cooperative
studies in the Gynecologic Oncology Group. Cancer 1993
Feb 15;71(4 Suppl):1697-701.

Stehman FB, Bundy BN, Thomas G, Keys HM,     
d'Ablaing G 3d, Fowler WC Jr, Mortel R, Creasman
WT. Hydroxyurea versus misonidazole with radiation in
cervical carcinoma: long-term follow-up of a Gynecologic
Oncology Group trial. J Clin Oncol 1993 Aug;11(8):
1523-8.

Stelzer KJ, Koh WJ, Kurtz H, Greer BE, Griffin TW.
Caffeine consumption is associated with decreased severe
late toxicity after radiation to the pelvis. Int J Radiat
Oncol Biol Phys 1994 Sep 30;30(2):411-7.

Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen
in human tumors: correlations between methods of
measurement and response to therapy. Summary of a
workshop held November 19-20, 1992, at the National
Cancer Institute, Bethesda, Maryland. Radiat Res 1993
Dec;136(3):422-34.

Strnad V, Sauer R, Tacev T. [Hypoxic radiotherapy. The
radioprotective effect of acute hypoxia in the radiotherapy
of tumors in the abdominal area]. Strahlenther Onkol
1994 Dec;170(12):700-3.  (Ger).

Thomas GM. Hypoxia and carcinoma of the cervix. Semin
Radiat Oncol 1994;4(1):9-15.

Uehara S, Masuda K, Hata K. [Hyperthermia in cervical
cancer]. Rinsho Hoshasen 1994;39(6):685-90.  (Jpn).

Vaupel P. Tissue oxygenation predicts survival in advanced
cervical cancer [abstract]. Eur J Cancer 1993;           
29A Suppl 6:S40.

Warenius HM. Fast neutron therapy. The UK experience.
Acta Oncol 1994;33(3):289-92.

West CM, Davidson SE, Burt PA, Hunter RD. The intrinsic
radiosensitivity of cervical carcinoma: correlations with
clinical data. Int J Radiat Oncol Biol Phys 1995 Feb 15;
31(4):841-6.

West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic
radiosensitivity and prediction of patient response to
radiotherapy for carcinoma of the cervix. Br J Cancer
1993 Oct;68(4):819-23.

Wiley AL Jr, Alqaisi ME, Vermund H, Scarantino CW,
Rakfal SM, Nelson CE, Christie KI. Interstitial
thermoradiotherapy in the management of refractory
malignant tumors [abstract].  In: ICRO'93 - International
Congress of Radiation Oncology - Preprinted abstracts
and programme; 1993 Jun 21-25; Kyoto, Japan. [place
unknown]: International Society for Radiation Oncology;
1993. p. 335.

Wolfson AH. Advances in definitive radiation therapy for
invasive cervical carcinoma. Clin Consult Obstet Gynecol
1995;7(2):135-40.

Yang HD. [Study of relationship between local and systemic
temperature during radiofrequency hyperthermia for
cancer of cervix]. Chung Kuo Chung Liu Lin Chuang
1994;21(2):98-100.  (Chi).

Zimmermann M, Schorcht J, Andree W. Theoretical and
experimental investigations of a newly developed
intracavitary applicator system for the radiothermotherapy
of gynaecological tumours. Int J Hyperthermia 1993
May-Jun;9(3):463-77.


Radiotherapy ñ Chemotherapy for
Locally Recurrent Disease


Choy D, Wong RL, Sham J, Wu PM, Foo DL, Ngan HY,
Ma HK. Vaginal template implant for cervical carcinoma
with vaginal stenosis or inadvertent diagnosis after
hysterectomy. Int J Radiat Oncol Biol Phys 1994 Jan 15;
28(2):457-62.

Garton GR, Gunderson LL, Webb MJ, Wilson TO,
Martenson JA Jr, Cha SS, Podratz KC. Intraoperative
radiation therapy in gynecologic cancer: the Mayo Clinic
experience. Gynecol Oncol 1993 Mar;48(3):328-32.

Gerard JP, Dargent D, Raudrant D, Braillon G, Gilly FN,
Romestaing P, Sentenac I, Rocher FP, Berger C,
Adeleine P, et al. [Role of peroperative radiotherapy in
the treatment of uterine cancers. Preliminary experience
in Lyon]. Bull Cancer Radiother 1994;81(3):186-95. 
(Fre).

Hockel M, Baussmann E, Mitze M, Knapstein PG. Are
pelvic side-wall recurrences of cervical cancer
biologically different from central relapses? Cancer 1994
Jul 15;74(2):648-55.

Karlan BY, Chamorro T, Fowler JM, Muderspach LI,
Greenberg S, Lagasse LD. Concurrent interstitial
radiotherapy and infusional chemotherapy for recurrent
gynecologic malignancies. Int J Gynecol Cancer 1993;
3(5):304-10.

Konski A, Neisler J, Phibbs G, Bronn D, Dobelbower RR Jr.
The use of intraoperative electron beam radiation therapy
in the treatment of para-aortic metastases from
gynecologic tumors: a pilot study. Am J Clin Oncol 1993;
16(1):67-71.

Martinez Monge R, Jurado M, Azinovic I, Aristu JJ,  
Tangco E, Viera JC, Berian JM, Calvo FA.
Intraoperative radiotherapy in recurrent gynecological
cancer. Radiother Oncol 1993 Aug;28(2):127-33.

Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Nisar
Syed AM, DiSaia PJ. Open interstitial brachytherapy for
the treatment of local-regional recurrences of uterine
corpus and cervix cancer after primary surgery. Gynecol
Oncol 1994 Feb;52(2):222-8.

Seegenschmiedt MH, Sauer R, Miyamoto C, Chalal JA,
Brady LW. Clinical experience with interstitial
thermoradiotherapy for localized implantable pelvic
tumors. Am J Clin Oncol 1993 Jun;16(3):210-22.

Stelzer KJ, Koh WJ, Greer BE, Cain JM, Tamimi HK, Figge
DC, Goff BA, Griffin TW. The use of intraoperative
radiation therapy in radical salvage for recurrent cervical
cancer: outcome and toxicity. Am J Obstet Gynecol 1995
Jun;172(6):1881-6; discussion 1886-8.

Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF,
Rawlings G. Long-term results of concurrent radiation
and chemotherapy for carcinoma of the cervix recurrent
after surgery. Int J Gynecol Cancer 1993;3(4):193-8.

Wilailak S, Srisupandit S, Tangtrakul S, Ballangpoti S,
Linasmita V, Bhamarapravati Y. Recurrence of cervical
carcinoma following radical hysterectomy and pelvic node
dissection. J Med Assoc Thai 1993 Jan;76 Suppl 1:69-73.


Surgery for Locally Recurrent Disease


Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel
PJ, Rutledge FN. Radical hysterectomy for recurrent
carcinoma of the uterine cervix after radiotherapy.
Gynecol Oncol 1994 Oct;55(1):29-35.

Crozier M, Morris M, Levenback C, Lucas KR, Atkinson
EN, Wharton JT. Pelvic exenteration for adenocarcinoma
of the uterine cervix. Gynecol Oncol 1995 Jul;58(1):74-8.

Gotsadze D, Charkviani L, Nemsadze G, Tsintsadze I,
Pirtskhalaishvili G. Continent urinary diversion (Gotsadze
Pouch) after pelvic exenteration for gynaecological
malignancies. Eur J Gynaecol Oncol 1994;15(5):369-71.

Gotsadze D, Pirtskhalaishvili G. Abdominal reservoirs for
continent urinary diversion. J Urol 1995 Sep;154(3): 
985-8.

Janser JC, Rodier JF, Rodier D, Vergnes Y. [Role of pelvic
exenterations in the treatment of cervix cancers. Apropos
of 41 surgically treated cases]. Chirurgie 1994-95;120(8):
409-14; 414-5.  (Fre).

Jurado Chacon M, Berian JM, Zudaire JJ. [Role of pelvic
exenteration in the treatment of some advanced or
recurrent gynecological cancers]. Prog Obstet Ginecol
1995;38(2):104-10.  (Spa).

Jurukovski JN, Davceva B. A personal experience with
surgical treatment of 246 patients with invasive cervical
carcinoma by Wertheim-Meigs' method. Paper presented
at: European Society of Gynaecological Oncology 8th
International Meeting: Prevention, early detection,
diagnosis, management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Lopez MJ, Standiford SB, Skibba JL. Total pelvic
exenteration: a 50-year experience at the Ellis Fischel
Cancer Center. Arch Surg  1994 Apr;129(4):390-5;
discussion 395-6. Published erratum appears in Arch Surg
1994 Jul;129(7):777.

Mendez L, Bernal A, Escudero P, Gonzalez G, Fajardo A.
[Pelvic exenteration, morbidity and survival]. Ginecol
Obstet Mex 1994 Jun;62:161-5.  (Spa).

Miller B, Morris M, Rutledge F, Mitchell MF, Atkinson EN,
Burke TW, Wharton JT. Aborted exenterative procedures
in recurrent cervical cancer. Gynecol Oncol 1993 Jul;
50(1):94-9.

Penalver M. Functional characteristics and follow-up of the
continent ileal colonic urinary reservoir. Paper presented
at: European Society of Gynaecological Oncology 8th
International Meeting: Prevention, early detection,
diagnosis, management and follow-up of gynaecological
malignancies; 1993 Jun 9-12; Barcelona, Spain.

Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W,
Kirk ME. Conservative surgery for recurrent or persistent
carcinoma of the cervix following irradiation: is
exenteration always necessary? Gynecol Oncol 1994 Mar;
52(3):353-9.

Selvaggi SM, Haefner HK, Lelle RJ, Pearl ML, Roberts JA.
Neovaginal cytology after total pelvic exenteration for
gynecological malignancies. Diagn Cytopathol 1995 Jul;
13(1):22-5.

Soeiro Fidalgo de Matos C, Nogaret JM, Philippson C,  
Veys I, Van Velthoven R. The place for surgery in
central recurrences of invasive cancer of cervix uteri.
Acta Chir Belg 1995 Jan-Feb;95(1):38-43.

Torres Lobaton A, Bastida Blanco A, Marquez Acosta G,
Hernandez Aten D, Roman Bassaure E, Rojo Herrera G.
[Pelvic exenteration for cancer of the uterine cervix
(prognostic factors)]. Ginecol Obstet Mex 1994 Jul;62:
189-93.  (Spa).


Chemotherapy for Stage IVB and Recurrent
Metastatic Disease


Ahn WS, Lippman SM, Kavanagh JJ, Silva EG, Hong WK,
Krakoff IH, Hittelman WN. Biological basis of response
of cervical squamous cell carcinoma to alpha interferon
and 13-CIS retinoic acid [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1993;34:A446.

Alberts DS, Garcia DJ. Salvage chemotherapy in recurrent or
refractory squamous cell cancer of the uterine cervix.
Semin Oncol 1994 Aug;21(4 Suppl 7):37-46.

Alberts DS, Modiano MR, Shamdas GJ, Childers J,    
Surwit E, Hatch K, Pruett L, Garcia D, Lippman SM.
Phase II trial of 13-cis-retinoic acid (13-CRA) plus
interferon-a2a (IFN) for advanced, heavily treated
squamous cell carcinoma of the cervix (SCCC) [abstract].
Proc Annu Meet Am Soc Clin Oncol 1993;12:A852.

Behbakht K, Massad LS, Yordan E, Winkelman L,    
Lincoln S, Eriksson J, DeGeest K, Kirschner C,
Wilbanks G. A bleomycin/ifosfamide/cisplatin regimen
exhibits poor activity against recurrent squamous
gynecologic cancers [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1993;12:A849.

Cervellino JC, Araujo CE, Sanchez O, Miles H,   
Nishihama A. Cisplatin and ifosfamide in patients with
advanced squamous cell carcinoma of the uterine cervix.
A phase II trial. Acta Oncol 1995;34(2):257-9.

Chambers SK, Lamb L, Kohorn EI, Schwartz PE, Chambers
JT. Chemotherapy of recurrent/advanced cervical cancer:
results of the Yale University PBM-PFU protocol.
Gynecol Oncol 1994 May;53(2):161-9.

Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand
JP, Chevallier B, Kerbrat P, de Forni M, Lhomme C,
Roche H, et al. Phase II study of pirarubicin (THP) in
patients with cervical, endometrial and ovarian cancer:
study of the Clinical Screening Group of the European
Organization for Research and Treatment of Cancer
(EORTC). Eur J Cancer 1993;29A(3):350-4.

Chauvergne J, Heron JF, Mayer F, Charrot-Chinet P,
Toulouse C. [Chemotherapy of cancers of the uterine
cervix with a combination of bleomycin, mitomycin,
cisplatin and etoposide]. Bull Cancer (Paris) 1993 Jan;
80(1):70-9.  (Fre).

Eckert RL, Agarwal C, Hembree JR, Choo CK, Sizemore N,
Andreatta-van Leyen S, Rorke EA. Human cervical
cancer. Retinoids, interferon and human papillomavirus.
Adv Exp Med Biol 1995;375:31-44.

Eisenhauer E, Lippman S, Arnold A, Massimini G.
Combination 13-cis-retinoic acid and interferon alpha-2a
in clinical trials of solid tumors [abstract]. Ann Oncol
1994;5 Suppl 5:A198.

Eisenhauer EA, Lippman SM, Kavanagh JJ, Parades-Espinoza M,
Arnold A, Hong WK, Massimini G,
Schleuniger U, Bollag W, Holdener EE, et al.
Combination 13-cis-retinoic acid and interferon alpha-2a
in the therapy of solid tumors. Leukemia 1994 Oct;8(10):
1622-5.

Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil,
and ifosfamide in the treatment of recurrent or advanced
cervical cancer. Gynecol Oncol 1995 Feb;56(2):235-8.

Filtenborg TA, Hansen HH, Aage Engelholm S, Rorth M. A
phase II study of ifosfamide, carboplatin and cisplatin in
advanced and recurrent squamous cell carcinoma of the
uterine cervix. Ann Oncol 1993 Jun;4(6):485-8.

Garton GR, Wilson TO, Hartmann LC, Long HJ, Podratz
KC. Neo-adjuvant M-VAC (Methotrexate, Vinblastine,
Doxorubicin, Cisplatin) chemotherapy for locally
advanced or metastatic cervical and vaginal cancer.  In:
Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer
treatment: an update. Presentations given at the 4th
International Congress on Anticancer Chemotherapy;
1993 Feb 2-5; Paris, France. Paris: Springer-Verlag;
1994. p. 482-4.

Glaubitz M, Vahl U, Gunter HH, Petry U, Luck HJ,  
Kuhnle H. [Chemotherapy in cervical cancer].
Tumordiagn Ther 1993;14(6):209-19.  (Ger).

Gonzales-de Leon C, Lippman SM, Kudelka AP, Edwards
CL, Kavanagh JJ. Phase II study of cisplatin, 5-fluorouracil
and interferon-alpha in recurrent carcinoma
of the cervix. Invest New Drugs 1995;13(1):73-6.

Hallum AV 3rd, Alberts DS, Lippman SM, Inclan L,
Shamdas GJ, Childers JM, Surwit EA, Modiano M,
Hatch KD. Phase II study of 13-cis-retinoic acid plus
interferon-alpha 2a in heavily pretreated squamous
carcinoma of the cervix. Gynecol Oncol 1995 Mar;56(3):
382-6.

Hirabayashi K, Okada E. Combination chemotherapy with
254-S, ifosfamide, and peplomycin for advanced or
recurrent cervical cancer. Cancer 1993 May 1;71(9):
2769-75.

Honda M, Hashimoto T, Matsui S, Kitanosono T, 
Munechika H, Hishida T, Moriyama S, Morimoto T,
Ichikawa K, Yanaihara T. Combination of arterial
infusion chemotherapy and irradiation for advanced
uterine cervix cancers [abstract].  In: ICRO'93 -
International Congress of Radiation Oncology -
Preprinted abstracts and programme; 1993 Jun 21-25;
Kyoto, Japan. [place unknown]: International Society for
Radiation Oncology; 1993. p. 276.

Hoskins P, Al-Saleh E, Pike J, Swenerton K. Combination
cisplatin (DDP) and etoposide (VP16) not only has a high
response rate in but also improves the well-being of
women with recurrent or advanced cervical cancer
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1995;
14:A815.

Ikeda M, Teshima K, Noda K, Yamagata S, Sugawa T,
Okamura S, Kubo H, Sugimoto O, Nakajima H,  
Yamabe T, et al. [Long-term administration of carmofur
as a post-operative adjuvant chemotherapy for cervical
adenocarcinoma. Cervical Adenocarcinoma Cooperative
Research Association]. Gan To Kagaku Ryoho 1994 Sep;
21(12):1967-74.  (Jpn).

Kavanagh JJ, Kudelka AP, Edwards CE, Girtanner RE,
Durivage HF, Howell ET. CPT-11 (irinotecan): phase II
study in refractory squamous cell carcinoma of the cervix
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1994;
35:A1397.

Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H,
Iwata M, Maeda O, Tomoda Y, Arii Y, Kuzuya K, et al.
Randomised study of immunotherapy with OK-432 in
uterine cervical carcinoma. Eur J Cancer 1993;29A(11):
1542-6.

Langer CJ, Godfrey S, Richter M, Dabrow M,     
Rosenblum N. Durable complete remission (CR) in
recurrent, metastatic squamous cell carcinoma of the
cervix (SCC-C) after treatment with bleomycin,
ifosfamide, and cisplatin (BIP) [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1995;14:A796.

Lara FU, Garcia-Rdz F, Zinser JW, Alcala F, Castaneda N,
Herrera A, Ramirez JL, Mota A, Martinez J.
Adenosquamous carcinoma of the uterine cervix (ACU).
Palliative, neoadjuvant (NA) and adjuvant (A)
chemotherapy (CT) [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1994;13:A879.

Lavoie A, Ouellet P, Tessier C. Chemotherapy of advanced
cervical cancer [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1993;12:A889.

Lira-Puerto V, Martinez R, Palma F, Silva A, Zepeda G. Site
of disease and response to chemotherapy in disseminated
squamous cell carcinoma of the cervix [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1994;13:A824.

Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard
JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP,
Rayson S. Phase II trial of methotrexate, vinblastine,
doxorubicin, and cisplatin in advanced/recurrent
carcinoma of the uterine cervix and vagina. Gynecol
Oncol 1995 May;57(2):235-9.

Lorvidhaya V. Epirubicin and cisplatin in recurrent,
metastatic or advanced carcinoma of the cervix. Gan To
Kagaku Ryoho 1995 Aug;22 Suppl 3:252-5.

Morris M, Burke T, Levenback C, Wharton JT,  
Gershenson D. Phase II study vinorelbine in advanced
squamous carcinoma of the uterine cervix (SCC):
preliminary results [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1995;14:A742.

Morris M, Gershenson DM, Burke TW, Mitchell MF,
Levenback C, Atkinson N, Wharton JT. A phase II study
of carboplatin and cisplatin in advanced or recurrent
squamous carcinoma of the uterine cervix. Gynecol Oncol
1994 May;53(2):234-8.

Muggia FM, Muderspach L. Platinum compounds in cervical
and endometrial cancers: focus on carboplatin. Semin
Oncol 1994 Apr;21(2 Suppl 2):35-41; quiz 42, 58.

Murad AM, Medina L, Andrade CA, Froimtchuk M,
Yamaguchi N. Single arm, open label multicentric, phase
II trial of chemotherapy (CT) with methotrexate (M),
vinblastine (V) doxorubicin (D) and cisplatin (C) (MVAC)
plus granulocyte colony stimulating factor (filgrastim) in
advanced recurrent cervical cancer (CC) [abstract].   
Proc Annu Meet Am Soc Clin Oncol 1994;13:A877.

Murad AM, Medina L, Andrade CA, Froimtchuk MJ,
Yamaguchi N. Phase II open label multicentric trial of
MVAC--methotrexate (M), vinblastine (V), doxorubicin
(A) and cisplatin (C) plus granulocyte colony stimulating
factor (filgrastim) in advanced recurrent cervical
carcinoma: final report [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1995;14:A774.

Murad AM, Oliveira M, Saldanha TM. Phase II trial of
isotretinoin and interferon alpha-2a in the treatment of
advanced recurrent cervical carcinoma. Int J Gynecol
Cancer 1994;4(6):414-8.

Murad AM, Triginelli SA, Ribalta JC. Phase II trial of BIC
(bleomycin, ifosfamide and carboplatin) in advanced
cervical cancer. Final report [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1993;12:A802.

Murad AM, Triginelli SA, Ribalta JC. Phase II trial of
bleomycin, ifosfamide, and carboplatin in metastatic
cervical cancer. J Clin Oncol 1994 Jan;12(1):55-9.

Ng HT, Yuan CC, Kan YY, Ho ES, Yen MS, Chao KC. An
evaluation of chemotherapy in patients with cancer of the
cervix and lymph node metastases. Arch Gynecol Obstet
1995;256(1):1-4.

Noda K, Terajima Y, Ogita Y, Kono I, Hirabayashi K,
Yakushiji M, Taguchi T. [Phase II clinical study of
RP56976 (docetaxel) in patients with carcinoma ovarii or
carcinoma colli uteri]. Gan To Kagaku Ryoho 1994 Oct;
21(14):2471-7.  (Jpn).

Obasaju CK, Cowan RA, Wilkinson PM. Recurrent cervical
cancer treated with cisplatin and methotrexate. Clin Oncol
(R Coll Radiol) 1993;5(4):203-6.

Omura GA. Chemotherapy for cervix cancer. Semin Oncol
1994 Feb;21(1):54-62.

Omura GA, Blessing J, Vaccarello L, Berman M, Mutch D,
Clarke-Pearson D, Anderson B. A randomized trial of
cisplatin (C) versus C + mitolactol (CM) versus C +
ifosfamide (CIFX) in advanced squamous carcinoma of
the cervix (SCC) by the Gynecologic Oncology Group
(GOG) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1995;14:A736.

Onishi Y, Hatae M, Hokanishi H. [Long time survival after
combination chemotherapy with cisplatin, vinblastine and
peplomycin for cervical cancer]. Nippon Sanka Fujinka
Gakkai Zasshi 1993 Jul;45(7):657-64.  (Jpn).

Park RC, Thigpen JT. Chemotherapy in advanced and
recurrent cervical cancer. A review. Cancer 1993 Feb 15;
71(4 Suppl):1446-50.

Petersen IA, Long HJ, Abu-Ghazaleh S, Brindle JS, Keeney
GL, Cha SS. North Central Cancer Treatment Group
(NCCTG) study of neoadjuvant methotrexate, vincristine,
adriamycin, cisplatin (MVAC) in locally advanced
cervical carcinoma [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1995;14:A765.

Potkul RK, Price FV, Bailey H, Gelder M, Rosenbluth R,
Durivage HJ. Irinotecan (CPT11) in advanced squamous
cell carcinoma of the cervix (phase II) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1995;14:A785.

Rebattu P, Fumoleau P, Roche H, Krakowski Y, Lentz A,
Mathieu Boue A, Van Glabbecke M. Phase II trial of
CPT11 in advanced cervical carcinoma [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1995;14:A737.

Rietbroek R, Postma A, Vording PZ, Gonzalez D,  
Gonzalez M, Schilthuis M, Kurth K, Bakker A,    
Bakker P, Veenhof C. Phase I/II trial of locoregional
hyperthermia (HT) and weekly cisplatin (CDDP) in
patients with a local recurrence of a cervical carcinoma or
locally advanced bladder carcinoma [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1994;13:A847.

Rietbroek R, Shilthuis M, Postma A, Zum Vorde Sive
Vording P, Gonzalez Gonzalez D, Bakker A, Bakker P,
Veenhof C. Weekly locoregional hyperthermia (HT) and
cisplatin (CDDP) in patients with a local recurrence of a
cervical carcinoma (CC) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1995;14:A816.

Roig LMV, Lotfi H, Olcese JE, Castro GL, Ciocca DR.
Effects of short-term tamoxifen administration in patients
with invasive cervical carcinoma. Anticancer Res 1993;
13(6B):2457-63.

Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE,
Recio FO. A phase II study of weekly cisplatin followed
by cisplatin and ifosfamide in advanced or recurrent
cervical carcinoma. Cancer 1993 Apr 1;71(7):2245-9.

Scarabelli C, Zarrelli A, Gallo A, Campagnutta E,    
Visentin C, Giorda G, De Marco L, Sopracordevole F,
De Piero G, Sasso GM, Parin A. Pelvic recurrences in
cervical cancer: multimodal treatment with sequential
intra-arterial chemotherapy and surgery. Reg Cancer
Treat 1994;7(1):12-6.

Singhal RM, Jindel R, Gupta AK. Bleomycin, cisplatinum
and ifosfamide infusion chemotherapy in
advanced/recurrent cancer of cervix. Indian J Cancer
1993 Dec;30(4):158-63.

Smith HO, Stringer CA, Kavanagh JJ, Gershenson DM,
Edwards CL, Wharton JT. Treatment of advanced or
recurrent squamous cell carcinoma of the uterine cervix
with mitomycin-C, bleomycin, and cisplatin
chemotherapy. Gynecol Oncol 1993 Jan;48(1):11-5.

Stornes I, Mejlholm I, Jakobsen A. A phase II trial of
ifosfamide, 5-fluorouracil, and leucovorin in recurrent
uterine cervical cancer. Gynecol Oncol 1994 Oct;55(1):
123-5.

Sutton GP, Blessing JA, DiSaia PJ, McGuire WP. Phase II
study of ifosfamide and mesna in nonsquamous carcinoma
of the cervix: a Gynecologic Oncology Group study.
Gynecol Oncol 1993 Apr;49(1):48-50.

Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY.
Phase II trial of ifosfamide and mesna in patients with
advanced or recurrent squamous carcinoma of the cervix
who had never received chemotherapy: a Gynecologic
Oncology Group study. Am J Obstet Gynecol 1993 Mar;
168(3 Pt 1):805-7.

Taguchi T. Clinical studies of CPT-11 in Japan.  In:    
Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer
treatment: an update. Presentations given at the 4th
International Congress on Anticancer Chemotherapy;
1993 Feb 2-5; Paris, France. Paris: Springer-Verlag;
1994. p. 809-12.

Thigpen JT, Vance R, Puneky L, Khansur T. Chemotherapy
as a palliative treatment in carcinoma of the uterine
cervix. Semin Oncol 1995 Apr;22(2 Suppl 3):16-24.

Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine
cervix: current status and future directions. Semin Oncol
1994 Apr;21(2 Suppl 2):43-54; quiz 55, 58.

Thigpen T, Vance RB, Khansur T. The platinum compounds
and paclitaxel in the management of carcinomas of the
endometrium and uterine cervix. Semin Oncol 1995 Oct;
22(5 Suppl 12):67-75.

Tobias JS. Management of advanced cervical carcinoma with
ifosfamide-containing combinations: UK experience with
adjuvant chemotherapy.  In: Salmon SE, editor. Adjuvant
therapy of cancer VII. Proceedings of the 7th
International Conference on the Adjuvant Therapy of
Cancer; 1993 Mar 10-13; Tucson, AZ. Philadelphia: J.B.
Lippincott Co.; 1993. p. 357-65.

Trinci M, Raffetto N, Salvatori F, Trinci C. [Loco-regional
intra-arterial chemotherapy combined with radiotherapy in
cervical carcinoma]. Radiol Med (Torino) 1993 Mar;
85(3):262-5.  (Ita).

Trudeau M, Souhami L, Seymour R, Arthur L, Stanimir G,
Roman T, Tsatoumas A, Thirlwell M, Leyland-Jones B,
Reinhold C, et al. A phase II trial of mitomycin,
ifosfamide and cisplatin (MIC) in patients (pts) with
recurrent or advanced cervical cancer [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1994;13:A841.

Tsuji K, Yamada R, Kawabata M, Mitsuzane K, Sato M,
Iwahashi M, Kitayama S, Nakano R. Effect of balloon
occluded arterial infusion of anticancer drugs on the
prognosis of cervical cancer treated with radiation
therapy. Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):
1337-45.

Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca
DR. Effects of short-term tamoxifen administration in
patients with invasive cervical carcinoma. Anticancer Res
1993 Nov-Dec;13(6B):2457-63.

Verma S, Prefontaine M, Bertrand M, Genest P,    
Dahrouge S. A pilot study of intra-arterial carboplatin in
patients with recurrent carcinoma of the cervix,
postradiation. Gynecol Oncol 1994 Jun;53(3):290-3.

Wadler S, Haynes H, Burk RD, Gallagher R, Schwartz EL,
Jennings S, Wallach R, Goldberg G, Smith H,  
Runowicz C. Clinical/pharmacokinetic (PK) trial of all-trans
retinoic acid (TRA) + interferon-alpha (IFN) in
advanced cervix cancer (CC) [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1994;13:A818.

Woolfson AD, McCafferty DF, McCarron PA, Price JH.
Liquid scintillation spectrometry of 5-fluorouracil in
cervical tissue following in vitro surface application of a
bioadhesive cervical patch. Pharm Res 1994 Sep;11(9):
1315-9.

Yanase T, Takayanagi T, Hanaoka JI, Takeuchi Y,
Tokunaga A. [A pilot study of CBDCA-ETOP-CDDP
combination therapy in refractory uterine cervical cancer
recurring with lymph node metastasis]. Gan To Kagaku
Ryoho 1995;22(9):1261-4.  (Jpn).

Zanetta G, Leventis C, Lo Monico S, Landoni F,     
Marzola M, Mangioni C. Bleomycin, ifosfamide and cis-platin
chemotherapy in recurrent and persistent cervical
cancer, a prospective study. Int J Gynecol Cancer 1995;
5(1):56-60.

Zanetta G, Torri W, Bocciolone L, Lucchini V, Mangioni C.
Factors predicting response to chemotherapy and survival
in patients with metastatic or recurrent squamous cell
cervical carcinoma: a multivariate analysis. Gynecol
Oncol 1995 Jul;58(1):58-63.


Palliative Radiotherapy for Stage IVB Disease


Biswal BM, Lal P, Rath GK, Mohanti BK. Hemostatic
radiotherapy in carcinoma of the uterine cervix. Int J
Gynaecol Obstet 1995;50(3):281-5.

Kraiphibul P, Srisupundit S, Kiatgumjaikajorn S,   
Pairachvet V. The experience in using whole pelvic
irradiation in management of massive bleeding from
carcinoma of the uterine cervix. J Med Assoc Thai 1993
Jan;76 Suppl 1:78-81.


NEW DIRECTIONS FOR RESEARCH IN
CERVICAL CANCER

Radiation Biology


Angioli R, Sevin BU, Perras JP, Untch M, Koechli OR,
Nguyen HN, Steren A, Schwade JG, Villani C, Averette
HE. In vitro potentiation of radiation cytotoxicity by
recombinant interferons in cervical cancer cell lines.
Cancer 1993 Jun 1;71(11):3717-25.

Durand RE, LePard NE. Modulation of tumor hypoxia by
conventional chemotherapeutic agents. Int J Radiat Oncol
Biol Phys 1994 Jun 15;29(3):481-6.


HPV Biology


Akasofu M, Oda Y. Immunohistochemical detection of p53 in
cervical epithelial lesions with or without infection of
human papillomavirus types 16 and 18. Virchows Arch
1995;425(6):593-602.

Alonio LV, Dalbert D, Mural J, Bartt O, Bazan G, Teyssie
AR. Early herpes simplex virus proteins as risk markers
for progression of papillomavirus cervical lesions: a
retrospective study. Cervix Low Female Genital Tract
1993;11(4):161-4.

Alvarez-Salas LM, Wilczynski SP, Burger RA, Monk BJ,
DiPaolo JA. Polymorphism of the HPV-16 E6 gene of
cervical carcinoma. Int J Oncol 1995;7(2):261-6.

Anderson SM, Brooke PK, Van Eyck SL, Noell H, Frable
WJ. Distribution of human papillomavirus types in genital
lesions from two temporally distinct populations
determined by in situ hybridization. Hum Pathol 1993;
24(5):547-53.

Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC.
Human papillomavirus type 18 associates with more
advanced cervical neoplasia than human papillomavirus
type 16. Hum Pathol 1993 Apr;24(4):432-7.

Baker VV. Molecular genetic abnormalities and cervical
cancer. Clin Consult Obstet Gynecol 1995;7(2):86-93.

Baker VV. Oncogene expression in cervical cancer. Cancer
Treat Res 1994;70:43-51.

Band V, Dalal S, Delmolino L, Androphy EJ. Enhanced
degradation of p53 protein in HPV-6 and BPV-1
E6-immortalized human mammary epithelial cells. EMBO J
1993;12(5):1847-52.

Berumen J, Casas L, Segura E, Amezcua JL, Garcia-Carranca A.
Genome amplification of human papillomavirus types 16 and 18
in cervical carcinomas is related to the retention of E1/E2
genes. Int J Cancer 1994 Mar 1;56(5):640-5.

Berumen J, Unger ER, Casas L, Figueroa P. Amplification
of human papillomavirus types 16 and 18 in invasive
cervical cancer. Hum Pathol 1995 Jun;26(6):676-81.

Bornstein J, Rahat MA, Abramovici H. Etiology of cervical
cancer: current concepts. Obstet Gynecol Surv 1995 Feb;
50(2):146-54.

Cardillo MR, Stamp GW, Pignatelli MN, Lalani EN.
Immunohistochemical analysis of p53 oncoprotein and
proliferating cell nuclear antigen (PCNA) in the cervix
uteri. Eur J Gynaecol Oncol 1993;14(6):484-90.

Chee YH, Namkoong SE, Kim DH, Kim SJ, Park JS.
Immunologic diagnosis and monitoring of cervical
cancers using in vitro translated HPV proteins. Gynecol
Oncol 1995 May;57(2):226-31.

Chen TM, Pecoraro G, Defendi V. Genetic analysis of in
vitro progression of human papillomavirus-transfected
human cervical cells. Cancer Res 1993 Mar 1;53(5):
1167-71.

Choo CK, Rorke EA, Eckert RL. Retinoid regulation of cell
differentiation in a series of human papillomavirus type
16-immortalized human cervical epithelial cell lines.
Carcinogenesis 1995;16(2):375-81.

DiPaolo JA, Popescu NC, Alvarez L, Woodworth CD.
Cellular and molecular alterations in human epithelial
cells transformed by recombinant human papillomavirus
DNA. Crit Rev Oncog 1993;4(4):337-60.

Gu Z, Pim D, Labrecque S, Banks L, Matlashewski G. DNA
damage induced p53 mediated transcription is inhibited by
human papillomavirus type 18 E6. Oncogene 1994 Feb;
9(2):629-33.

Hagmar B, Christensen JJP, Johansson B, Kalantari M,   
Ryd W, Skyldberg B, Walaas L, Warleby B, Kristensen
GB. Implications of human papillomavirus type for
survival in cervical squamous cell carcinoma. Int J
Gynecol Cancer 1995;5(5):341-5.

Jeon S, Lambert PF. Integration of human papillomavirus
type 16 DNA into the human genome leads to increased
stability of E6 and E7 mRNAs: implications for cervical
carcinogenesis. Proc Natl Acad Sci U S A 1995 Feb 28;
92(5):1654-8.

Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS,
Han SM, Lorincz AT, Hedrick L, Cho KR. Human
papillomavirus 16 E6 expression disrupts the p53-mediated
cellular response to DNA damage. Proc Natl
Acad Sci U S A 1993;90(9):3988-92.

Kinoshita M, Shin S, Hamada SI, Aono T. Human
papillomavirus integration into the host cell genome
during the developmental stage of cervical cancer. Rinsho
Kagaku 1993;22(3):162-7.

Koffa M, Koumantakis E, Ergazaki M, Malamoumitsi V,
Spandidos DA. Detection of ras gene mutations and HPV
in lesions of the human female reproductive tract. Int J
Oncol 1994 Aug;5(2):189-95.

Konya J, Veress G, Hernadi Z, Soos G, Czegledy J, 
Gergely L. Correlation of human papillomavirus 16 and
18 with prognostic factors in invasive cervical neoplasias.
J Med Virol 1995 May;46(1):1-6.

Koulos JP, Wright TC, Mitchell MF, Silva E, Atkinson EN,
Richart RM. Relationships between c-Ki-ras mutations,
HPV types, and prognostic indicators in invasive
endocervical adenocarcinomas. Gynecol Oncol 1993 Mar;
48(3):364-9.

Lee JH, Kang YS, Koh JW, Park SY, Kim BG, Lee ED, Lee
KH, Park KB, Seo YL. p53 gene mutation is rare in
human cervical carcinomas with positive HPV sequences.
Int J Gynecol Cancer 1994;4(6):371-8.

Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P,
Hockenbery D, Lockett S, Herman B. Bcl-2
protooncogene expression in cervical carcinoma cell lines
containing inactive p53. J Cell Biochem 1995 Mar;57(3):
509-21.

Liang XH, Volkmann M, Klein R, Herman B, Lockett SJ.
Co-localization of the tumor-suppressor protein p53 and
human papillomavirus E6 protein in human cervical
carcinoma cell lines. Oncogene 1993 Oct;8(10):2645-52.

Milde-Langosch K, Albrecht K, Joram S, Schlechte H,
Giessing M, Loning T. Presence and persistence of HPV
infection and p53 mutation in cancer of the cervix uteri
and the vulva. Int J Cancer 1995 Nov 27;63(5):639-45.

Park TW, Fujiwara H, Wright TC. Molecular biology of
cervical cancer and its precursors. Cancer 1995;     
76(10 Suppl):1902-13.

Patrick DR. Biochemical characterization of the human
papillomavirus type 16 e7 oncoprotein and its interaction
with the retinoblastoma growth suppressor gene product
[dissertation]. [Philadelphia]: Univ. of Pennsylvania;
1993. 221 p.  Available from: University Microfilms
International, Ann Arbor, MI; AAD94-13887.

Rose BR, Thompson CH, Tattersall MH, Elliott PM,
Dalrymple C, Cossart YE. Identification of E6/E7
transcription patterns in HPV 16-positive cervical cancers
using the reverse transcription/polymerase chain reaction.
Gynecol Oncol 1995 Feb;56(2):239-44.

Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann
CO, Horowitz IR, Icenogle JP, Reeves WC. Human
papillomavirus and disease-free survival in FIGO stage Ib
cervical cancer. J Infect Dis 1995;172(5):1184-90.

Wake N. [Application of antisense oligonucleotides into
treatment of human cervical carcinoma]. Nippon Sanka
Fujinka Gakkai Zasshi 1994 Aug;46(8):742-8.  (Jpn).

Watanabe S, Kanda T, Yoshiike K. Growth dependence of
human papillomavirus 16 DNA-positive cervical cancer
cell lines and human papillomavirus 16-transformed
human and rat cells on the viral oncoproteins. Jpn J
Cancer Res 1993 Oct;84(10):1043-9.

Yamada T, Yamashita T, Nishikawa T, Fujimoto S, 
Fujinaga K. Biologic activity of human papillomavirus
type 16 E6/E7 cDNA clones isolated from SiHa cervical
carcinoma cell line. Virus Genes 1995;10(1):15-25.

Ylitalo N, Bergstrom T, Gyllensten U. Detection of genital
human papillomavirus by single-tube nested PCR and
type-specific oligonucleotide hybridization. J Clin
Microbiol 1995;33(7):1822-8.


HPV Immunology and Vaccine Prospects


Apple RJ, Becker TM, Wheeler CM, Erlich HA.
Comparison of human leukocyte antigen DR-DQ disease
associations found with cervical dysplasia and invasive
cervical carcinoma. J Natl Cancer Inst 1995 Mar 15;
87(6):427-36.

Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM,
Wheeler CM. HLA DR-DQ associations with cervical
carcinoma show papillomavirus-type specificity.         
Nat Genet 1994 Feb;6(2):157-62.

Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM,
Wheeler CM. HLA DR-DQ disease associations with
cervical carcinoma show human papillomavirus-type
specificity [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1994;35:A1723.

Baay MF, Duk JM, Burger MP, de Bruijn HW, Stolz E,
Herbrink P. Follow-up of antibody responses to human
papillomavirus type 16 E7 in patients treated for cervical
carcinoma. J Med Virol 1995 Mar;45(3):342-7.

Baay MF, Duk JM, Burger MP, Walboomers J,               
ter Schegget J, Groenier KH, de Bruijn HW, Stolz E,
Herbrink P. Antibodies to human papillomavirus type 16
E7 related to clinicopathological data in patients with
cervical carcinoma. J Clin Pathol 1995 May;48(5):410-4.

Bell MC, Edwards RP, Partridge EE, Kuykendall K,  
Conner W, Gore H, Turbat-Herrara E, Crowley-Nowick
PA. CD8+ T lymphocytes are recruited to neoplastic
cervix. J Clin Immunol 1995 May;15(3):130-6.

Coleman N, Stanley MA. Analysis of HLA-DR expression
on keratinocytes in cervical neoplasia. Int J Cancer 1994
Feb 1;56(3):314-9.

Connor ME, Davidson SE, Stern PL, Arrand JR, West
CML. Evaluation of multiple biologic parameters in
cervical carcinoma: high macrophage infiltration in
HPV-associated tumors. Int J Gynecol Cancer 1993;3(2):103-9.

Crawford L. Prospects for cervical cancer vaccines. Cancer
Surv 1993;16:215-29.

Cromme FV, van Bommel PF, Walboomers JM, Gallee MP,
Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ,
Meijer CJ. Differences in MHC and TAP-1 expression in
cervical cancer lymph node metastases as compared with
the primary tumours. Br J Cancer 1994 Jun;69(6):   
1176-81.

Cromme FV, Walboomers JMM, Van Oostveen JW, Stukart
MJ, De Gruijl TD, Kummer JA, Leonhart AM,
Helmerhorst TJM, Meijer CJLM. Lack of granzyme
expression in T lymphocytes indicates poor cytotoxic T
lymphocyte activation in human papillomavirus-associated
cervical carcinomas. Int J Gynecol Cancer 1995;5(5):
366-73.

Das S, Bal N, Roychowdhury J, Chattopadhyay U.
Immunoglobulins, immune complexes and antitumor
antibodies as prognostic indicators in carcinoma of uterine
cervix. J Exp Clin Cancer Res 1993;12(2):91-9.

Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P,
Wiklund F, Hallmans G, Stendahl U. A population-based
seroepidemiological study of cervical cancer. Cancer Res
1994 Jan 1;54(1):134-41.

Dillner J, Wiklund F, Lenner P, Eklund C,
Frederiksson-Shanazarian V, Schiller JT, Hibma M, Hallmans
G, Stendahl U. Antibodies against linear and conformational
epitopes of human papillomavirus type 16 that
independently associate with incident cervical cancer.  
Int J Cancer 1995 Jan 27;60(3):377-82.

Dillner L, Fredriksson A, Persson E, Forslund O, Hansson
BG, Dillner J. Antibodies against papillomavirus antigens
in cervical secretions from condyloma patients. J Clin
Microbiol 1993 Feb;31(2):192-7.

Dillner L, Zellbi A, Avall-Lundqvist E, Heino P, Eklund C,
Pettersson CA, Forslund O, Hansson BG, Grandien M,
Bistoletti P, et al. Association of serum antibodies against
defined epitopes of human papillomavirus L1, E2, and E7
antigens and of HPV DNA with incident cervical cancer.
Cancer Detect Prev 1995;19(5):381-93.

Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV,
Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew
JS, Young LS, et al. The association of an HPV16
oncogene variant with HLA-B7 has implications for
vaccine design in cervical cancer. Nat Med 1995 May;
1(5):464-70.

Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM,
Gallee MP, Hart AA, Muller M, Trimbos JB,
Helmerhorst TJ. Prognostic significance of serum
antibodies to human papillomavirus-16 E4 and E7
peptides in cervical cancer. Cancer 1994 Oct 15;74(8):
2307-13.

Gemignani M, Maiman M, Fruchter RG, Arrastia CD,
Gibbon D, Ellison T. CD4 lymphocytes in women with
invasive and preinvasive cervical neoplasia. Gynecol
Oncol 1995 Dec;59(3):364-9.

Gupta MM, Jain R, Parashari A, Singh V, Sharma S.
Circulating immune profile in patients with pre-cancer
and cancer of the cervix: a cross sectional study among
Indian women. Bull Cancer (Paris) 1993 Oct;80(10): 
852-6.

Helland A, Borresen AL, Kristensen G, Ronningen KS.
DQA1 and DQB1 genes in patients with squamous cell
carcinoma of the cervix: relationship to human
papillomavirus infection and prognosis. Cancer Epidemiol
Biomarkers Prev 1994 Sep;3(6):479-86.

Hellstrom I, Hellstrom KE. Tumor immunology--an
overview. Ann N Y Acad Sci 1993 Aug 12;690:24-33.

Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ. The
expression of histocompatibility-related leukocyte antigens
in the pathway to cervical carcinoma. Am J Clin Pathol
1994 Jan;101(1):5-12.

Hilders CG, Houbiers JG, van Ravenswaay Claasen HH,
Veldhuizen RW, Fleuren GJ. Association between
HLA-expression and infiltration of immune cells in cervical
carcinoma. Lab Invest 1993 Dec;69(6):651-9.  Comment
in: Lab Invest 1993 Dec;69(6):635-8.

Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered
HLA expression by metastatic cervical carcinoma cells as
a factor in impaired immune surveillance. Gynecol Oncol
1995 Jun;57(3):366-75.

Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren
GJ. Isolation and characterization of tumor-infiltrating
lymphocytes from cervical carcinoma. Int J Cancer 1994
Jun 15;57(6):805-13.

Hines JF, Ghim SJ, Schlegel R, Jenson AB. Prospects for a
vaccine against human papillomavirus. Obstet Gynecol
1995;86(5):860-6.

Hines JF, Jenson AB, Barnes WA. Human papillomaviruses:
their clinical significance in the management of cervical
carcinoma. Oncology (Huntingt) 1995 Apr;9(4):279-85;
discussion 286-8, 291.

Honma S, Tsukada S, Honda S, Nakamura M, Takakuwa K,
Maruhashi T, Kodama S, Kanazawa K, Takahashi T,
Tanaka K. Biological-clinical significance of selective loss
of HLA-class-I allelic product expression in squamous-cell
carcinoma of the uterine cervix. Int J Cancer 1994
Jun 1;57(5):650-5.

Juranic Z, Vuckovic-Dekic L, Durbaba M. Humoral
immunity in patients with carcinoma of the uterine cervix
--effects of radiation therapy. Neoplasma 1993;40(5): 
297-300.

Juranic Z, Vuckovic-Dekic L, Durbaba M. Immune reactive
proteins in patients irradiated for cervical cancer. One
year follow up. Neoplasma 1994;41(4):225-8.

Kast WM, Brandt RMP, Drijfhout JW, Melief CJM. Human
leukocyte antigen-A2.1 restricted candidate cytotoxic T
lymphocyte epitopes of human papillomavirus type 16 E6
and E7 proteins identified by using the processing-defective
human cell line T2. J Immunother 1993;14(2):
115-20.

Labeit D, Labeit S, Berger M, Gallati H, Rosenberg R,
Friese K. [Interferon-alpha controls HPV infection in
cervix epithelium]. Zentralbl Gynakol 1995;117(11): 
566-77.  (Ger).

Lenner P, Dillner J, Wiklund F, Hallmans G, Stendahl U.
Serum antibody responses against human papillomavirus
in relation to tumor characteristics, response to treatment,
and survival in carcinoma of the uterine cervix. Cancer
Immunol Immunother 1995 Mar;40(3):201-5.

Mandelblatt J. Squamous cell cancer of the cervix, immune
senescence and HPV: is cervical cancer an age-related
neoplasm? Adv Exp Med Biol 1993;330:13-26.

Melief CJ, Kast WM. Prospects for T cell immunotherapy of
tumours by vaccination with immunodominant and
subdominant peptides. Ciba Found Symp 1994;187:    
97-104; discussion 104-12.

Mercedes Bravo M, Lucia Combita A, Mesa M, Varela A,
Orozco O, Martinez G. [Antiprotein E7 humoral response
of papilloma virus type 16 recognized by means of
synthetic peptides and recombinant protein]. Rev Colomb
Obstet Ginecol 1995;46(1):33-40.  (Spa).

Muller M, Viscidi RP, Ulken V, Bavinck JN, Hill PM,
Fisher SG, Reid R, Munoz N, Schneider A, Shah KV,  
et al. Antibodies to the E4, E6, and E7 proteins of human
papillomavirus (HPV) type 16 in patients with HPV-associated
diseases and in the normal population. J Invest
Dermatol 1995 Jan;104(1):138-41.

Nakano T, Oka K, Sugita T, Tsunemoto H. Antitumor
activity of Langerhans cells in radiation therapy for
cervical cancer and its modulation with SPG
administration. In Vivo 1993 May-Jun;7(3):257-63.

Onda T, Kanda T, Zanma S, Yasugi T, Watanabe S, 
Kawana T, Ueda K, Yoshikawa H, Taketani Y,  
Yoshiike K. Association of the antibodies against human
papillomavirus 16 E4 and E7 proteins with cervical
cancer positive for human papillomavirus DNA.          
Int J Cancer 1993 Jun 19;54(4):624-8.

Paez CG, Yaegashi N, Sato S, Yajima A. Prevalence of
serum IgG antibodies for the E7 and L2 proteins of
human papillomavirus type 16 in cervical cancer patients
and controls. Tohoku J Exp Med 1993 Jun;170(2):    
113-21.

Soutter WP, Kesic V. Treatment of cervical intraepithelial
neoplasia reverses CD4/CD8 lymphocyte abnormalities in
peripheral venous blood. Int J Gynecol Cancer 1994;4(4):
279-82.

Stoian M, Repanovici R. Identification of antibodies against
human papillomavirus type 16 E4 and E7 proteins in sera
of patients with cervical neoplasias. Rev Roum Virol
1994 Jul-Dec;45(3-4):185-92.

Strickler HD, Dillner J, Schiffman MH, Eklund C, Glass
AG, Greer C, Scott DR, Sherman ME, Kurman RJ,
Manos M. A seroepidemiologic study of HPV infection
and incident cervical squamous intraepithelial lesions.
Viral Immunol 1994;7(4):169-77.

Sun Y. Serologic markers of human papillomavirus
associated cervical cancer [dissertation]. [Baltimore
(MD)]: Johns Hopkins Univ.; 1994. 193 p.  Available
from: University Microfilms International, Ann Arbor,
MI; AAD94-29578.

Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Booth M,
Walboomers JM, Shah KV, Viscidi RP. Human
papillomavirus-related serological markers of invasive
cervical carcinoma in Brazil. Cancer Epidemiol
Biomarkers Prev 1994 Jun;3(4):341-7.

Sun Y, Shah KV, Muller M, Munoz N, Bosch XF, Viscidi
RP. Comparison of peptide enzyme-linked
immunosorbent assay and radioimmunoprecipitation assay
with in vitro-translated proteins for detection of serum
antibodies to human papillomavirus type 16 E6 and E7
proteins. J Clin Microbiol 1994 Sep;32(9):2216-20.

Torres LM, Cabrera T, Concha A, Oliva MR,             
Ruiz-Cabello F, Garrido F. HLA class I expression and
HPV-16 sequences in premalignant and malignant lesions
of the cervix. Tissue Antigens 1993 Feb;41(2):65-71.

Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Munoz N, Shah
KV. Serologic response in human papillomavirus-associated
invasive cervical cancer. Int J Cancer 1993
Nov 11;55(5):780-4.

Vuckovic-Dekic L, Spremo B, Stanojevic-Bakic N,    
Garzicic B, Durbaba M. Immunosuppressive and
cytogenetic effects of pelvic irradiation on the peripheral
lymphocytes of patients with cervical cancer. One year
follow-up. Arch Immunol Ther Exp (Warsz) 1994;42(1):
63-6.

Last updated: 31 December 1996